Annual Report - Mental Health Research Institute

2010
Annual Report
Mental Health
Research Institute
Image: Microscopic image of a human cerebrum

Vision
To be a global leader in research that improves the lives of people affected
by mental illness including psychotic illness (schizophrenia and depression)
and neurodegenerative diseases (dementia and Alzheimer’s disease).
Mission
• To undertake sustainable, high quality, basic scientific, clinical and public
health research
• To promote understanding of, and investment in, research through advocacy
• To educate clinicians and researchers
• To provide expert commentary on the scientific basis of mental/psychiatric
illness and dementia
Structure
The Institute is governed by a Board which is legally responsible for ensuring
that the Institute’s work is directed towards its stated objectives. This Board
comprises the Deans from the Medical Faculties of Monash University and
The University of Melbourne, the Institute’s Executive Director, and up to 12
other voluntary members.
The Institute is formally affiliated with The University of Melbourne, Monash
University and Melbourne Health.
2010 was Linh Lam’s second year working as a research assistant at MHRI. She joined the Institute after completing
her honours year and now works on cell culture, histology, APP purification, animal work, molecular biology and
other laboratory duties. Research assistants provide essential support to senior scientists. Linh enjoys the friendly
atmosphere and colleagues she works with at MHRI, as well as the contribution she can make to society.
The image Linh holds shows alpha-synuclein, a protein thought to aggregate in Parkinson’s disease.

Contents
4 Board of Directors
8 Chair’s Report
10 Executive Director’s Report
14 Rebecca L Cooper Laboratory
18 Behavioural Neuroscience Laboratory
22 Molecular Psychopharmacology /
Northern Psychiatry Research Centre
25 Neuropathology Laboratory
26 Oxidation Biology Laboratory
29 Synaptic Neurobiology Laboratory
30 Clinical Research Group
34 Clinical Discovery Unit
36 Victorian Brain Bank Network
38 Psychotropic Drug Advisory Service
41 The Dax Centre
44 Development and Communications
48 Publications
56 Financials
87 Personnel
95 Donations (Thank you)
111 Further Information

4
Board of Directors
CHAIR – Dr Sandra Hacker AO
MBBS, DPM, FRANZCP, FAICD
Sandra Hacker is a psychiatrist. She works in private practice and as Liaison Psychiatrist at the Heart/Lung
Transplant Unit. She is Chair of the Australian Health Ethics Committee of the National Health and Medical
Research Council and a Director of the Dax Centre.
Dr Hacker was appointed to the MHRI Board in 2000 and became Chair in 2008. She is Chair of the
Institute’s Policy and Human Resources and Nomination Committees, and a member of the Audit and Risk
Management Committee.
DEPUTY CHAIRMAN – Mr Trevor Clark OAM
ACIS, FAMI, FAICD, CPM
Trevor Clark is the Director of management consultancy, TM Clark & Associates. He has been awarded
a Medal of the Order of Australia, recognising his outstanding contribution to the community.
Mr Clark was appointed to the MHRI Board in 1998 and became Deputy Chair in 2002. He is Chair of the
Institute’s Development Council and a member of the Policy and Human Resources
and Nomination Committees.
EXECUTIVE DIRECTOR – Laureate Professor Colin Masters
BMedSc (Hons), MBBS, MD, Hon DLitt WAust, FRCPath, FRCPA, FAA, FTSE
Colin Masters is a Laureate Professor at The University of Melbourne and a former Director of Prana
Biotechnology. He is one of the world’s best known authorities on Alzheimer’s disease.
Professor Masters was appointed as the Institute’s Executive Director in 2007. He is an ex officio member
of the Institute’s Audit and Risk Management, Policy and Human Resources, Intellectual Property and
Commercialisation, and Scientific Advisory Committees.
Images (from left to right): Dr Sandra Hacker AO | Mr Trevor Clark OAM | Laureate Professor Colin Masters

Professor James Angus AO
BSc, PhD, FAA
James Angus is Dean of the Faculty of Medicine, Dentistry and Health Sciences at The University of
Melbourne. He is also a Fellow and former Member of Council at the Australian Academy of Science.
Professor Angus was appointed to the MHRI Board in 2003. He is Chairman of the Institute’s Scientific
Advisory Committee and a member of the Nominations Committee.
Mr Rob Gerrand
BA, FAMI, FAICD
Rob Gerrand heads the marketing and communications consultancy Gerrand & Associates. He is also
Chair of Parks Victoria, a Director of Alfred Health and Chair of Healthy Parks Healthy People Global Ltd.
He is a former General Manager of Group Public Affairs at ANZ. Previous board appointments include the
Financial Planning Association of Australia, the Koorie Heritage Trust and the Melbourne Convention and
Marketing Bureau. He was the Founding President of the Monash Alumni Association, and in 1994 was
appointed Adjunct Professor at Deakin University. He is a published author.
Mr Gerrand was appointed to the MHRI Board in 1995 and is a member of the Audit and Risk Management
Committee. He is a member of the Institute’s Development Council and represents the MHRI Board on the
Project Committee of the Melbourne Neuroscience Project.
Ms Jennifer Labourne
BBus, FCPA
Ms Labourne was Deputy Chair of Health Purchasing Victoria, is a member of the Board of Parks Victoria
and Director of Finance & Business Services at Colac Area Health. She was previously a partner at Ernst
& Young and has been involved on various committees of the Australian Society of Certified Practicing
Accountants (CPAs).
Jennifer Labourne was appointed to the MHRI Board in 2007. She is Chair of the Institute’s Audit and Risk
Management Committee.
Images (from left to right): Professor James Angus AO | Mr Rob Gerrand | Ms Jennifer Labourne
5

6
Board of Directors
continued
Mr Andrew Stripp
MSc (Clin Psychol), BBSc(Hons)
Andrew Stripp is the Deputy Chief Executive Officer at Alfred Health. Previous roles include Director,
Strategic Projects, Department of Human Services (DHS) and Director, Southern Metropolitan Region (DHS).
Mr Stripp was appointed to the MHRI Board in July 2009.
Professor Steve Wesselingh
MBBS, FRACP, PhD
Professor Steve Wesselingh is Dean of the Faculty of Medicine, Nursing and Health Sciences at Monash
University. Prior to taking up the Deanship in 2007, Professor Wesselingh was Director of the Burnet Institute.
From 1994 to 1997 he was on the Board of the Australian Society for Medical Research (ASMR), acting as
President in 1998. He is recognised internationally as an expert in viruses that affect the human brain.
He has held National Health and Medical Research Council (NHMRC) Program and Project Grants and
also a number of National Institutes of Health (NIH, USA) and Australian Research Council (ARC) grants.
Professor Wesselingh was appointed to the MHRI Board in 2007 and is a member of the Scientific
Advisory Committee.
Professor Ingrid Winship
MBChB, MD, FRACP, FACD
Ingrid Winship is Professor of Adult Clinical Genetics at The University of Melbourne and Executive Director
of Research, Melbourne Health. Previous appointments include Head, Adult and Cancer Genetics,
Genetic Health Services Victoria (2004-2006) and Associate Dean, Research, Faculty of Medical and
Health Sciences, University of Auckland (1999-2004) and Clinical Director, Northern Regional Genetic
Service, Auckland District Health Board (1994-2004).
Professor Winship was appointed to the MHRI Board in June 2009.
Images (from left to right): Mr Andrew Stripp | Professor Steve Wesselingh | Professor Ingrid Winship

Development Council
The Institute’s Development Council supports
the Institute’s fundraising activities.
Chairman, Trevor Clark OAM
Peter Bennell
David Dean
Rob Gerrand
Doug George AM
Ian Farrington
Roger Flynn
Geoff Marshall
George McMaster
Jenny Mills
Martin Ryan
Scientific Advisory Committee
Chairman, Professor James Angus
Professor Steve Wesselingh
Professor Sam Berkovic
Professor John Furness
Professor Bruce Tonge
Professor Assen Jablensky
Professor Tony Burgess
Professor Colin Masters (ex officio)
Organisational Memberships
Australian Association of
Medical Research Institutes
(AAMRI - includes The Australian Synchrotron)
Australia Israel Chamber of Commerce
BioMelbourne Network
Bio21
Mental Health Council of Australia
Mental Illness Fellowship of Victoria
National Neuroscience Facility
Neurosciences Victoria
Research Australia
Annual General Meeting
The Mental Health Research Institute’s Annual
General Meeting will be held on 19th May, 2011.
7

8
Chair’s Report
Dr Sandra Hacker AO
It has been a busy and exciting year implementing our strategic plan to support our vision to be a
global leader in research that improves the lives of people affected by mental illness.
Critical to our strategic plan was the need to develop and raise the profile of our brand. To address this,
the Board decided that our corporate image should be updated. A new logo was adopted to represent
the progressive nature of the Institute, which is at the forefront of mental illness research.
The logo represents a modern day puzzle. A dislodged blue piece symbolises the solution that we strive
to find each day through our research, which will enable better diagnosis, treatment and, ideally, the
prevention of mental illness. The colours chosen for our new corporate logo are friendly and soothing for
our many stakeholders who face the day to day turmoil of living with, or caring for someone who has a
mental illness.
The Melbourne Neuroscience Project continued to keep us busy throughout the year. Completion of the
Austin facility is expected in early 2011 and the Parkville facility in mid 2011. These two facilities, along
with a Centre for Translational Neuroscience at the Royal Melbourne Hospital, have been named the
Melbourne Brain Centre. Much work is under way to ensure equipment is in place so that our researchers
can continue their important work immediately on re-location. We look forward to celebrating the opening
of these two buildings in 2011.
Over the last eighteen months we have seen a number of Directors leave the board. We thank Jennifer
Williams and Katarina Klaric for their hard work over the years. In particular, we owe great thanks to
Professor Gad Trevaks who worked tirelessly for the Institute over a great many years. As recent additions to
the Board we welcome Professor Ingrid Winship, Executive Director of Research at Melbourne Health and
Mr Andrew Stripp, Deputy Chief Executive Officer at the Alfred Hospital.
The tireless efforts of our Development Council have resulted in $1.34 million being raised this year to
support the Institute’s activities. In addition, they have been focusing on the establishment of some
exciting new fundraising events. A highlight will be a culinary event at Crown Entertainment Centre that
will see teams led by Shannon Bennett of Vue de Monde in Melbourne and Matt Moran of ARIA in Sydney
battle it out to prove once and for all which city has the best food.
Once again, we must thank the Victorian State Government who offer continued support through both
the Department of Health and the Department of Innovation, Industry and Regional Development who
provide both recurrent and project grants including Operational Infrastructure Support.
Dr Sandra Hacker AO

The image Dr Hacker holds shows how Purkinje cells (the large cell bodies) are typically arranged in a
single row at the junction of the molecular and granular layers of the cerebellum 9

10
Executive Director’s Report
Professor Colin L. Masters MD
The highlight of 2010 has been the commitment by the Federal Government’s Cooperative Research
Centre (CRC) Program to advance Australia’s research efforts in the area of Mental Health. The Mental
Health Research Institute (MHRI) successfully led a bid that attracted $23 million to establish the CRC
for Mental Health with partners including CSIRO, Pfizer, Mercy Health, Edith Cowan University, Hall & Prior
and the McCusker Foundation.
The CRC for Mental Health will conduct research to identify and develop biomarkers for the diagnosis of
various mental illnesses and develop new and more effective therapeutics for their treatment. Another $27
million was awarded to a group including our neighbours, Orygen Youth Health, to focus on youth mental
health issues.
This unprecedented amount of funding for mental health research will provide a much needed boost to
further our research activities and gain a better understanding of mental illnesses including Alzheimer’s
disease, Parkinson’s disease and psychotic illness such as schizophrenia and mood disorders.
The CRC for Mental Health will be based on the successful Australian Imaging, Biomarkers and Lifestyle
(AIBL) study, a clinical cohort established to predict early signs of Alzheimer’s disease, with similar cohorts
being established to assist with studies into psychoses and Parkinson’s disease.
The AIBL study has continued to attract interest around the world. It has secured further funding from
pharmaceutical companies and from CSIRO through the Science and Industry Endowment Fund. Such
funding will ensure that the study continues for at least the next three years.
Our Kearney Visiting Professor, Julie Anderson from California’s Buck Institute, gave the 17th Annual John
Cade Lecture this year. Professor Anderson presented an interesting and well-attended public lecture on
the role of iron in Parkinson’s disease and the development of new drugs to treat this debilitating disease.
Professor Colin Masters holds an image of C. elegans as seen under a microscope. These worms offer a
new research tool to model diseases of ageing and identify new drugs.

12
Executive Director’s Report
continued
A number of MHRI researchers have been recognised this year for their professional achievements including:
• Professor Ashley Bush, who was among 28 leaders in technological science, engineering and innovation
elected as Fellows of the Australian Academy of Technological Sciences and Engineering (ATSE) and
was also joint recipient of The Royal Australian and New Zealand College of Psychiatrists’ Shering-Plough
Senior Research Award, recognising excellence in research in psychiatry;
• Dr Blaine Roberts and Dr James Duce, who received the new Young Investigator Award from the
Bethlehem Griffiths Research Foundation;
• Professor Michael Berk, who was Highly Commended for his Outstanding Individual Achievement in
Mental Healthcare in the Victorian Public HealthCare Awards;
• Professor Catriona McLean, who was awarded the Crawford Mollison Prize by the AMA for ‘outstanding
work’ in the field of Pathology in Victoria as well as the Noel Callahan Medal from the Irish Neurological
Society. She also received the National Citation award for outstanding contribution to student learning from
the Australian Learning and Teaching Council (ALTC) and an Honourable mention for the TAMSS Teaching
Recognition award.
During the year, Melbourne welcomed Professor Ian Everall to the position of Cato Professor of Psychiatry
and Head of the Department of Psychiatry, The University of Melbourne. We have been working closely
with Professor Everall since his arrival to coordinate neuropsychiatry research efforts and we look forward
to continuing this important partnership in 2011.
The year ahead will be very exciting as we finalise our plans for relocation to the new Parkville Facility of the
Melbourne Brain Centre in October 2011. We are currently reviewing our equipment needs and completing
space allocation in readiness for our move.
We thank both the State and Commonwealth Governments for their assistance in providing purpose built
facilities to house some of the world’s best neuroscientists from MHRI, The University of Melbourne and
Florey Neuroscience Institutes.
John and Lorraine Bates are generous donors to the Institute. We are grateful for their support and the
wonderful support we receive from each of our donors. A full list of donors appears later in this report.
The image being held by John and Lorraine is of a stain for iron accumulation in neurons within the brain.
Colin L. Masters MD

14
Rebecca L Cooper Laboratory
Head: Professor Brian Dean
The Rebecca L Cooper Laboratory aims to identify the molecular pathways that are affected by
schizophrenia, bipolar disorder and major depressive disorders. Understanding the pathophysiology
of these diseases will enable rationale-based drug design that targets the proteins or RNA involved in
disease processes. Such drugs will improve the wellbeing of people who suffer from these debilitating
disorders, many of whom do not achieve satisfactory outcomes from the treatments currently available.
Highlights
Identifying a subgroup within patients with schizophrenia
Elizabeth Scarr and her colleagues in the Muscarinic Receptor Group continue to investigate why a
sub-group has lost approximately 75% of their cortical muscarinic M1 receptors. This subgroup, identified by
Elizabeth in 2009, comprises about 25% of all cases of schizophrenia within the Victorian Brain Bank Network.
The group are comparing changes in the expression of all known genes in the brains of people in this
subgroup to those of other people with schizophrenia who have not lost muscarinic receptors, as well as
control subjects. This study will also compare gene expression in mice that do not have muscarinic M1
receptors (through genetic engineering) to that in wild type mice.
It appears that the different pathways are altered in the cortex of subjects with decreased levels of
muscarinic receptors. This evidence strongly suggests that there are different biochemical causes of
this form of schizophrenia, compared with the disorder affecting people who have not lost muscarinic
receptors. This project is funded by the National Health and Medical Research Council (NHMRC).
The group is now investigating pathways in the brain that are only altered in this subgroup. This will help
elucidate the underlying cause of this form of schizophrenia, potentially revealing new ways to treat
people who experience it.

Proinflammatory pathways and depression
In 2009, the Rebecca L Cooper Laboratory was the first to show a 150% increase in transmembrane tumour
necrosis factor in the cortex of subjects with depression; an increase not apparent in schizophrenia.
Changes in the same protein have now been found in bipolar disorder as well.
Since tumour necrosis factor is a central molecule in the proinflammatory pathways, this initially suggested
that those pathways were affected in depression. However, new data suggest that changes in the brains of
people with mood disorders are more likely to reflect a role for tumour necrosis factor in cell to cell signalling.
Brian Dean and the team are now looking at the tumour necrosis factor driven pathways in mood
disorders to understand how they can cause depression.
Staff achievements
Brian Dean’s NHMRC Fellowship was renewed and he was elected President of Biological Psychiatry
Australia, President of the Melbourne Chapter of the Society of Neuroscience and Treasurer of Collegium
Internationale Neuro-Psychopharmacologicum, the Worldwide Neuropsychopharmacology Society.
Brian was also invited to address the announcement of the NHMRC Fellowship Program by the Honorable
Mark Butler MP, Minister for Mental Health and Ageing.
Elizabeth Scarr won an Australian Research Council (ARC) Future Fellowship, was a member of the
Executive Committee of the Australian Society for Psychiatric Research and is a member of the Executive
Committee of Biological Psychiatry Australia. Elizabeth was invited to the Ministerial announcement of the
ARC Future Fellowship Program where she met Senator Kim Carr, Minister for Innovation, Industry, Science
and Research.
Myoung Suk Seo and Won Je Jeon won travel awards to the Second Asian Congress of Schizophrenia
Research in Seoul, Korea.
15

Rebecca L Cooper Laboratory
continued
Conferences & presentations
Australian Society for Neuroscience, Sydney, Australia (January 2010)
Schizophrenia Research Society Conference, Florence, Italy (April 2010)
The CINP World Congress, Hong Kong (June 2010)
Combio, Melbourne, Australia (October 2010)
Society for Neuroscience, San Diego, USA (November 2010)
Annual Meeting of the American College of Neuropsychopharmacology, Miami, USA (December 2010)
Professor Brian Dean is head of the Rebecca L Cooper Laboratory and one of the longest serving researchers at the Mental Health Research Institute.
He leads a group of scientists working to better understand what happens in the brain of people who suffer depression, bipolar disorder and schizophrenia.
Much of his research utilises post-mortem brain tissue from the Victorian Brain Bank Network.
The image Brian holds is from an imaging study showing muscarinic receptors in tissue samples from the brains of people with schizophrenia. The one on
the right is from the subgroup identified by Brian’s team who have lost most of these receptors. 17

18
Behavioural
Neuroscience Laboratory
Head: Associate Professor Maarten van den Buuse
The Behavioural Neuroscience Laboratory uses behavioural animal models to study brain
neurotransmitter mechanisms involved in schizophrenia. We use state-of-the-art automated equipment
for in vivo experiments, including photocell activity meters, automated video analysis of behaviour,
prepulse inhibition of startle and models of learning and memory in rodents. This in vivo work is
complemented with human studies, receptor binding autoradiography, and molecular studies.
Highlights
Stress, BDNF and schizophrenia
The ‘two-hit’ hypothesis of schizophrenia states that stress early in development increases vulnerability
to later stressful events, leading to a higher risk of developing psychosis. Previous work in the laboratory
established animal models to study this interaction and suggested an important role of the neurotrophic
factor, BDNF.
Maren Klug continued her PhD project to study the effects of neurodevelopmental stress in geneticallymodified
mice that only produce about half of the normal levels of BDNF. These mice are being treated
with stress hormone. The long-term effects of this combined genetic and treatment approach is
characterised in a battery of behavioural tests, including learning and memory.
Rachel Hill was instrumental in establishing neurochemical methods to assess the impact of
neurodevelopmental stress on the brain, such as on BDNF levels and NMDA glutamate receptors.
While Maren’s initial work was done on mice from a breeding colony at the Mental Health Research
Institute, Sally Martin established a new breeding colony of these animals at the Florey Neuroscience
Institutes which will facilitate the transition of this work into the new Melbourne Brain Centre in 2011.
Elizabeth Manning commenced a PhD project looking at another aspect of this ‘two-hit’ model: chronic
treatment with metamphetamine, which may induce psychosis in vulnerable individuals.
Shane Thwaites also started a PhD project and established an EEG-based model of sensory gating
in rats. Shane is currently assessing the effect of different acute and chronic treatments relevant to
schizophrenia in this new animal model, which may become a valuable resource to investigate the effects
of neurodevelopmental factors in schizophrenia-like behaviour.
This work on neurodevelopmental stress and schizophrenia is supported by a Project Grant from the
National Health and Medical Research Council (NHMRC).

Reelin and behaviour
Paul Halley and Maaike Labots characterised behavioural changes in mice with a genetic deficit in reelin
production. This protein plays an important role in brain development and its levels are reduced in the
brains of patients with schizophrenia.
Reelin heterozygous mice showed marked sex-specificity in their behavioural changes. Further studies
by Jac Kee Low and Perrin Kwek demonstrated that removing the source of sex steroid hormones could
influence the behavioural deficits seen in these mice, as studied in behavioural tests of psychosis-like
behaviour and of sensory gating (the process by which the brain responds to external stimuli). The role
of reelin in schizophrenia was the subject of a successful project application to the NHMRC enabling this
work to continue in 2011.
Sex steroid hormones and neurodevelopment
Supported by a NHMRC Project Grant, Andrea Gogos and Perrin Kwek continued their pharmacological
studies on how oestrogen and testosterone can modulate behaviour and central neurotransmitter activity.
They published an extensive pharmacological study suggesting that oestrogen blocks disruption of
prepulse inhibition by an action on the dopamine system in the brain. Prepulse inhibition is a model of
sensory gating that is disrupted in schizophrenia. This effect of oestrogen was confirmed by receptor
binding studies performed by Carolina Chavez and Marianne Hollaus, which showed changes in
dopamine D2 receptor density and dopamine transporter density, but not several other neurotransmitter
parameters, in rats which had different circulating levels of oestrogen.
Rachel Hill continued her work on developmental aspects of sex steroid hormone involvement in
behaviour. She published on enhanced levels of BDNF in the hippocampus of mice with a genetic
deficit of the serotonin-2C receptor. She also demonstrated sex dependent and region-specific changes
in the activity of the BDNF receptor, TrkB, in mice with a genetic deficit of BDNF production. Candy Wu
commenced a PhD project and worked with Rachel to study the interaction of serotonin-1A receptor
function and BDNF in mice. This work is expected to elucidate the interaction of BDNF and serotonin in
developmental animal models of schizophrenia and depression.
19

20
Behavioural
Neuroscience Laboratory
continued
Glutathione
Levels of the endogenous radical scavenger, glutathione, are reduced in the brain in schizophrenia.
In collaboration with Ashley Bush, Michael Berk and David Copolov, Olivia Dean and Chris Choy published
research on an animal model of experimentally-induced glutathione depletion. Olivia described
disruptions of prepulse inhibition regulation in these animals, whereas Chris Choy showed that a previously
published deficit in short-term spatial memory could be reversed if the animals were treated with the
glutathione precursor, N-acetyl-cysteine.
These findings may help to understand the involvement of oxidative stress in schizophrenia and the
mechanisms by which drugs that counteract oxidative stress may be clinically beneficial.
Staff achievements
Maarten van den Buuse organised, chaired and presented a symposia at the CINP Congress in Hong
Kong, and at the Australasian Cognitive Neuroscience Conference in Melbourne.
Wendy Adams was awarded her PhD at The University of Melbourne (thesis title: Investigating the role of
serotonin in the hippocampus in schizophrenia: lesion studies in animal behavioural models) and is now
pursuing postdoctoral studies at the University of British Columbia, Vancouver.
Maaike Labots and Emma Ruimschotel completed internships (Honours equivalent) in the laboratory and
obtained their degrees at Leiden University and the University for Applied Science, Institute for Life Sciences
and Chemistry, Utrecht, The Netherlands, respectively. Jac Kee Low was awarded her BSc (Hons) degree at
The University of Melbourne.
Conferences & presentations
Australasian Schizophrenia Conference, Sydney, Australia (September 2010)
Serotonin Club meeting, Montreal, Canada (July 2010)
Society for Neuroscience meeting, San Diego, USA (November 2010)
Australian Neuroscience Society meeting, Sydney, Australia (January 2010)
Australasian Cognitive Neuroscience Conference, Melbourne, Australia (November 2010)
Collegium Internationale Neuro-Psychopharmacologicum Meeting, Hong Kong (July 2010)

John and Lorraine Bates have supported research at the Mental Health Research Institute through regular donation for over 20 years. “MHRI does ground
breaking research into mental illness” says John,“particularly schizophrenia, which is of great importance to us”. Because of the generosity of donors like John
and Lorraine, the Institute can complete high risk pilot projects that can lead to new discoveries, and purchase equipment that can accelerate research progress.
The image John and Lorraine hold shows a light micrograph of a section through the cerebellum of the brain.
21

22
Molecular Psychopharmacology /
Northern Psychiatry Research Centre
Head: Associate Professor Suresh Sundram
The Molecular Psychopharmacology Laboratory is dedicated to understanding the molecular pathology of
psychotic disorders such as schizophrenia and bipolar disorder. It aims to develop better and more effective
markers and interventions for these illnesses. We do this by investigating how psychotropic medications and
drugs interact with receptors and intracellular signalling mechanisms in nerve cells (neurons).
The understanding gained from this work can then be tested in clinical populations through the Northern
Psychiatry Research Centre (NPRC) leading to the development of new treatments and markers. Moreover,
the NPRC can collect clinical material and biological samples that can be examined in the laboratory to
better understand these disorders.
Highlights
Investigating how antipsychotic drugs work
The mainstay of treatment for psychotic disorders including schizophrenia and bipolar disorder are
antipsychotic drugs. These agents have been in use for over 50 years but we still have a limited
understanding of how they work.
The Molecular Psychopharmacology Laboratory has been working to understand why one antipsychotic
drug, clozapine, is effective in people for whom other antipsychotic drugs are not. From this we hope to
gain insight into the pathology of psychotic disorders and more effective ways of treating them.
We have previously described a novel pathway of action where clozapine interacts with the epidermal
growth factor (EGF) system to signal intracellularly to the mitogen activated protein kinase / extracellular
signal regulated kinase (MAPK/ERK) cascade in brain cells. The EGF system has been implicated in the
pathology of schizophrenia and is involved in regulating many cell and brain processes that may be
disturbed in the illness.
Avril Pereira and her team have subsequently been investigating which proteins are activated in the brain
consequent to clozapine treatment. In collaboration with Peter Crouch, David Bowser and Anthony White
from The University of Melbourne, this work received a three year NHMRC Project Grant commencing in
2010. Two further papers have been submitted for publication.
In parallel with the laboratory-based aspects of the project, Sujeevan Sinnatamby and the NPRC have
been collecting clinical data and biological samples from people who are receiving treatment with
clozapine. We will use these data to determine if there are specific genetic variants that can predict
response to clozapine treatment. Biological samples are being collected with the help of funding from the
Marian and EH Flack Trust.

The development of this type of screening test will
help prevent unnecessary exposure to the toxic
effects of clozapine for many people, and streamline
potential responders to earlier and more effective
intervention.
This work has been sustained by the generous and
ongoing support of One in Five to understand the
pathology of schizophrenia and hopefully develop
more effective interventions. Our preliminary data
have demonstrated results strongly supporting
our hypothesis that the EGF system correlates
with symptoms in people with treatment-resistant
schizophrenia treated with clozapine.
Sensory integration in schizophrenia
In collaboration with Olivia Carter and students,
the group is examining sensory deficits in
schizophrenia. Previous research has shown that
healthy individuals are both accurate and fast
when it comes to integrating visual information in
different areas of visual space. In contrast, people
with schizophrenia tend to be selectively impaired
on tasks that assess visual integration.
This study has demonstrated that integration of sensory
information is affected across a number of psychotic
disorders and shows some correlation with symptoms.
The group are currently testing whether this deficit
is also present in other sensory modalities. They
have developed an auditory version of the test in
conjunction with Dr Ken McAnally from Defence
Science and Technology Organisation (DSTO).
Such findings will inform us about the changes in
brain function with reference to specific symptoms
across the range of psychotic disorders.
Dr Avril Pereira knew that science was what she wanted to do from a very early age.
Her parents encouraged this interest and when she was still quite young gave her a fairly
serious microscope, which led Avril to dissecting leaves and pricking her thumb to draw blood
for examination. But it was early career work with patients at the Royal Melbourne Hospital that
really fostered her interest in medical research.
Avril has worked at the Mental Health Research Institute since 1996. She is now a senior
researcher in the Molecular Psychopharmacology Laboratory, examining how antipsychotic
drugs work in brain cells.
The image Avril holds is that of mouse cortex showing EGF receptors stained brown on the
surface of the neuron (brain cell). 23

24
Molecular Psychopharmacology /
Northern Psychiatry Research Centre
continued
Improved Health Care delivery
The NPRC, through Russell D’Souza, is undertaking
two major studies examining new treatments for
people with schizophrenia. They are also about
to commence three studies examining new
treatments for people with bipolar disorder and
major depression opening new therapeutic options
for these illnesses. Through grant funding from
beyondblue, Suresh Sundram and the Northern
Clinical Research Centre demonstrated that
acculturation is a significant mediator of major
depression and anxiety in people with chronic
physical disorders.
Staff achievements
Suresh Sundram was appointed as an external
consultant to the Australian Human Rights
Commission on mental health issues. In
conjunction with Alison Harrington and Gary
Ennis, Suresh also received a Gold Medal in the
2010 Victorian Public HealthCare Awards for their
novel method of patient observation in acute
adult psychiatric inpatient units, which resulted in
improved patient and staff safety.
Vaidy Swaminathan received a three year postgraduate
scholarship from the Schizophrenia
Research Institute.
Avril Pereira was awarded an Early Career
Investigator Award by the Australasian
Schizophrenia Conference.
Conferences & presentations
IndoGlobal Psychiatry Initiative Annual Meeting,
Jaipur, India (January 2010)
Schizophrenia International Research Conference,
Florence, Italy (April 2010)
International Mental Health Conference:
Schizophrenia: Where do we go from here?,
Invercargill, New Zealand (May 2010)
Collegium Internationale Neuro-
Psychopharmacologicum Meeting,
Hong Kong (July 2010)
Australasian Schizophrenia Conference,
Sydney, Australia (September 2010)
Biological Psychiatry Australia Meeting,
Melbourne, Australia (September 2010)
International Conference on Schizophrenia,
Chennai, India (October 2010)
Society for Bipolar Disorder India,
Mumbai, India (October 2010)
The Melbourne Brain Symposium,
Melbourne, Australia (November 2010)

Neuropathology Laboratory
Head: Professor Colin Masters
This group is building a better understanding of the molecular mechanisms that contribute to
Alzheimer’s disease.
Specifically, the work aims to isolate the proteins responsible for the neuro-toxicity observed in
Alzheimer’s disease. Isolation of the protein species responsible for Alzheimer’s disease would provide
a great insight into how the disease is caused and its processes.
New information would be used to guide the development of new drugs to prevent or stop the
progression of the disease.
Highlights
Disease marker identification
Over the past year we have improved our techniques to look at peptides in the blood through an
international collaboration with Professor Edward Dratz from Montana State University. Preliminary results,
obtained by Scott Lafoon, indicate that there are several differences in proteins present in diseased
individuals as compared to healthy people. We are continuing the collaboration and aim to identify
proteins that may provide an early diagnosis of Alzheimer’s disease.
Isolation of toxic proteins
In our quest to identify the protein responsible for cell death in Alzheimer’s disease, we have further
developed the methods by which we isolate proteins. By using a wide variety of techniques we are able to
isolate several different forms of the most likely protein, the amyloid beta (Aß) peptide. We are now in the
process of developing further techniques to stabilise this protein for further characterisation. To achieve
high quality identification of the proteins using an advanced Mass Spectrometer we have developed a
collaborative arrangement with Dr Tara Pukala from Adelaide University.
In addition, we have moved from small scale methods to a much larger preparative protocol, which
should provide quite a large amount of protein for future identification and biophysical studies.
Identification of detergent agents to inhibit amyloid formation
An important step toward the overall objective to identify toxic proteins involved in Alzheimer’s disease is
the use of detergents to release proteins from the tissue. In addition to releasing protein, these detergents
are also useful for keeping the isolated protein stable so that further studies may be conducted.
Thus we decided to identify detergents able to reduce the aggregation of the Aß peptide. We screened
96 detergents and identified 30 compounds that inhibit the aggregation process. These detergents will
now be used to further improve our isolation protocols.
25

26
Oxidation Biology Laboratory
Head: Professor Ashley Bush
The Oxidation Biology Laboratory conducts research into Alzheimer's disease and other
neurodegenerative illnesses including Parkinson's disease, Motor neurone disease, Huntington's disease,
dementia with Lewy Bodies and Niemann Pick Disease Type C.
Directed by NHMRC Australia Fellow Professor Ashley Bush, the laboratory examines three major themes in
order to develop new therapeutic approaches based on insights gained:
• Oxidative stress in neurological disorders;
• The molecular and cellular basis of neurotoxicity associated with the deposition of aggregating proteins
in neurodegenerative disorders;
• Understanding the interactions between cellular proteins and biologically important metals.
Researchers believe that the hallmark proteins associated with Alzheimer's disease - the Amyloid Precursor
Protein (APP) and its cleavage product amyloid beta (Aß) - are components of the system that regulates
the import and export of the vital trace metals - copper, zinc and iron - within the brain. Even a subtle
imbalance in the normally tight regulation of metals can permit these proteins to interact abnormally and
generate destructive free radicals by redox chemistry.
Highlights
James Duce identified a novel role for APP as a ferroxidase, involved in regulating iron levels within cells.
These ground-breaking results, which showed that the iron-regulating (or ‘ferroxidase’) activity is 75%
decreased in Alzheimer’s disease brain tissue, were published in the high impact ‘Cell’ journal and help
to explain the elevation of iron in neurons in Alzheimer’s disease.
This paper has since opened up a large field of enquiry that ramifies to other organs and diseases,
with separate new projects developing on systemic and brain iron homeostasis. As a testament to
the importance of these findings, James has been invited to present lectures at several international
conferences and universities throughout the year, and also wrote an intensive review entitled ‘Biological
Metals and Alzheimer’s disease: Implications for Therapeutics and Diagnostics’ which was recently
published in the Progress in Neurobiology journal.
James has also been actively involved in an additional line of research, in close collaboration with Blaine
Roberts and other external research groups. Together they are determining the importance of copperbinding
in superoxide dismutase 1 (SOD1). This work is of relevance to amyotrophic lateral sclerosis, a form
of Motor neurone disease, which affects nerve cells in the brain and spinal cord that control voluntary
muscle movement.
Linh Lam holds an image showing a light micrograph of a section through the cerebellum of the brain.

Ya Hui Hung continued to investigate the interaction of copper and cholesterol and how these interactions
may impact on the neurodegenerative process. This work was discussed in her major review article on
the role of copper in the brain and Alzheimer’s disease published in the Journal of Biological Inorganic
Chemistry. A figure illustrating the copper transport pathway in brain cells prepared by Ya Hui also
featured on the journal cover.
In 2010, Ya Hui established a novel line of research for our laboratory into Niemann Pick Disease Type C
(NPC or ‘Childhood Alzheimer’s’). This fatal neurodegenerative disorder shares a number of pathological
features with Alzheimer’s disease. The project will investigate the role of metals in the pathogenesis of NPC
and related diseases. Preliminary findings showed that, in parallel to Alzheimer’s disease, there are indeed
changes in metal content in the brain tissue from a mouse model of NPC. This work helped to forge a new
collaboration with Dan Ory from Washington University School of Medicine.
C. elegans Ageing and Neurodegeneration Unit
Gawain McColl operates our invertebrate laboratory in which he is developing transgenic models
for Alzheimer's and Parkinson's diseases. He established a roundworm ‘C. elegans’ model of
neurodegeneration in which he plans to examine the role of metals in ageing, as well as to discover
and evaluate new drugs to treat these neurodegenerative conditions. An article related to this work was
published in Cell Metabolism and describes how lowered insulin-like signalling results in metabolic and
physiological changes that impact on lifespan.
27

28
Oxidation Biology Laboratory
continued
Translational Medicine Unit
In partnership with Melbourne pharmaceutical
company Prana Biotechnology Ltd, Robert Cherny
and David Finkelstein have overseen a team
responsible for biological evaluation of a novel
drug for the treatment of Parkinson's disease.
Preclinical performance of the drug, PBT434, was
presented at the 2nd World Parkinson's Congress in
Glasgow in September 2010.
Achievements
Ashley Bush received the Royal Australian
and New Zealand College of Psychiatrists
Schering-Plough Senior Research Award and
was successful in obtaining both a Senior
Principal Research Fellowship and an Australia
Fellowship from the National Health and Medical
Research Council. The highly prestigious Australia
Fellowship was awarded for his proposal entitled
‘Translational Therapeutics and Diagnostics for
Alzheimer’s Disease’.
The group also received a NHMRC Project Grant,
ARC Linkage Grant and NHMRC Program Grant.
Conferences & presentations
4th Annual Alzheimer's and Parkinson's Disease
Symposium, Sydney, Australia (April 2010)
RANZCP 2010 Congress, Auckland, New Zealand
(May 2010)
American Aging Association’s 39th Annual Meeting,
Portland, Oregon, USA (June 2010)
The Alzheimer's Association International
Conference on Alzheimer's Disease, Honolulu, USA
(July 2010)
2nd World Parkinson Congress, Glasgow, UK
(September-October 2010)
CSIRO Preventative Health Flagship Scientific
Retreat, Adelaide, Australia (October 2010)
The 60th Fujihara Seminar ‘Zinc Signal and Cellular
Functions’, Osaka, Japan (October 2010)
2nd Metallomics Research Forum, Kyoto, Japan
(November 2010)
Boden Research Conference 2010 ‘Metals
in Biological Systems’, Canberra, Australia
(November-December 2010)

Synaptic Neurobiology Laboratory
Heads: Dr Paul Adlard and Associate Professor David Finkelstein
This laboratory focuses on understanding the role of metals in both normal and pathological aging,
with a specific focus on understanding the basic cellular requirements for normal learning and memory.
These studies will help provide direction for future drug therapy into conditions such as Alzheimer’s
disease and normal age-related cognitive decline.
Work in this Unit is funded by the Joan and Peter Clemenger Trust.
Highlights
Paul Adlard showed that the loss of presynaptic zinc release into the cortical glutamatergic synapse
causes cognitive impairment. The animal model involved (ZnT3 knockouts) could be regarded as a
phenocopy for Alzheimer’s disease, where synaptic zinc is trapped by amyloid and does not reach critical
post-synaptic targets. He also found that ZnT3 levels decline with ageing, and that cognitive loss in aged
mice (and in ZnT3 knockout mice) is rescued by treatment with zinc ionophores clioquinol and PBT2.
These drugs, in development for Alzheimer’s disease, may therefore have potential as treatment not only
for Alzheimer’s disease, but also for age-related cognitive decline – a much more common complaint
(Adlard et al, Journal of Neuroscience, 2010).
The group presented a winning bid to host the next International Society for Zinc Biology meeting, to be
held in Melbourne, Australia in January 2012. This conference will bring scientists together from around the
globe to share their latest results in the field of zinc biology.
During 2010, we also initiated collaboration with researchers to provide us with a mouse model of
schizophrenia (M1 knockout). This model will allow us to explore the underlying mechanisms of the
impaired working memory that characterises schizophrenia.
Conferences & presentations
Zinc Signalling and Cellular Functions meeting, Osaka, Japan (October 2010)
Australian Neuroscience Society, Auckland, New Zealand (January 2010)
29

30
Clinical Research Group
Head: Dr Kathryn Ellis
The Clinical Research Group aims to detect and understand biological, clinical and cognitive
differences between healthy ageing and dementia, including Alzheimer’s disease. The group
collects, stores and analyses data from human participants and human tissue samples.
The multi-disciplinary team includes neuropsychologists, research nurses, molecular biologists,
neuroimagers and bioinfomaticians. The group is currently involved in:
• Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing;
• the Dominantly Inherited Alzheimer’s Network (DIAN) study;
• the Rates of Change in Cognition (ROCS) study;
• the AIBL Active Clinical Trial;
• the Older Australian Twin Study (OATS);
• Dementia Collaborative Research Centre - Early Risk Diagnosis and Prevention.
Highlights
The AIBL Study
The group has assessed and analysed data from over half of the 1112 person cohort. Scientists are currently
analysing data looking for early diagnostic markers. The first phase of this study has been successfully
completed and resulted in the partner Universities and organisations committing to a second phase of the
AIBL study, which will run until 2013. Early results suggest some promising areas to explore further.
Alan Rembach received funding from The Mason Foundation for a project that aims to develop a
non-invasive blood-based test that can be used to determine an individual’s risk and/or provide early
diagnosis of Alzheimer’s disease. Alan is working with Blaine Roberts, using high throughput, multiple
analyte detection platforms, to detect plasma metals to help identify those at risk of developing the
disease. The Mason Foundation has funded the project as part of its efforts to achieve enduring positive
impact in the areas of Chronic Fatigue Syndrome and Alzheimer’s disease through medical research.
Work on finding a potential biomarker commenced using High Performance Liquid Chromatography
(HPLC) to fractionate AIBL baseline plasma samples. Proteins were further separated using 2D sodium
dodecyl sulphate Polyacrylamide gel electrophoresis (SDS-PAGE). Work is continuing to identify proteins
that vary in controls versus Alzheimer’s participants.
Fifteen years ago, Bill Moseley heard Professor Colin Masters talking about his research on the radio. He was calling for healthy ageing volunteers to take part.
Bill had recently retired and, encouraged by his wife, decided he could spare the time to help out.
Bill didn’t have any friends or family with dementia. He just thought it was a worthwhile cause, and one that he was in a position to help. Since then Bill has
completed numerous memory tests, MRI scans and blood tests and even a lumbar puncture as a volunteer for a range of studies including the current Australian
Imaging Biomarkers and Lifestyle (AIBL) study of ageing.
The image Bill holds shows how the plaques in Alzheimer’s disease are seen in post-mortem brain tissue when viewed under a miscroscope.

32
Clinical Research Group
continued
NHMRC success and a physical exercise trial
The group began a new NHMRC funded trial in collaboration with the National Ageing Research
Institute. The AIBL Active study is led by Professor Nicola Lautenschlager and will build on previous work
to investigate the effectiveness of physical activity in delaying the progression of cognitive decline and
cardiovascular disease (as measured by brain imaging). This is one of four new studies associated with
AIBL that were successful in receiving NHMRC grants for 2011.
Rate of Change Study
The AIBL Rate of Change Study (AIBL- ROCS) is nearing completion. Nearly 200 volunteers from the AIBL
group have been assessed at short intervals (1-3 months apart) with a brief cognitive assessment.
The study aims to improve methods and trial design for future clinical studies of Alzheimer’s disease so that
subjects are required for shorter time frames in order to decide whether or not treatments are effective.
Data from this study has been presented at last year’s International Conference on Alzheimer’s Disease
(ICAD) and the study has been well received by participants.
Dominantly Inherited Alzheimer’s Network
The DIAN study led by Washington University School of Medicine in St. Louis is a six-year, $16 million
international research collaboration dedicated to understanding dominantly inherited forms of
Alzheimer’s disease. This rare form of the disease is caused by an inherited genetic mutation and usually
strikes earlier in life.
Investigators hope to enrol volunteers from various USA sites, one site in the UK, and an Australian consortium.
MHRI’s Clinical Research Group is leading Melbourne’s contribution to this important study.
Internal growth
Due to growth in research activity, four Neuropsychology research assistants have joined the group to
assist with ongoing assessment of AIBL participants. The team has also grown to include four post-doctoral
research students.
A new Liquid Nitrogen tank has been custom made and delivered to cater for ongoing participant sample
storage and to house future replenishments of the AIBL cohort and other CRG’s study samples.

Dementia Collaborative Research Centres
The group is playing a key role in phase two of the Dementia Collaborative Research Centres (DCRC),
being a partner of DCRC - Early Risk Diagnosis and Prevention. We have a number of projects focusing on
blood biomarkers for Alzheimer’s disease, in addition to a study of a brain imaging compound which may
have clinical utility in the coming years. This exciting work is being conducted in collaboration with the
Australian National University, Austin Health and Edith Cowan University among other DCRC partners.
Knowledge transfer
The CRG disseminates its research to both the scientific community and the general public. Research from
our group has been presented at a number of scientific conferences, as listed below.
In conjunction with Alzheimer’s Australia, Victoria, we hold a yearly function for participants in the
AIBL study. This includes presentations from leading scientists and provides a forum for questions and
discussion. Participants are also kept up to date via regular mail-outs.
Conferences & presentations
Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) and Related Disorders,
Hawaii, USA (July 2010)
International Psychogeriatric Association (IPA) Regional Meeting,
Santiago de Compostela, Spain (September 2010)
14th Congress, Pacific Rim College of Psychiatrists,
Brisbane, Australia (October 2010)
43rd National Conference of the Australian Association of Gerontology,
Hobart, Australia (November 2010)
Science of AIBL Day,
Melbourne, Australia (December 2010)
33

34
Clinical Discovery Unit
Head: Professor Michael Berk
The Clinical Discovery Unit aims to further understand the underlying pathology of mental illness and to
assist in the discovery of better treatments for people with these illnesses.
This collaboration between Barwon Health and the Mental Health Research Institute is investigating
oxidative and inflammatory stress and psychiatric illnesses. At present, the group is conducting clinical
trials investigating antioxidant treatments for psychiatric illnesses and working together on laboratorybased
projects aimed at clarifying the underlying mechanisms.
As part of the successful Cooperative Research Centre (CRC) bid, a number of trials developing novel
therapies based on these pathways are pending.
The Unit is involved in a range of trials to test the benefits of the antioxidant N-acetyl cysteine (NAC) on the
symptoms of disorders including bipolar disorder, depression and autism. In conjunction with these trials,
magnetic resonance spectroscopy is being used to investigate changes in biomarkers following NAC treatment.
Highlights
NAC in bipolar disorder
In this trial all participants were given NAC for two months, after which participants were randomised to
either continue NAC treatment or receive a placebo. Participants continued on the trial for a further six
months and regular interviews were conducted to assess changes in participants’ symptoms. This study
has been completed with the open label phase showing promising results. Results of the maintenance
(randomised) phase will be available in the coming year.
NAC in major depression
This clinical trial is using a double blind, randomised design. As with the bipolar disorder trial, participants
are maintained on their usual treatment and in addition were given either NAC or placebo. Participants
take trial medication for three months. Four weeks following the end of the trial, a follow-up visit is
conducted to establish how participants’ symptoms have changed following the discontinuation of NAC.
The recruitment for this study exceeded the target of 180 participants with 269 people currently taking part.
Recruitment will cease in late January 2011 and results will be analysed midyear.
NAC in autism
There is a lack of evidence clearly exploring the underlying pathophysiology of autism. This disorder not
only has a debilitating effect on the child diagnosed, but also a large impact on the families of people
who care for these children.

Current treatments are often suboptimal and
many have little supporting scientific evidence.
There is however, evidence to suggest alterations
in oxidative and inflammatory pathways in autism
that may contribute to the disorder.
The new study aims to investigate NAC (compared
to placebo) in a small group of children with newly
diagnosed autism. The trial will include a six month
treatment phase followed by two discontinuation
visits to assess the child’s progress both while on
NAC and after completion of the trial. This project is
being undertaken by PhD student, Kristi Villagonzalo.
Future directions
In addition to our new trial in autism, Michael Berk
and his team are planning to explore alternative
treatments to depression and early intervention
in mood disorders. A series of projects examining
the biological foundations of both psychiatric
illness and the effect of NAC are planned. These
include MRS studies, analysis of peripheral markers,
and investigation of the relationship of biological
markers to changes in symptomatology. Studies
of mitochondrially acting agents for bipolar
disorder, and of statins and aspirin in depression
are planned as part of the Cooperative Research
Centre (CRC).
Staff Achievements
In 2010, the Unit has received a National Health
and Medical Research Council (NHMRC) Project
Grant, two separate Australian Rotary Health
Research Fund grants, a successful application for
a NHMRC Post Doctoral Training Fellowship, grants
from commercial partners and continued support
from the Stanley Medical Research Institute.
Conferences & presentations
ISBD Biennial Conference 2010,
Sao Paulo, Brazil (March 2010)
IMH 2010 Masterclass,
Vancouver, Canada (April 2010)
International Society for Affective Disorders 5th
Biennial Conference,
Vancouver, Canada (April 2010)
163rd Annual Meeting American
Psychiatric Association,
New Orleans, Louisiana, USA (May 2010)
Collegium Internationale Neuro-
Psychopharmacologicum,
Hong Kong, China (June 2010)
Annual Norwegian Early Intervention Conference,
Bergen, Norway (September 2010)
Swedish Psychiatric Association,
Gothenburg & Malmoe, Sweden (October 2010)
Danish Society of Affective Disorders,
Copenhagen, Denmark (October 2010)
Society for Neuroscience Meeting,
San Diego, California, USA (November 2010)
Australasian Society for Psychiatric Research,
Sydney, Australia (December 2010)
35

36
Victorian Brain Bank Network
Head: Professor Catriona McLean
The Victorian Brain Bank Network (VBBN) collects, processes and stores post-mortem human brains
and related samples from individuals who have had neurological diseases (i.e. Alzheimer’s disease,
Motor neurone disease and Parkinson’s disease) or psychiatric disorders (i.e. bipolar mood disorder,
depression and schizophrenia), as well as normal ‘control’ cases.
The VBBN facilitates the study of brain diseases by providing tissue to researchers who use current
technologies to unlock our understanding of how brain diseases occur. It is hoped that this will
lead to improvements in diagnosis including early diagnostic tests, therapeutic interventions and
preventative strategies.
The VBBN also provides a vital neuropathological diagnostic service and supports continued education of
medical and allied health professionals.
Highlights
Brain and/or spinal cord donations
The VBBN has a total of 895 cases available for research, with 45 new donations received in 2010. New
donations included cases diagnosed with Alzheimer’s disease, Frontotemporal dementias, Huntington’s
disease, Lewy body disease, Motor neurone disease, Multiple sclerosis, Parkinson’s disease, schizophrenia
and control ‘normal’ cases. The VBBN collection makes up 42% of the cases that are available for
research within Australia.
Tissues provided to researchers
The VBBN provided tissue to 56 Australian and international research projects in 2010. The main research
focus of these new and existing projects included Alzheimer’s disease and other dementias, Motor
neurone disease, schizophrenia and bipolar disorder. The Rebecca L Cooper Research Laboratory and
the Oxidation Biology Laboratory located at MHRI were among the tissue recipients.
This equates to 5,849 diseased and ‘control’ samples being provided to researchers.
Research outcomes utilising tissue from the VBBN resulted in 49 Australian and International publications
and presentations in 2010.

Conferences & presentations
International Society for Biological and Environmental Repositories (ISBER), ‘Diversity in Biobanking:
Embracing differences, harnessing commonalities’, Rotterdam, The Netherlands (May 2010)
Acknowledgment
The VBBN would like to acknowledge the generosity shown by the donor and donor families in donating
tissue to the VBBN. It is an act of great foresight and kindness to give at a time of loss, so that others may
be helped in the future. The clinicians and researchers who benefit from these donations are very grateful
to the donors and their families who support them in these decisions.
37

38
Psychotropic Drug Advisory Service
Head: Professor Nicholas Keks
The Psychotropic Drug Advisory Service provides the latest information on medicines used in psychiatry,
as well as other drugs that can affect behaviour, thought and perception. Unbiased information is
provided to psychiatrists, other medical practitioners, health care providers, consumers, carers and
support agencies.
The service responds to approximately 2000 enquiries each year. Most are received by telephone,
however email enquiries are increasing. Requests for in-service training seminars and presentations to
consumer and carer groups are welcome.
The Department of Health funds the service and clinical support is provided by Professor Nicholas Keks at
Monash University.
Highlights
Medications play an integral role in health management for people with a mental illness to alleviate the
distressing symptoms that they experience. Managing these illnesses often requires the combination of a
number of therapies that must be adapted and tailored to the unique needs of the individual.
Drug treatments for mental illness are far from ideal and do not provide a cure. For some, the first
medication they trial resolves their symptoms with few adverse effects. Others trial numerous options
before optimal treatment is achieved. Finding an acceptable balance between therapeutic benefits and
side effects is not always easy. Routine monitoring is required to ensure patient safety.
The Psychotropic Drug Advisory Service can advise on current treatment options, comparison of agents,
possible interactions with other medicines or complementary treatments. Information is available on the
use of medicines in special groups such as the elderly, young, those with other physical conditions and
pregnant or breast feeding women.

Presentations
Each year Christine Culhane provides current information to a variety of professional and
community groups.
Christine presented a poster at the Collegium Internationale Neuropsychopharmacologicum Biannual
Congress in Hong Kong in June 2010 and was invited to present at a satellite meeting of the Pharmacy
Australia Congress for the Australian Association of Consultant Pharmacists in Melbourne in November.
Strong links are maintained with a number of community groups and carer support organisations across
Victoria including MIND Australia, and the Association of Relatives and Friends of the Emotionally and
Mentally Ill. A number of presentations to staff and consumer carer groups have been provided.
Professional Development
It is important in an ever changing environment to maintain currency and keep abreast of drugs in
development, newly marketed drugs, adverse events and best practice. Reviewing the latest literature as
well as attending professional development forums ensures that the information provided maintains a
high quality and is current.
Conferences & presentations
CINP: Biannual meeting of the International College of Neuropsychopharmacologicum,
Hong Kong (June 2010)
Society of Hospital Pharmacists of Australia Annual Meeting,
Melbourne, Australia (November 2010)
Pharmacy Australia Congress Australian Association of Consultant Pharmacists Forum,
Melbourne, Australia (November 2010)
39

The Dax Centre
Head: Dr Eugen Koh
New beginnings
The Dax Centre promotes mental health and wellbeing by fostering a greater understanding of the
mind, mental illness and trauma through art and creativity. The Dax Centre has emerged out of the
Cunningham Dax Collection, which has operated as a Unit within the Mental Health Research Institute
(MHRI) for the past 20 years.
The Centre is preparing for a series of transitions that will take effect in 2011. It will move from being part
of MHRI to being an independent incorporated entity, and from being an art gallery to becoming a
multifaceted organisation: a hub for all who are interested in the art and mind.
As part of the change, the Dax Centre is due to relocate to the new Melbourne Brain Centre facility at
The University of Melbourne in late 2011. The new gallery will feature a semi-permanent exhibition and an
access gallery for three temporary exhibitions each year. Two of these exhibitions will display works from
the Cunningham Dax Collection, while one will feature work from external groups and organisations. This
purpose built space will provide a state-of-the-art gallery, education resource centre, media room and
curatorial and storage space, ensuring the long-term future of the Collection.
The Cunningham Dax Collection, which has been in operation for more than 30 years, will continue
to exist in its own right as a collection of creative works within the Dax Centre. It is anticipated that this
internationally recognised collection will continue to grow from comprising 15,000 works to over 20,000
works over the next five to ten years.
In the past, the centre has focused on the collection and exhibition of art by people with experience of
mental illness or trauma. In recent years, it has evolved to become a multifaceted institution where the
emotional world is explored through art in many different ways. In addition to the usual activities of an art
institution, such as acquisition, preservation and exhibition, the Dax Centre has developed an education
program that is more assertive and diverse than those commonly found in galleries and museums.
Graeme Doyle, ‘Untitled’, 1978, ballpoint pen and coloured pencil on paper, 36 x 27 cm
Image across: Dr Eugen Koh first joined the Cunningham Dax Collection in 1999 as Senior Lecturer in Art in Psychiatry. He became the director when Dr Eric
Cunningham Dax retired in 2002. He is a consultant psychiatrist and psychoanalytic psychotherapist in private practice. He chairs the Art in Mental Health
Working Group at St Vincent’s, which explores ways of using creative arts in a modern mental health service. Eugen is also a painter himself. The artwork Dr
Eugen Koh holds is one of the works from the Cunningham Dax Collection, now a part of the Dax Centre. 41

42
The Dax Centre
continued
Education
The Dax Centre continued its successful collaboration with MHRI in running Mindfields, an innovative
education program that incorporates art, mental health and neuroscience. It provides an invaluable
educational resource to VCE students and teachers in regional and metropolitan schools and is the only
program of its kind in Australia.
The education team also continued work on the Dax Pack, a new educational resource for Year 11 and
12 Psychology students and teachers. It will provide ideas and activities to assist teachers to create a
safe and supportive classroom environment for teaching about mental health. The Dax Pack will address
frequently held myths and misconceptions associated with mental illness through engaging, classroom
based activities and will also provide online interactive activities for VCE students.
Exhibitions
Throughout 2010, the Centre continued to expand its exhibition program, touring exhibitions to more
regional and rural areas, including Orange, Wodonga and Parliament House in Canberra.
Onsite exhibitions explored a range of themes and included a collaboration with the Jewish Holocaust
Centre, resulting in Out of the Dark: the Emotional Legacy of the Holocaust - a selection of artworks made by
survivors, child survivors and children of survivors of the Holocaust. It explored the psychological effects of
the Holocaust within and throughout these generations.
This was followed by Avoiding the Void, an exhibition that reflected on and engaged with existential ideas
and concerns, and Youth, Interrupted, which presented artworks created by young people in their teens
and twenties whose lives were disrupted by mental illness or trauma. The works used in this exhibition
were created in a variety of contexts ranging from psychiatric hospital art programs (1950s–1980s) to
contemporary settings, including private studios, community art programs, VCE and tertiary art programs,
and a Sri Lankan disaster relief camp.
The final exhibition of 2010 was Picturing Mother and Child, which featured artworks from the Cunningham
Dax Collection that depicted the mother-child relationship, exploring them from psychoanalytic and art
historical perspectives.

‘000 Funding
$320
$100
$220
$250
$50
$10 Donations
State government - general operations
State government - projects
Philanthropy - general operations
Philanthropy - projects
Revenue from programs
Research
The Centre continues to develop the Art and the Emotional World of Children project, designed to
enhance the emotional literacy of primary-aged children through art. Led by the Dax Centre, a group of
primary school teachers and mental health and art therapy consultants are working together to establish
the model for the program, which will include practical activities based around the art curriculum.
It will produce unique innovative educational resources, a legacy that will benefit generations to come.
The program will be trialled in several primary schools in Melbourne in 2011 with the aim of widespread
implementation through teacher training by 2013.
Funding
The Dax Centre receives funding from the Victorian Government and philanthropic trusts for its core
operations. Outreach programs such as touring exhibitions, its rural education program and other
innovative projects are dependent on funding from philanthropic trusts and private donors.
Onsite Exhibitions
Picturing Mother and Child, 17 November 2010 - 9 April 2011
Youth, Interrupted, 15 April - 6 November 2010
Avoiding the Void, 3 February - 10 April 2010
Out of the Dark: the Emotional Legacy of the Holocaust, 21 October 2009 - 23 January 2010
Touring Exhibitions
Beyond the Three Trees, Orange Regional Gallery, 16 April – 30 May 2010
Healing Childhood Trauma, Family Therapy Conference, Melbourne Exhibition Centre, 6 – 8 October 2010
Beyond the Three Trees, Wodonga Arts Space, 13 October – 7 November 2010
Healing Childhood Trauma, Parliament House, Canberra, 8 November – 10 December 2010
43

44
Development and Communications
Head: Mr Ross Johnstone
The Development and Communications Unit is responsible for raising funds for research and awareness
of the Institute and its work. Investment in research through philanthropy is essential if the Institute is
to continue to pursue new and innovative pilot projects that might not otherwise be funded through
competitive scientific grants. We are very grateful to the individuals, businesses and philanthropic trusts
and foundations that support us.
Program and equipment funding
While competition for philanthropic funding continues to increase, we have been fortunate to receive
project grants from the Joan and Peter Clemenger Trust, The Marian and EH Flack Trust and The Mason
Foundation, as well as generous ongoing support from a number of trusts as listed in the donation pages
of this report.
A number of major gifts from individuals have enabled the purchase of new equipment, often in memory
of loved ones who have passed away after a struggle with psychiatric or neurodegenerative illness.
Events
The Institute continued its partnership with the Royal Yacht Club of Victoria to hold the 4th annual Mental
Health Cup in February 2010. Businesses each sponsored one of eighteen yachts that raced across the
bay with their corporate guests. A raffle on the day added to the excitement of the trophy presentations
and helped contribute to the $50,000 raised through this event.
A new team member was recruited to coordinate the growing number of events aimed at raising both
funds and awareness. MHRI hosted a popular Comedy Fundraiser held at the Comic’s Lounge in March
and is responsible for developing a new culinary event to be launched in April 2011, which is expected to
become a highlight of the Melbourne social calendar.

One in Five continue to present popular events to raise funds for research. A new board was formed and
is working to build the profile of the organisation. Participants in the annual Bolt Blowers Retro Surf event
enjoyed great weather for the first time in the 5-year history of the event. The Extremely Long Lunch was
held in August at Albert by the Lake and record numbers joined the Extreme Challenge in October as
they took on the Melbourne Marathon on World Mental Health Day. One in Five is a highly valued partner
providing vital funding for psychiatric research and we greatly appreciate the enormous amount of time
and effort this volunteer group puts into the activities undertaken. Particular thanks go to Ryan Wavish and
Linda Karafili who organise the Extreme Challenge every year.
MHRI also benefited from a fundraising dinner presented by Disha, who funded the purchase of a new
gel imaging system for the Rebecca L Cooper Laboratory.
Donor relations
Our individual donors play a huge role in the development of the Institute, providing ongoing funding for
new projects and for equipment imperative to our work. In 2010, we conducted our inaugural donor survey,
enhancing our understanding of who our donors are and how they would like us to engage with them.
Results are impacting the way we communicate with existing donors and how we appeal for new ones.
In recognition of the transformative impact donors can make by leaving a gift to a charity in their Will,
the Institute engaged an experienced Bequest Officer to develop a strategy and engage donors in
discussions about this method of support. As a result a number of donors have confirmed their intention
to leave a bequest to the Institute in their Will.
45

46
Development and Communications
continued
Outreach
The Institute continued to host school visits as part of the Mindfields education program for VCE
psychology students, presented in partnership with the Cunningham Dax Collection. Our researchers and
guest speakers from the Mental Illness Fellowship delivered talks about the brain and mental illness to over
200 VCE students many of whom travelled from rural and outer suburban schools.
The Institute launched a new program of casual but informative evenings called Wine & Wisdom.
Donors and others were invited to hear a short lecture on schizophrenia in May and Alzheimer’s disease in
September, before enjoying some conversation over a glass of wine.
Thanks to John and Alison Kearney, the Institute was again able to present both a public and a scientific
lecture by an esteemed international guest. The annual John Cade public lecture was presented by
Professor Julie Andersen, the MHRI Kearney Visiting Professor 2010 from the Buck Institute for Age Research
in California, who is an expert on Parkinson’s disease.
Development Council
As always, the Institute is grateful for the support of the Development Council, which provides invaluable
advice and assistance to help us achieve our fundraising and public relations goals. The Council is
chaired by the Institute’s Deputy Chair, Trevor Clark OAM, and includes fellow Board member, Rob Gerrand,
as well as other volunteer members drawn from the business community. We were pleased to welcome
David Dean to the committee this year.
Branding
Following the Institute’s Strategic Review, a major branding project was undertaken. A new logo, created
pro bono by The Egg, was adopted in September 2010 and the team is working to develop the brand
across all our communications.
Dr Eugen Koh holds one of the artworks from ‘Melancholia’, an upcoming exhibition at The Dax Centre.
Joan Rodriquez, ‘The Phantom’, 1991, mixed media on paper, 60.9 x 57.2 cm

48
Publications
Annual Report 2010
Adlard PA, Parncutt JM, Finkelstein DI, Bush AI: Cognitive Loss
in Zinc Transporter-3 Knock-Out Mice: A phenocopy for the
synaptic and memory deficits of Alzheimer’s disease?
Journal of Neuroscience 2010, 30(5):1631-1636.
Aggarwal S, Dodd S, Berk M. Restless leg syndrome
caused by olanzapine: a case series. Current Drug Safety.
2010:5(2) 139-141.
Barakat A, Scarr EL, Dean B, Evin G: Decreased neuregulin
c-terminal fragments in schizophrenia prefrontal cortex
brodmann’s area. Schizophrenia Research 2010, 124(1-3):
200-207.
Baum L, Chan IHS, Cheung SKK, Goggins WB, Mok V, Lam L,
Leung V, Hui E, Ng C, Woo J, Chiu HFK, Zee BCY, Cheng W,
Chan MH, Szeto S, Lui V, Tsoh J, Bush AI, Lam CWK, Kwok T:
Serum zinc is decreased in Alzheimer’s disease and serum
arsenic correlates positively with cognitive ability.
Biometals 2010, 23(1):173-179.
Berk L, Hallam KT, Colom F, Vieta E, Hasty M, Macneil C,
Berk M: Enhancing medication adherence in patients with
bipolar disorder. Human Psychopharmacology: Clinical
and Experimental 2010, 25(1):1-16.
Berk M, Dean O, Hewitt K, Bush A, Kapczinski F, Jeavons S,
Gama C, Malhi G, Copolov D, Cobb H, Fernandes B:
Glutathione and redox biology in Bipolar Disorder; from
pathophysiology to novel treatments. International Journal
of Neuropsychopharmacology 2010, 13(1):11.
Berk M, Dodd S, Dean OM, Kohlmann K, Berk L, Malhi GS:
The validity and internal structure of the Bipolar Depression
Rating Scale: data from a clinical trial of N-acetylcysteine
as adjunctive therapy in bipolar disorder. Acta
Neuropsychiatrica 2010, 22(5):237-242.
Berk M, Hallam K, Malhi GS, Henry L, Hasty M, Macneil C,
Yucel M, Pantelis C, Murphy B, Vieta E, Dodd S, McGorry PD:
Evidence and implications for early intervention in bipolar
disorder. Journal of Mental Health 2010, 19(2):113-126.
Berk M, Henry LP, Elkins, KS, Harrigan SM, Harris MG, Herrman H,
Jackson HJ, McGorry PD. The impact of smoking on clinical
outcomes after First Episode Psychosis: Longer-term outcome
findings from the EPPIC 800 follow-up study. The Journal of
Dual Diagnosis. 2010; 6: 212-234
Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I,
Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B,
Otmar R, Ng F, Copolov DL, Bush AI. Qualitative methods
in early-phase drug trials: Data and methods from a RCT of
trial of N-acetyl cysteine in schizophrenia. Journal of Clinical
Psychiatry. 2010; 34: 382-385.
Berk M, Ng F, Dodd S, Goldberg JF, Malhi GS: Do we need to
flick the switch? The need for a broader conceptualization
of iatrogenic course aggravation in clinical trials of bipolar
disorder. Psychiatry Clinical Neuroscience 2010, 64(4): 367-371.
Boer S, Sanchez D, Reinieren I, van den Boom T, Udawela M,
Scarr E, Ganfornina MD, Dean B: Decreased kainate
receptors in the hippocampus of apolipoprotein D knockout
mice. Progress in Neuro-Psychopharmacology and Biological
Psychiatry 2010, 34(2):271-278.
Boland MP, Hatty CR, Separovic F, Hill AF, Tew DJ,
Barnham KJ, Haigh CL, James M, Masters CL, Collins SJ:
Anionic phospholipid interactions of the prion protein n
terminus are minimally perturbing and not driven solely by the
octapeptide repeat domain. Journal of Biological Chemistry
2010, 285(42):32282-32292.
Boon WC, van den Buuse M, Wegener N, Martin S, Chua HK,
Bush AI, Masters CL, Adlard PA, Li Q-X: Behavioural
phenotype of APPC100.V717F transgenic mice
over-expressing a mutant A beta-bearing fragment is
associated with reduced NMDA receptor density.
Behavioural Brain Research 2010, 209(1):27-35.
Botella-Lopez A, Cuchillo-Ibanez I, Cotrufo T, Mok SS, Li Q-X,
Barquero MS, Dierssen M, Soriano E, Saez-Valero J: beta-amyloid
controls altered Reelin expression and processing in
Alzheimer’s disease. Neurobiology of Disease 2010, 37(3):682-691.

Publications
Annual Report 2010
Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P,
Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA,
Martins RN, Masters CL, Rowe CC, Salvado O, Grp AR:
beta-Amyloid burden in the temporal neocortex is related to
hippocampal atrophy in elderly subjects without dementia.
Neurology 2010, 74(2):121-127.
Boyd A, Klug G, Schonberger LB, McGlade A, Brandel JP,
Masters CL, Collins SJ: Iatrogenic Creutzfeldt-Jakob disease in
Australia: time to amend infection control measures for
pituitary hormone recipients? Medical Journal of Australia
2010, 193(6):366-369.
Brazier MW, Volitakis I, Kvasnicka M, White AR, Underwood JR,
Green JE, Han S, Hill AF, Masters CL, Collins SJ: Manganese
chelation therapy extends survival in a mouse model of M1000
prion disease. Journal of Neurochemistry 2010, 114(2):440-451.
Bush AI: Calcium is not all. Neuron 2010, 65(2):143-144.
Callaly T, Ackerly CA, Hyland ME, Dodd S, O’Shea M, Berk M:
A qualitative evaluation of a regional Early Psychosis Service
3 years after its commencement. Australian Health Review
2010, 34(4):382-385.
Callaly T, Hyland M, Trauer T, Dodd S, Berk M: Readmission to an
acute psychiatric unit within 28 days of discharge: identifying
those at risk. Australian Health Review 2010, 34(3):282-285.
Callaly T, von Treuer K, Dodd S, Berk M: Mental health services
for young people - the challenge of integrating services.
Acta Neuropsychiatrica 2010, 22(3):158-160.
Caragounis A, Price KA, Soon CPW, Filiz G, Masters CL, Li Q-X,
Crouch PJ, White AR: Zinc induces depletion and
aggregation of endogenous TDP-43. Free Radical Biology
and Medicine 2010, 48(9):1152-1161.
Castle D, Gilbert M, Lauder S, Murray G, Chamberlain J,
White C, Berk M, Berk L: Group-based psychosocial
intervention for bipolar disorder Reply. British Journal
Psychiatry 2010, 197(3):246.
Castle D, Holdsworth C, Chamberlain J, Berk M, Berk L,
Lauder S, Murray G, Schweitzer I, Piterman L, Gilbert M.
A randomised trial of a comprehenisive group-based
psychosocial intervention for bipolar disorder. British Journal
of Psychiatry. 2010; 196: 383-388.
Castle D, White C, Chamberlain J, Berk M, Berk L, Lauder S,
Murray G, Schweitzer I, Piterman L, Gilbert M: Group-based
psychosocial intervention for bipolar disorder:
randomised controlled trial. British Journal of Psychiatry 2010,
196(5):383-388.
Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A,
van den Buuse M: The effect of estrogen on dopamine and
serotonin receptor and transporter levels in the brain:
An autoradiography study. Brain Research 2010, 1321:51-59.
Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G,
Ames D, Ellis KA, Szoeke C, Martins RN, O’Keefe GJ,
Salvado O, Masters CL, Rowe CC and the Australian Imaging,
Biomarkers and Lifestyle Research Group: Relationship
between atrophy and ß-amyloid deposition in Alzheimer
disease. Annals of Neurology 2010, 67(3):317-324.
Chetelat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P,
Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN,
Ames D, Masters CL, Rowe CC and the Australian Imaging,
Biomarkers and Lifestyle (AIBL) Research Group: Larger
temporal volume in elderly with high versus low beta-amyloid
deposition. Brain 2010, 133(11):3349-3358.
Choy KHC, Dean O, Berk M, Bush AI, van den Buuse M:
Effects of N-acetyl-cysteine treatment on glutathione
depletion and a short-term spatial memory deficit in
2-cyclohexene-1-one-treated rats. European Journal of
Pharmacology 2010, 649(1-3):224-228.
Collins SJ, McGlade A, Boyd A, Masters CL, Klug G: 14-3-3
protein detection and sporadic CJD: the status quo serves
well while awaiting progress. Journal of Neurology,
Neurosurgery and Psychiatry 2010, 8(11):1181.
49

50
Publications
Annual Report 2010
Collins SJ, Schuur M, Boyd A, Lewis V, Klug GM, McGlade A,
van Oosterhout A, Breedveld G, Oostra BA, Masters C,
Van Duijn CM: No evidence for prion protein gene locus
multiplication in Creutzfeldt-Jakob disease. Neuroscience
Letters 2010, 472(1):16-18.
Conus P, Abdel-Baki A, Harrigan S, Lambert M, McGorry PD,
Berk M: Pre-morbid and outcome correlates of first episode
mania with psychosis: Is a distinction between schizoaffective
and bipolar 1 disorder valid in the early phase of
psychotic disorders? Journal of Affective Disorders 2010,
126(1-2):88-95.
Conus P, Cotton S, Schimmelmann BG, Berk M, Daglas R,
McGorry PD, Lambert M: Pretreatment and outcome
correlates of past sexual and physical trauma in 118 bipolar
1 disorder patients with a first episode of psychotic mania.
Bipolar Disorders 2010, 12(3):244-252.
Conus P, Ward J, Lucas N, Cotton S, Yung AR, Berk M,
McGorry PD: Characterisation of the prodrome to a first
episode of psychotic mania: Results of a retrospective study.
Journal of Affective Disorders 2010, 124(3):341-345.
Coulson CE, Williams LJ, Henry MJ, Berk M, Lubman DI,
Brennan SL, Nicholson GC, Kotowicz MA, Korn S, Pasco JA:
Patterns of alcohol use and associated physical and lifestyle
characteristics according to new Australian guidelines.
Australia and New Zealand Journal of Psychiatry 2010,
44(10):946-951.
Crouch PJ, Hung LW, Soon CP, Tew DJ, Perez KA, Adlard PA,
Bush AI, Masters CL, Cherny RA, Li QX, Donnelly PS,
Barnham KJ, White AR: The molecular mechanism of action
for metal-ligand complexes as potential therapeutics for
Alzheimer’s and other neurodegenerative diseases.
Journal of Neurochemistry 2010, 115(1):10.
Dean B, Cowie T, Sundram S, Pantelis C, Gibbons A, Scarr E:
decreased cortical muscarinic receptors define a subgroup
of subjects with schizophrenia. Schizophrenia Research 2010,
117(2-3):252.
Dean B, Tawadros N, Scarr E, Gibbons AS: Regionally-specific
changes in levels of tumour necrosis factor in the dorsolateral
prefrontal cortex obtained postmortem from subjects with
major depressive disorder. Journal of Affective Disorders 2010,
120(1-3):245-248.
Dean O, Bush AI, Berk M, Copolov DL, van den Buuse, M:
Interaction of glutathione depletion and psychotropic drug
treatment in prepulse inhibition in rats and mice.
Pharmacology, Biochemistry and Behaviour. 2010, 97(2):293-300.
Dignam P, Parry P, Berk M: Detached from attachment:
neurobiology and phenomenology have a human face.
Acta Neuropsychiatrica 2010, 22(4):202-206.
Dodd S, Brnabic AJM, Berk L, Fitzgerald PB, de Castella AR,
Filia S, Filia K, Kelin K, Smith M, Montgomery W, Kulkarni J,
Berk M: A prospective study of the impact of smoking on
outcomes in bipolar and schizoaffective disorder.
Comparative Psychiatry 2010, 51(5):504-509.
Dodd S, Kulkarni J, Berk L, Ng F, Fitzgerald PB, de Castella AR,
Filia S, Filia K, Montgomery W, Kelin K, Smith M, Brnabic A,
Berk M: A prospective study of the impact of subthreshold
mixed states on the 24-month clinical outcomes of bipolar 1
disorder or schizoaffective disorder. Journal of Affective
Disorders 2010, 124(1-2):22-28.
D’Souza, R, Piskulic D, Sundram S: A brief dyadic group based
psychoeducation program improves relapse rates in recently
remitted bipolar disorder: A pilot randomised controlled trial.
Journal of Affective Disorders 2010, 120(1-3):272-276.
Duce JA, Bush AI: Biological metals and Alzheimer’s disease:
Implications for therapeutics and diagnostics. Progessive
Neurobiology 2010, 92(1):1-18.
Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K,
Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH,
Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE,
Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI:
Iron-export ferroxidase activity of beta-amyloid precursor
protein is inhibited by zinc in Alzheimer’s disease. Cell 2010,
142(6):857-867.

Publications
Annual Report 2010
Dunai J, Labuschagne I, Castle DJ, Kyrios M, Rossell SL:
Executive function in body dysmorphic disorder.
Psychological Medicine 2010, 40(9):1541-1548
Eichelsdoerfer JL, Evans JA, Slaugenhaupt SA, Cuajungco MP:
Zinc dyshomeostasis is linked with the loss of mucolipidosis
IV-associated TRPML1 Ion Channel. Journal of Biological
Chemistry 2010, 285(45):34304-34308.
Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL,
Salvado O, Szoeke C, Ames D: Addressing population
aging and Alzheimer’s disease through the Australian
Imaging Biomarkers and Lifestyle Study: Collaboration with
the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s
and Dementia 2010, 6(3):291-296.
Evin G, Barakat A, Masters CL: BACE: Therapeutic target and
potential biomarker for Alzheimer’s disease. International
Journal of Biochemistry & Cell Biology 2010, 42(12):1923-1926.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo
J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M,
Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI:
PBT2 rapidly improves cognition in Alzheimer’s disease:
Additional Phase II Analyses. Journal of Alzheimers Disease
2010, 20(2):509-516.
Fink G, Editor in Chief. Stress of War, Conflict and Disaster.
Elsevier, Amsterdam 2010.
Fodero-Tavoletti MT, Villemagne VL, Paterson BM, White AR,
Li Q-X, Camakaris J, O’Keefe GJ, Cappai R, Barnham KJ,
Donnelly PS: Bis(thiosemicarbazonato) Cu-64 complexes for
Positron Emission Tomography imaging of Alzheimer’s disease.
Journal of Alzheimers Disease 2010, 20(1):49-55.
Francey SM, Nelson B, Thompson A, Parker AG, Kerr M,
Macneil C, Fraser R, Hughes F, Crisp K, Harrigan S, Wood SJ,
Berk M, McGorry PD: Who needs antipsychotic medication in
the earliest stages of psychosis? A reconsideration of benefits,
risks, neurobiology and ethics in the era of early intervention.
Schizophrenia Research 2010, 119(1-3):1-10.
Fullerton JM, Tiwari Y, Agahi G, Heath A, Berk M, Mitchell PB,
Schofield PR: Assessing oxidative pathway genes as risk
factors for bipolar disorder. Bipolar Disorders 2010,
12(5):550-556.
Gavrilescu M, Rossell S, Stuart GW, Shea TL, Innes-Brown H,
Henshall K, McKay C, Sergejew AA, Copolov D, Egan GF:
Reduced connectivity of the auditory cortex in patients with
auditory hallucinations: a resting state functional magnetic
resonance imaging study. Psychological Medicine 2010,
40(7):1149-1158.
George AJ, Gordon L, Beissbarth T, Koukoulas I,
Holsinger RMD, Perreau V, Cappai R, Tan SS, Masters CL,
Scott HS, Li Q-X: A serial analysis of gene expression profile
of the Alzheimer’s disease Tg2576 Mouse Model.
Neurotoxicology Research 2010, 17(4):360-379.
George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI,
Masters CL, Li Q-X, Culvenor JG: alpha-synuclein transgenic
mice reveal compensatory increases in Parkinson’s
disease-associated proteins DJ-1 and Parkin and have
enhanced alpha-synuclein and PINK1 levels after
Rotenone treatment. Journal of Molecular Neuroscience
2010, 42(2):243-254.
Gibbons AS, Thomas EA, Scarr E, Dean B: Low density
lipoprotein receptor-related protein and Apolipoprotein E
expression is altered in schizophrenia. Frontiers in Psychiatry
2010, Vol1, Article 19 doi:10.3389/Ppsyt.2010.00019.
Gibbs ME, Bowser DN: Astrocytic adrenoceptors and learning:
alpha(1)-Adrenoceptors. Neurochemistry International 2010,
57(4):404-410.
Gogos A, Gavrilescu M, Davison S, Searle K, Adams J,
Rossell SL, Bell R, Davis SR, Egan GF: Greater superior than
inferior parietal lobule activation with increasing rotation
angle during mental rotation: An fMRI study.
Neuropsychologia 2010, 48(2):529-535.
51

52
Publications
Annual Report 2010
Gogos A, Joshua N, Rossell SL: Use of the Repeatable Battery
for the Assessment of Neuropsychological Status (RBANS) to
investigate group and gender differences in schizophrenia
and bipolar disorder. Australian and New Zealand Journal of
Psychiatry 2010, 44(3):220-229.
Gogos A, Kwek P, Chavez C, van den Buuse M. Estrogen
treatment blocks 8-hydroxy-2-dipropylaminotetralin- and
Apomorphine-induced disruptions of prepulse inhibition:
Involvement of Dopamine D-1 or D-2 or Serotonin 5-HT1A,
5-HT2A, or 5-HT7 Receptors. Journal of Pharmacology and
Experimental Therapeutics 2010, 333(1):218-227.
Gomes FA, Kauer-Sant’Anna M, Magalhaes PV, Jacka FN,
Dodd S, Gama CS, Cunha A, Berk M, Kapczinski F. Obesity is
associated with previous suicide attempts in bipolar disorder.
Acta Neuropsychiatrica. April 2010, 22(2):63-67.
Gray LJ, Dean B, Kronsbein HC, Robinson PJ, Scarr E:
Region and diagnosis-specific changes in synaptic proteins in
schizophrenia and bipolar 1 disorder. Psychiatry Research
2010, 178(2):374-380.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW,
Möller HJ, Kasper S WFSBP Task Force On Treatment
Guidelines For Bipolar Disorders. The World Federation of
Societies of Biological Psychiatry (WFSBP) Guidelines for the
Biological Treatment of Bipolar Disorders: Update 2010 on the
treatment of acute bipolar depression. World J Biol Psychiatry.
2010,11(2):81-109.
Guipponi M, Li Q-X, Hyde L, Beissbarth T, Smyth GK,
Masters CL, Scott HS: SAGE analysis of genes differentially
expressed in presymptomatic TgSOD1(G93A) Transgenic
Mice identified cellular processes involved in early stage of
ALS pathology. Journal of Molecular Neuroscience 2010,
41(1):172-182.
Gunn AP, Masters CL, Cherny, RA: Pyroglutamate-Aß:
Role in the natural history of Alzheimer’s disease.
International Journal of Biochemistry and Cell Biology 2010,
42(12):1915-1918.
Haeffner F, Barnham KJ, Bush AI, Brinck T: Generation of soluble
oligomeric beta-amyloid species via copper catalyzed
oxidation with implications for Alzheimer’s disease: A DFT study.
Journal of Molecular Modeling 2010, 16(6):1103-1108.
Haigh CL, Marom, SY, Collins SJ: Copper, endoproteolytic
processing of the prion protein and cell signalling. Frontiers in
Bioscience 2010, 15:1086-1104.
Hare DJ, George JL, Grimm R, Wilkins S, Adlard PA, Cherny RA,
Bush AI, Finkelstein DI, Doble P: Three-dimensional elemental
bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine
lesioned mouse brain. Metallomics 2010, 2(11):745-753.
Harrison CF, Lawson VA, Coleman BM, Kim YS, Masters CL,
Cappai R, Barnham KJ, Hill AF: Conservation of a
glycine-rich region in the prion protein is required for uptake
of prion infectivity. Journal of Biological Chemistry 2010,
285(26):20213-20223.
Horne MK, Nisbet DR, Forsythe JS, Parish CL: three-dimensional
nanofibrous scaffolds incorporating immobilized BDNF
promote proliferation and differentiation of cortical neural
stem cells. Stem Cells and Development 2010, 19(6):843-852.
Hung YH, Bush AI, Cherny RA: Copper in the brain and
Alzheimer’s disease. Journal of Biological Inorganic Chemistry
2010, 15(1):61-76.
Jacka FN, Kremer PJ, Leslie ER, Berk M, Patton GC,
Toumbourou JW, Williams JW: Associations between diet
quality and depressed mood in adolescents: Results from the
Australian Healthy Neighbourhoods Study. Australian and
New Zealand Journal of Psychiary 2010, 44(5):435-442.
Jacka FN, Pasco JA, Mykletun A, Williams LJ, Hodge AM,
O’Reilly SL, Nicholson GC, Kotowicz MA, Berk M. Association
of Western and traditional diets with depression and anxiety in
women. Am J Psychiatry. 2010 Mar;167(3):305-311.
Jones NC, Martin S, Megatia I, Hakami T, Salzberg MR,
Pinault D, Morris MJ, O’Brien TJ, van den Buuse M: A genetic
epilepsy rat model displays endophenotypes of psychosis.
Neurobiology of Disease 2010, 39(1):116-125.

Publications
Annual Report 2010
Kato T, Kapczinski F, Berk M. Mitochondrial dysfunction and
oxidative stress. In: Yatham LN, Maj M, editors. Bipolar disorder:
clinical and neurobiological foundations. Hoboken NJ,
John Wiley and Sons, 2010.
Kelin K, Berk M, Spann M, Sagman D, Raskin J, Walker D,
Perahia D: Duloxetine 60 mg/day for the prevention of
depressive recurrences: post hoc analyses from a recurrence
prevention study. International Journal of Clinical Practice
2010, 64(6):719: 726.
Kishigami H, Nagano S, Bush AI, Sakoda S. Monomerized
Cu,Zn-superoxide dismutase induces oxidative stress through
aberrant Cu binding. Free Radical Biology and Medicine
2010, 48(7):945-952.
Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E,
de Castella A, Berk M, Dodd S, Fitzgerald PB, Davis SR:
Piloting the effective therapeutic dose of adjunctive selective
estrogen receptor modulator treatment in postmenopausal
women with schizophrenia. Psychoneuroendocrinology 2010,
35(8):1142-1147.
Labuschagne I, Castle DJ, Dunai J, Kyrios M, Rossell SL:
An examination of delusional thinking and cognitive styles in
body dysmorphic disorder. Australian and New Zealand
Journal of Psychiatry 2010, 44(8):706-712.
Lawson VA, Haigh CL, Roberts B, Kenche VB, Klemm HMJ,
Masters CL, Collins SJ, Barnham KJ, Drew SC: Near-infrared
fluorescence imaging of apoptotic neuronal cell death in
a live animal model of Prion disease. ACS Chemical
Neuroscience 2010, 1(11):720-727.
Lawson VA, Lumicisi B, Welton J, Machalek D, Gouramanis K,
Klemm HM, Stewart JD, Masters CL, Hoke DE, Collins SJ, Hill AF:
Glycosaminoglycan sulphation affects the seeded misfolding
of a mutant prion protein. PLoS One 2010, 5(8):9.
Lee JY, Cho E, Kim TY, Kim DK, Palmiter RD, Volitakis I,
Kim JS, Bush AI, Koh JY: Apolipoprotein E ablation decreases
synaptic vesicular zinc in the brain. Biometals 2010,
23(6):1085-1095
Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL,
Bush AI: Tau protein: Relevance to Parkinson’s disease.
International Journal of Biochemistry & Cell Biology 2010,
42(11):1775-1778.
Li HY, Kim WS, Guillemin GJ, Hill AF, Evin G, Garner B:
Modulation of amyloid precursor protein processing by
synthetic ceramide analogues. Biochimica et Biophysica
Acta. Molecular and Cell Biology of Lipids 2010,
1801(8):887-895.
Lim S, Paterson BM, Fodero-Tavoletti MT, O’Keefe GJ,
Cappai R, Barnham KJ, Villemagne VL, Donnelly PS: A copper
radiopharmaceutical for diagnostic imaging of Alzheimer’s
disease: a bis(thiosemicarbazonato)copper(II) complex that
binds to amyloid-beta plaques. Chemical Communications
2010, 46(30):5437-5439.
Lubman DI, Berk M: Pharmacotherapy for co-occurring
alcohol and drug disorders in schizophrenia and bipolar
disorder: where is the evidence? Acta Neuropsychiatrica
2010, 22(2):95-97.
Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B,
Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J,
Fowler C, Gupta V, Hudson P, Laughton K, Masters CL,
Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC,
Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V,
Martins RN: Plasma amyloid-beta as a biomarker in
Alzheimer’s disease: The AIBL Study of Aging. Journal of
Alzheimers Disease 2010, 20(4):1233-1242.
Macneil CA, Hasty MK, Berk M, Henry L, Evans M, Daglas R,
McGorry PD, Conus P: First Episode Bipolar Disorder:
Outcomes from a manualised psychotherapy intervention.
Bipolar Disorders 2010, 12:35-36.
Macneil CA, Hasty MK, Conus P, Berk M: Termination of
therapy: what can clinicians do to maximise gains?
Acta Neuropsychiatrica 2010, 22(1):43-45.
53

54
Publications
Annual Report 2010
Magalhaes PVS, Berk M, Cereser KM, Kunz M, Gomes FA,
Fernandes BS, Jakobson L, Kapczinski F, Gama CS. Validity of
the Portuguese version of the Bipolar Depression Rating Scale.
Acta Neuropsychiatrica 2010, 22(2):100-101.
McColl G, Rogers AN, Alavez S, Hubbard AE, Melov S, Link CD,
Bush AI, Kapahi P, Lithgow GJ: Insulin-like signaling determines
survival during stress via posttranscriptional mechanisms in C.
elegans. Cell Metabolism 2010, 12(3):260-272.
McLeod MC, Scarr E, Dean B: Effects of benzodiazepine
treatment on cortical GABA(A) and muscarinic receptors:
Studies in schizophrenia and rats. Psychiatry Research 2010,
179(2):139 -146.
Money TT, Scarr E, Udawela M, Gibbons AS, Jeon WJ, Seo MS,
Dean B: Treating schizophrenia: Novel targets for the
cholinergic system. CNS Neurological Disorders - Drug Targets
2010 9(2):241-256.
Mykletun A, Jacka F, Williams L, Pasco J, Henry M,
Nicholson GC, Kotowicz MA, Berk M: Prevalence of mood
and anxiety disorder in self reported irritable bowel syndrome
(IBS). An epidemiological population based study of women.
BMC Gastroenterology 2010, 5(10):88.
Nisbet DR, Rodda AE, Horne MK, Forsythe JS, Finkelstein DI:
Implantation of functionalized thermally gelling xyloglucan
hydrogel within the brain: Associated neurite infiltration
and inflammatory response. Tissue Engineering Part A 2010,
16(9):2833-2842.
Nisbet RM, Harrison CF, Lawson VA, Masters CL, Cappai R,
Hill AF: Residues surrounding the glycosylphosphatidylinositol
anchor attachment site of PrP modulate prion infection:
Insight from the resistance of rabbits to prion disease.
Journal of Virology 2010, 84(13): 6678-6686.
Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK,
Mulligan RS, Ellis JR, Ackermann U, O’Keefe G, Jones G,
Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC: In Vivo
measurement of vesicular monoamine transporter Type 2
density in Parkinson disease with F-18-AV-133. Journal of
Nuclear Medicine 2010, 51(2):223-228.
Olshina MA, Angley LM, Ramdzan YM, Tang JW, Bailey MF,
Hill AF, Hatters DM: Tracking mutant huntingtin aggregation
kinetics in cells reveals three major populations that include
an invariant oligomer pool. Journal of Biological Chemistry
2010, 285(28):21807-21816.
Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC,
Kotowicz MA, Berk M: Clinical implications of the cytokine
hypothesis of depression: The association between use of
statins and aspirin and the risk of major depression.
Psychotherapy and Psychosomatics 2010, 79(5):323-325.
Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ,
Kotowicz MA, Schneider HG, Leonard BE, Berk M.
Association of high-sensitivity C-reactive protein with
de novo major depression. British Journal of Psychiatry.
2010; 197: 372-377.
Pereira A, Zhang B, Malcolm P, Fink G, Sundram S:
Antipsychotic drug modulation of downstream targets of
the EGF-ERK cell signaling pathway in prefrontal cortex and
striatum. International Journal of Neuropsychopharmacology
2010, 13(1):104.
Perreau VM, Orchard S, Adlard PA, Bellingham SA, Cappai R,
Ciccotosto GD, Cowie TF, Crouch PJ, Duce JA, Evin G,
Faux NG, Hill AF, Hung YH, James SA, Li Q-X, Mok SS, Tew DJ,
White AR, Bush AI, Hermjakob H, Masters CL: A domain level
interaction network of amyloid precursor protein and A beta
of Alzheimer’s disease. Proteomics 2010, 10(12):2377-2395.
Pettikiriarachchi JTS, Parish CL, Shoichet MS,
Forsythe JS Nisbet DR: Biomaterials for brain tissue engineering.
Australian Journal of Chemistry 2010, 63(8):1143-1154.
Rekas A, Knott RB, Sokolova A, Barnham KJ, Perez KA, Masters
CL, Drew SC, Cappai R, Curtain CC, Pham CLL: The structure
of dopamine induced alpha-synuclein oligomers. European
Biophysics Journal Biophysics Letters 2010, 39(10):1407-1419.
Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G,
Fripp J, Tochon-Danguy H, Morandeau L, O’Keefe G, Price R,
Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C,
Salvado O, Head R, Martins R, Masters CL, Ames D,

Publications
Annual Report 2010
Villemagne VL: Amyloid imaging results from the Australian
Imaging, Biomarkers and Lifestyle (AIBL) Study of aging.
Neurobiological Aging 2010, 31(8):1275-1283.
Scarr E, Money T, Dean B: Decreased mu opioid receptor
availability in subjects with schizophrenia who died by suicide.
Schizophrenia Research 2010, 117(2-3):487.
Singleton WCJ, McInnes KT, Cater MA, Winnall WR, McKirdy R,
Yu Y, Taylor PE, Ke BX, Richardson DR, Mercer JFB,
La Fontaine S: Role of glutaredoxin1 and glutathione in
regulating the activity of the copper-transporting P-type
ATPases, ATP7A and ATP7B. Journal of Biological Chemistry
2010, 285(35):27111-27121.
Smith DG, Ciccotosto GD, Tew DJ, Perez K, Curtain CC,
Boas JF, Masters CL, Cappai R, Barnham KJ: Histidine 14
modulates membrane binding and neurotoxicity of the
Alzheimer’s disease amyloid-beta peptide. Journal of
Alzheimers Disease 2010, 19(4):1387-1400.
Soon CPW, Crouch PJ, Turner BJ, McLean CA, Laughton KM,
Atkin JD, Masters CL, White AR, Li Q-X: Serum matrix
metalloproteinase-9 activity is dysregulated with disease
progression in the mutant SOD1 transgenic mice.
Neuromuscular Disorders 2010, 20(4):260-266.
Tabrett CA, Harrison CF, Schmidt B, Bellingham SA, Hardy T,
Sanejouand YH, Hill AF, Hogg PJ: Changing the solvent
accessibility of the prion protein disulfide bond markedly
influences its trafficking and effect on cell function.
Biochemical Journal 2010, 428:169-182
Torkamani A, Dean B, Schork NJ, Thomas EA: Coexpression
network analysis of neural tissue reveals perturbations in
developmental processes in schizophrenia. Genome
Research 2010, 20(4):403-412.
van den Buuse M, Choy C, Klug M, Hill R: Studying the
‘two-hit’ hypothesis of schizophrenia in rats and mice: role of
Brain-Derived Neurotrophic Factor (BDNF). International
Journal of Neuropsychopharmacology 2010, 13(1):68.
van den Buuse M: Modeling the positive symptoms of
schizophrenia in genetically modified mice: pharmacology
and methodology aspects. Schizophrenia Bulletin 2010,
36(2):246-270.
Villagonzalo KA, Dodd S, Dean O, Gray K, Tonge B, Berk M.
Oxidative pathways as a drug target for the treatment of
autism. Expert Opinion in Therapeutic Targets 2010;
14(12); 1301-1310.
Villagonzalo KA, Dodd S, Ng F, Mihaly S, Langbein A,
Berk M: The utility of the Mood Disorders Questionnaire as a
screening tool in a methadone maintenance treatment
program. International Journal of Psychiatry in Clinical
Practice 2010, 14(2):150-153.
Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC,
White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA,
Faux NG, Masters CL, Barnham KJ: Blood-borne amyloid-beta
dimer correlates with clinical markers of Alzheimer’s disease.
Journal of Neuroscience 2010, 30(18):6315-6322.
Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G,
Masters CL, Rowe CC: C-11-PiB PET A(Bri) Imaging in
Worster-Drought Syndrome (Familial British Dementia):
A Case Report. Journal of Alzheimers Disease 2010,
19(2):423-428.
Williams L, Jacka F, Pasco J, Henry M, Dodd S, Nicholson G,
Kotowicz M, Berk M: The prevalence of mood and anxiety
disorders in Australian women. Australasian Psychiatry 2010,
18(3):250-255.
Zheng ZQ, White C, Lee J, Peterson TS, Bush AI, Sun GY,
Weisman GA, Petris MJ: Altered microglial copper
homeostasis in a mouse model of Alzheimer’s disease.
Journal of Neurochemistry 2010, 114(6):1630-1638.
55

56
Audited Financial Statements
for the year ended 31 December 2010
DIRECTORS' REPORT
The Directors present this report on The Mental Health Research Institute (MHRI) for the year ended 31 December 2010.
Description of the short- and long-term objective
MHRI’s long term vision is to become a global leader in research that improves the lives of people affected by mental illness
including psychotic illness and neurodegenerative disease. Our immediate objective is to conduct sustainable, basic
neuroscience, clinical and public health research of the highest quality.
Details of the entity’s strategy for achieving those short- and long-term objectives
MHRI has adopted a growth strategy in order to meet its long- and short- term objectives and is aiming to increase our revenue
(both grant income and philanthropic donations), increase the number of researchers working at the Institute and grow the
number of publications in high quality scientific journals.
Principal Activities
MHRI engages in basic medical research in neuroscience, clinical and public health research. The Institute has two major
research streams; Neurodegeneration and Neuropsychiatry.
Details of how those activities assisted in achieving the entity’s short- and long-term objectives
Our activities have resulted in us achieving key growth objectives in 2010 by sustainably growing our overall income base year
on year by 13% and by increasing our peer reviewed grant income year on year by 6%.
Details of how the entity measures its performance, including any key performance indicators used by the entity
The Institute’s performance is measured by annual revenue, including revenue from peer-reviewed grants and the number of
publications in high impact scientific journals and cited in other publications.
The Year Ahead
MHRI has established a state-of-the-art research facility in Parkville in collaboration with the University of Melbourne and the
Florey Neuroscience Institutes. This building will be completed in mid to late 2011 and our researchers engaged in
wet-laboratory research will co-relocate into this new facility.
In addition, the Cunningham Dax Collection will be relocated to the Parkville facility to become the human face of
neuroscience research. A new incorporated entity, The Dax Centre Ltd, will be established to manage and to expand the
education activities around the collection.
ABN 48 101 228 451

Audited Financial Statements
for the year ended 31 December 2010
Directors
The names and qualifications of each person who has been a Director during the period and to date of this report are:
Dr Sandra Hacker AO, MBBS, DPM, FRANZCP, FAICD - Chair
Mr Trevor Clark OAM, ACIS, FAMI, FAICD, CPM - Deputy Chair
Mr Rob Gerrand, BA, FAMI, FAICD
Laureate Professor Colin Masters, BMedSc (Hons), MBBS, MD, Hon DLitt WAust, FRCPath, FRCPA, FAA, FTSE - Executive Director
Professor James Angus, BSc, PhD, FAA (Leave of absence since November 2010)
Professor Steve Wesselingh, MBBS, FRACP, PhD
Ms Katarina Klaric, BA, LLB, LLM - resigned 27 May 2010
Ms Jennifer Labourne, BBus, FCPA
Professor Ingrid Winship, MBChB, MD, FRACP, FACD
Mr Andrew Stripp, MSc (Clin Psychol), BBSc (Hons)
The Directors have been in office since the start of the period to the date of this report unless otherwise stated.
Ms Lisa Keam, Chief Operating Officer, held the position of company secretary at the end of the financial period.
57

58
Audited Financial Statements
for the year ended 31 December 2010
Directors Meetings
During the financial period, 20 meetings of directors (including committees) were held.
Attendances by each director were as follows;
Committee Meetings
Directors’ Intellectual Development Audit & Risk Cunningham Dax
Meetings Property & Council Management Advisory
Commercialisation Committee
Committee
Eligible Attended Eligible Attended Eligible Attended Eligible Attended Eligible Attended
Dr S Hacker 4 4 4 4 1 1
Mr T Clark 4 4 11 11
Prof C Masters 4 4 0 0 4 4
Mr R Gerrand 4 4 11 8 4 2
Prof J Angus 4 0
Ms K Klaric 2 2 0 0 2 1
Ms J Labourne 4 4 4 4
Prof S Wesselingh 4 2
Prof I Winship 4 2
Mr A Stripp 4 4 4 0
No Board Member received any benefit from the Institute, apart from Professor Colin Masters, who received remuneration in
respect of his employment as Executive Director.

Audited Financial Statements
for the year ended 31 December 2010
Member’s guarantee
If the company is wound up, the Constitution states that each member is required to contribute a maximum of $25 each
towards meeting any outstanding obligations of the company. At 31 December 2010, the number of members was 30.
Independence Declaration
The lead auditor’s independence declaration for the period has been received and can be found on page 20
of this report.
Dr Sandra Hacker
Chair
Signed at Melbourne, dated this 11th day of April 2011.
59

60
Audited Financial Statements
for the year ended 31 December 2010
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2010
Research Capital Asset Revaluation Unrealised gain Accumulated Total
Funds Reserves Reserve on Investment Deficit/Surplus
Reserve
$ $ $ $ $ $
Balance 1 January 2010 2,799,402 5,713,141 - 66,068 (1,800,113) 6,778,498
Net surplus for period - - - - 11,320,569 11,320,569
Other comprehensive income - - 2,526,383 (12,464) - 2,513,919
Transfer from accumulated
Deficit/Surplus (1,485,204) 11,005,660 - - (9,520,456) -
Transfers to/from reserves 50,882 1,200,000 - - - 1,250,882
Balance at
31 December 2010 1,365,080 17,918,801 2,526,383 53,604 - 21,863,868
Research Asset Revaluation Unrealised gain Accumulated Total
Funds Reserves Reserve on Investment Deficit/Surplus
Reserve
$ $ $ $ $ $
Balance 1 July 2009 2,818,475 5,713,141 - 37,874 (1,266,404) 7,303,086
Net deficit for period - - - - (533,709) (533,709)
Other comprehensive income - - - 28,194 - 28,194
Transfers to/from reserves (19,073) - - - - (19,073)
Balance at
31 December 2009 2,799,402 5,713,141 - 66,068 (1,800,113) 6,778,498
The accompanying notes form part of this financial report

Audited Financial Statements
for the year ended 31 December 2010
STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2010
INCOME
NOTE 12 months 6 months
to 31 Dec 10 to 31 Dec 09
Grants 2(A) 7,938,047 3,373,315
Contract research fees 2,161,894 1,251,819
Public support 2(B) 1,897,685 598,569
Interest 249,493 116,923
Dividends 8,950 3,160
Other revenue 397,690 480,158
TOTAL INCOME excluding asset recognition and relocation grant 12,653,759 5,823,944
EXPENDITURE
Salaries and on costs 7,590,898 3,642,464
Scientific equipment purchases 7 (E) 69,790 30,763
Scientific consumables 1,475,667 865,375
Scientific support 1,111,331 715,355
Depreciation 3 (B) 938,655 418,188
Infrastructure expenses 1,152,509 685,508
Provision for doubtful debts - -
TOTAL EXPENDITURE 12,338,850 6,357,653
NET SURPLUS / (DEFICIT) before asset recognition and relocation grant 314,909 (533,709)
Land asset recognised on transfer of Committee of Management 2(C) 8,981,000 -
Relocation grant income - Cunningham Dax Collection 2(D) 2,024,660 -
NET SURPLUS/ (DEFICIT) 13 11,320,569 (533,709)
OTHER COMPREHENSIVE INCOME
Gain on revaluation of property 12 2,526,383 -
Net change in market value of investments recognised directly in equity (12,463) 28,194
TOTAL COMPREHENSIVE SURPLUS (DEFICIT) FOR PERIOD 13,834,489 (505,515)
The accompanying notes form part of this financial report
61

62
Audited Financial Statements
for the year ended 31 December 2010
CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2010
NOTE 12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Inflows/(Outflows) Inflows/(Outflows)
CASH FLOWS FROM OPERATING ACTIVITIES
Grants received 7,922,020 3,486,419
Public support received 1,897,685 598,569
Interest received 241,898 242,962
Dividends received 451 3,160
Contract research fees received 2,370,546 1,075,228
Other revenue received 436,780 523,798
Payments to suppliers and employees (12,242,040) (6,389,364)
Payments for scientific equipment (75,004) (21,571)
Net cash provided by operating activities 16(B) 552,336 (480,799)
CASH FLOWS FROM INVESTING ACTIVITIES
Fixed asset purchases (835,560) (93,072)
Net sale/(purchase) of investments (523,397) 349,533
Redemption of Dax relocation funds 3,224,660 -
Payments for Dax building construction (2,216,929) -
Net cash used by investing activities (351,226) 256,461
CASH FLOWS FROM FINANCING ACTIVITIES
Net (decrease)/increase in cash held 201,110 (224,338)
Cash and cash equivalents at the beginning of the financial period 373,166 597,504
Cash and cash equivalents at the end of the financial period 16(A) 574,276 373,166
The accompanying notes form part of this financial report

Audited Financial Statements
for the year ended 31 December 2010
BALANCE SHEET AS AT 31 DECEMBER 2010
ASSETS
CURRENT ASSETS
NOTE 31 December 2010 31 December 2009
Cash and cash equivalents 4 574,276 373,166
Trade and other receivables 5 1,428,127 769,660
Stock on Hand 5(A) 23,287 -
Financial assets 6 5,068,523 4,545,126
TOTAL CURRENT ASSETS 7,094,213 5,687,952
NON-CURRENT ASSETS
Financial assets 6 159,658 163,622
Property, plant and equipment 7 18,488,005 2,726,515
Cunningham Dax relocation account 6,11 - 3,132,430
MHRI accommodation relocation account 6,11 10,688,031 10,047,226
TOTAL NON-CURRENT ASSETS 29,335,694 16,069,793
TOTAL ASSETS 36,429,907 21,757,745
CURRENT LIABILITIES
Trade and other payables 8 2,876,908 647,833
Unexpended project grants 9 150,000 223,876
Provisions for employee benefits 10 777,782 858,806
TOTAL CURRENT LIABILITIES 3,804,690 1,730,515
NON-CURRENT LIABILITIES
Provisions for employee benefits 10 73,318 69,076
Cunningham Dax relocation account 11 - 3,132,430
MHRI accommodation relocation account 11 10,688,031 10,047,226
TOTAL NON-CURRENT LIABILITIES 10,761,349 13,248,732
TOTAL LIABILITIES 14,566,039 14,979,247
NET ASSETS 21,863,868 6,778,498
The accompanying notes form part of this financial report
63

64
Audited Financial Statements
for the year ended 31 December 2010
BALANCE SHEET AS AT 31 DECEMBER 2010 - Continued.
EQUITY
NOTE 31 December 2010 31 December 2009
Research funds 12 1,365,080 2,799,402
Capital reserves 12 17,918,801 5,713,141
Asset revaluation reserve 12 2,526,383 -
Unrealised gain on investment reserve 1(G) 53,604 66,068
Accumulated deficit 13 - (1,800,113)
TOTAL EQUITY 21,863,868 6,778,498
The accompanying notes form part of this financial report

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010
NOTE 1: STATEMENT OF ACCOUNTING POLICIES
The financial report is a general purpose financial report that has been prepared in accordance with Accounting
Standards - Reduced Disclosure Requirements and other authoritative pronouncements of the Australian Accounting
Standards Board and the requirements of the Corporations Act 2001.
The financial report covers the Mental Health Research Institute as an individual entity.
Reporting Basis and Conventions
The financial report has been prepared on an accruals basis and is based on historical cost convention and except
where stated, does not take account of current valuations of non-current assets, except for land and buildings
valued at fair value, and listed shares valued at market value.
The following is a summary of the material accounting policies adopted by the company in the preparation of the
financial report. The accounting policies have been consistently applied unless otherwise stated.
(A) PROPERTY, PLANT AND EQUIPMENT
Property
MHRI occupy a Crown Land site at 155 Oak Street, Parkville. This site was previously leased by MHRI. During 2010,
MHRI was delegated responsibility to manage the site as a Committee of Management. The value of the land had
not been recognised as a controlled asset previously, and is now recognised at fair value based on a valuation
prepared for the Valuer-General in 2009. The buildings at 155 Oak Street, Parkville were previously recognised as
controlled assets, and have been revalued during the 2010 year based on the same valuation.
Plant and Equipment
Plant and equipment are measured on the cost basis. The carrying amount of plant and equipment is reviewed
annually to ensure it is not in excess of the recoverable amount from these assets. Due to the nature of the Institute’s
funding, capital equipment acquired for scientific purposes prior to June 2004 was fully written off against grants in
the year of purchase. All assets with a purchase value of less than $2,000 are written off in the year of purchase.
Depreciation
Scientific and non-scientific plant and equipment are shown as fixed assets in the Balance Sheet and depreciated
on a straight line basis over the expected useful life of the asset from the time the asset is held ready for use.
Building & Improvements 5% - 20%
Equipment, Furniture & Fittings 10% to 33.33%
Scientific Equipment 10% to 33.33%
65

66
Audited Financial Statements
for the year ended 31 December 2010
(B) EMPLOYEE BENEFITS
Provision is made for the Institute’s liability for employee entitlements arising from services rendered by employees
to balance date. Employee entitlements expected to be settled within one year have been measured at their
nominal amount and recorded as Current Liabilities. Other employee entitlements payable later than one year
have been measured at the present value of the estimated future cash outflows to be made for those entitlements.
(C) TAX STATUS
The Institute has been endorsed as an income tax exempt charitable entity and a deductible gift recipient under
provisions of the Income Tax Assessment Act 1997. Donations of $2 or more made to the Institute are tax deductible.
(D) INCOME RECOGNITION
Grant funding is recognised as income as the obligations under the funding agreement have been met.
Unexpended Grants relating to specific projects are shown as a Current Liability in the Balance Sheet as the funds
are not controlled.
Donations are brought to account as revenue when they are received.
Revenue from the rendering of a service is recognised upon the delivery of the service.
Interest revenue is recognised on a proportional basis taking into account the interest rates applicable to the
financial assets.
Dividend revenue is recognised when the right to receive a dividend has been established.
(E) CAPITAL FUNDS
The Capital Reserves represents gains related to the recognition of the property at Oak Street, Parkville and in fixed
assets of MHRI.
(F) SPECIAL PURPOSE FUNDS
Donations are brought to account as revenue when they are received. Where any specified obligations have not
yet been met nor the relevant expenditure incurred, the unexpended balances have been transferred to special
purpose funds.
1. Directed donations fund
These funds are held to be used in accordance with the wishes of the donors.
2. Perpetual fund
The Claudia Wright appeal is a perpetual fund in which the capital is maintained and the income derived is directed
towards specified research at the Institute.
3. Development reserve fund
Funds raised by the Institute to maintain a capital base for ongoing research are held in a special purpose fund.
Expenditure from this fund requires board approval.

Audited Financial Statements
for the year ended 31 December 2010
(G) FINANCIAL ASSETS
The Institute classifies its other investments in the following categories: held to maturity investments and available for
sale investments. The classification depends on the purpose for which the investments were acquired. Management
determines the classification of its investments at initial recognition.
Held to maturity investments
These investments have fixed maturities and it is the Institute’s intention to hold these investments to maturity.
Investments are stated at amortised cost using the effective interest rate method.
Available for sale financial assets
Available for sale financial assets include any financial assets not included in the above category.
Available for sale financial assets are reflected at fair value. Unrealised gains and losses arising from changes in fair
value are taken directly to equity.
The fair value of investments that are actively traded in organised financial markets is determined by reference to
quoted bid prices at the close of business on the balance sheet date.
(H) RECEIVABLES
Debtors are recognised at the amount receivable and are due for settlement within the terms stated, usually thirty
days from the end of the month in which the debt is recognised.
(I) PAYABLES
Creditors are paid according to Institute policy, currently within thirty days from the end of the month in which the
liability is recognised.
(J) GOODS & SERVICES TAX (GST)
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred
is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of
acquisition of the asset or as part of an item of expense. Receivables and payables in the Balance Sheet are shown
inclusive of GST.
(K) CASH AND CASH EQUIVALENTS
Cash and cash equivalents include cash on hand, deposits held at call with banks, other short term high liquid
investments with original maturities of three months or less.
(L) LEASES
Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged
as expenses in the periods in which they are incurred.
67

68
Audited Financial Statements
for the year ended 31 December 2010
(M) MEMBERS’ GUARANTEE
The Company is limited by guarantee. If the company is wound up, the Constitution states that each member is
required to contribute a maximum of $25 each towards meeting any outstanding obligations of the company.
At 31 December 2010, the number of members was 30.
(N) MONIES HELD IN TRUST - ACCOMMODATION AND RELOCATION GRANT
The Institute is in receipt of an $8,000,000 grant from the Victorian government which is held in trust until the
anticipated relocation to the Parkville medical precinct. Under the agreement, the Institute must hold this grant
(and the compounding interest) for the sole purpose of accommodation and relocation. Should the anticipated
relocation not take place, the Institute has agreed to a total refund to the Victorian government.
Therefore, the accommodation and relocation grant (and the compounding interest) has not been recognised
through the Income Statement.
The Institute has applied funds which were held in trust for the relocation of the Cunningham Dax gallery to the
Parkville medical precinct.
(P) IMPAIRMENT OF ASSETS
At each reporting date, the Institute reviews the carrying values of its tangible assets to determine whether there is
any indication that those assets have been impaired. Where it is not possible to estimate the recoverable amount of
an individual asset, the Institute estimates the recoverable amount of the cash-generated unit to which it belongs.
(Q) CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENT
The Directors evaluate estimates and judgements incorporated into the financial report based on historical
knowledge and best available current information. Estimates assume a reasonable expectation of future events and
are based on current trends and economic data, obtained both externally and within the Institute.
Key estimates - impairment
The Institute assesses impairment at each reporting date by evaluating conditions specific to the institute that may
lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined.
Value-in-use calculations performed in assessing recoverable amounts incorporate a number of key estimates.
(R) COMPARATIVE FIGURES
Where required by accounting standards, comparative figures have been adjusted to conform to changes in
presentation for the current financial period.
(S) ROUNDING
The Institute has applied the relief available to it under ASIC Class Order 98/100 and accordingly, amounts in the
financial report and Directors’ report have been rounded off to the nearest dollar.

Audited Financial Statements
for the year ended 31 December 2010
(T) CHANGE IN ACCOUNTING PERIOD IN THE PRIOR PERIOD
The Institute changed its financial reporting period from a balance date at 30 June to end the financial reporting
period at 31 December in 2009. The Directors anticipated the revised financial reporting period would align the
financial reports for the period with the operational outcomes. The comparative financial period covered by this
financial report is for the six months beginning on 1 July 2009 and ending on 31 December 2009 to facilitate this
change. ASIC granted an instrument of relief under s340(1) of the Corporations Act 2001 allowing the change in
reporting period.
(U) ACCOUNTING STANDARDS ISSUED NOT YET OPERATIVE
The Institute has considered the potential future impact of relevant Australian Accounting Standards issued at the
date of this report but not yet operative, and have determined the implementation of these Standards will not result
in any material adjustments or changes to accounting policies.
(V) EARLY ADOPTION OF ACCOUNTING STANDARDS
The Institute has elected to adopt the Reduced Disclosure Requirements available through early adoption of AASB
1053 and AASB 2010-2. The Reduced Disclosure Requirements aim to improve the relevance and clarity of
financial reporting.
69

70
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 2: INCOME
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
(A) GRANT INCOME - GOVERNMENT & STATUTORY BODIES
(1) State Government Grants
(i) Operating grants
Brought forward from previous period 161,566 -
Received in current period 2,626,605 1,178,430
Capital commitment - -
Less carried forward to next period - (161,566)
2,788,171 1,016,864
(ii) Project grants
Brought forward from previous period 15,280 15,280
Received in current period 96,664 47,585
Less carried forward to next period (15,280) (15,280)
96,664 47,585
Total State Government Grants 2,884,835 1,064,449
The Mental Health Research Institute was supported by the Victorian Government’s operational infrastructure support program.
We received income of $628,266 from the program in the year and spent these funds in support of operational infrastructure.
(2) Federal Government Grants
(i) Project grants
Brought forward from previous period 62,310 453,958
Received in current period 4,913,833 1,717,476
Less grants received in advance carried forward to next period (150,000) (62,310)
4,826,143 2,109,124
(ii) Postgraduate research grants
Received in current period - -
Total Federal Government Grants 4,826,143 2,109,124

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
(3) Other Grants
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Brought forward from previous period - -
Received in current period 227,069 199,742
Less carried forward to next period - -
Total Other Grants 227,069 199,742
TOTAL GRANTS 7,938,047 3,373,315
(B) PUBLIC SUPPORT INCOME
Donations and bequests as listed in this report are allocated
and used in accordance with the wishes of the donors.
- Unspecified donations 304,986 138,871
- Directed donations 894,338 346,354
- Foundation funds 166,428 109,093
- Perpetual fund donations 302,037 -
- Sales 6,618 4,251
- Other Dax Gallery 223,278 -
TOTAL PUBLIC SUPPORT INCOME 1,897,685 598,56
(C) LAND ASSET RECOGNISED ON TRANSFER OF RESPONSIBILTY
Land at 155 Oak Street 8,981,000 -
The Institute was appointed Committee of Management over the
Crown Land site at 155 Oak Street, Parkville. The land is recognised
as an asset of the Institute, as the Institute has responsibility for the site.
(D) RELOCATION GRANT INCOME
Grant received for Dax Relocation and interest received on
invested funds 2,024,660 -
Income received in a prior period specifically for the purpose
of relocating the Dax Collection to a new building. Income is now
recognised as the funds have been expended for the specified purpose.
71

72
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 3: NON- OPERATING
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
(A) AUDITORS REMUNERATION
Remuneration of auditor
- auditing the accounts 13,500 10,500
(B) DEPRECIATION
Buildings and building improvements 328,876 156,347
Equipment, furniture and fittings 60,742 23,750
Scientific assets 549,037 238,091
NOTE 4: CASH AND CASH EQUIVALENT ASSETS
NOTE 5: TRADE AND OTHER RECEIVABLES
NOTE 5(A): STOCK
Total depreciation 938,655 418,188
Cash on hand 2,499 1,831
Cash at bank 433,892 326,300
Cunningham Dax gallery cash at bank 137,885 45,035
574,276 373,166
Trade debtors 710,481 637,784
Less provision for doubtful debts - -
Accrued income 681,790 20,845
Other debtors 35,856 111,031
1,428,127 769,660
Stock on Hand 23,287 -
23,287 -

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 6: FINANCIAL ASSETS
CURRENT
NON-CURRENT
NOTE 7: PROPERTY, PLANT AND EQUIPMENT
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Term deposits at cost 5,068,523 4,545,126
5,068,523 4,545,126
Cunningham Dax relocation account - 3,132,430
Shares in listed corporations, at fair value 159,658 163,622
MHRI accommodation relocation account 10,688,031 10,047,226
The Mental Health Research Institute occupies premises situated
at 155 Oak Street, Parkville, Victoria 3052 on Crown Land gazetted
as a Mental Health Reserve.
(A) CONTROLLED AS COMMITTEE OF MANAGEMENT
10,847,689 13,343,278
Land at fair value 8,981,000 -
Buildings and improvements at fair value 5,016,000 5,880,158
Less accumulated depreciation (1,335,000) (4,441,165)
Fair value for land and buildings controlled as Committee
of Management is based on the value advised by the
Department of Health at the time of delegation of responsibilty.
3,681,000 1,438,993
73

74
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
(B) ASSETS UNDER CONSTRUCTION
(C) OWNED ASSETS
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Dax Collection at the Melbourne Brain Centre 4,357,202 -
The Melbourne Brain Centre is a collaboration between
the Mental Health Research Institute, the University of Melbourne,
the Florey Neuroscience Institutes, Austin Health and Melbourne Health.
The Mental Health Research Institute has received grant funding
to assist with the construction and relocation to the new site (refer Note 11).
During the year, construction of the new premises for the Dax
Collection commenced, but the Collection has not yet been relocated.
Equipment, furniture and fittings at cost 470,597 419,743
Less accumulated depreciation (326,766) (266,024)
143,831 153,719
Scientific equipment at cost 2,992,860 2,252,654
Less accumulated depreciation (1,667,888) (1,118,851)
1,324,972 1,133,803
TOTAL PROPERTY, PLANT AND EQUIPMENT 18,488,005 2,726,515

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
(D) MOVEMENT IN CARRYING AMOUNTS
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Building Building under Equipment Scientific Total
Land & improvements construction furniture & fittings equipment
Carrying Amount 1 Jan 2010 - 1,438,993 - 153,719 1,133,803 2,726,515
Additions - 44,500 4,357,202 50,854 740,206 5,192,762
Disposals - - - - - -
Depreciation - (328,876) - (60,742) (549,037) (938,655)
Recognised as controlled asset 8,981,000 - - - - 8,981,000
Revaluation to Fair Value - 2,526,383 - - - 2,526,383
Impairment - - - - - -
Carrying Amount 31 Dec 2010 8,981,000 3,681,000 4,357,202 143,831 1,324,972 18,488,005
(E) SCIENTIFIC EQUIPMENT
Scientific equipment purchased during the year to 31 December 2010
above $2000 has been capitalised and depreciated in accordance with the policy
described in Note 1(A). Purchases under this amount have been expensed
through the Income Statement. 75,004 30,763
75

76
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 8: TRADE AND OTHER PAYABLES
NOTE 9: UNEXPENDED PROJECT GRANTS
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Trade creditors and accruals 2,575,436 299,039
2,575,436 299,039
GST, Superannuation and PAYG Liability 301,472 348,794
301,472 348,794
2,876,908 647,833
State Government Project Grants - 161,566
Federal Government Project Grants 150,000 62,310
Other Grants - -
NOTE 10: PROVISIONS FOR EMPLOYEE BENEFITS
CURRENT
NON-CURRENT
150,000 223,876
Employee entitlements - annual leave 475,393 578,833
Employee entitlements - long service leave 298,746 264,973
Employee entitlements - employee benefits 3,643 15,000
777,782 858,806
Employee entitlements - long service leave 73,318 69,076

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 11: UNEXPENDED RELOCATION GRANT
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
MHRI Accommodation relocation account
Trust funds invested 8,000,000 8,000,000
Interest received 2,391,216 2,043,814
Term deposit 10,391,216 10,043,814
Interest accrued 296,815 3,412
Total unexpended / (shortfall) 10,688,031 10,047,226
Cunningham Dax relocation account
Trust Funds invested 2,900,000 2,900,000
Interest received 391,153 269,203
Term deposit 3,291,153 3,169,203
Cash Held - 2,751
Costs of construction and relocation (4,423,695) (66,500)
Interest accrued - 26,976
Total unexpended / (shortfall) (1,132,542) 3,132,430
The shortfall in construction costs is included in trade creditors at 31 December 2010.
The Dax shortfall is to be paid from Health and Hospitals Fund contributions.
In the event this funding is unavailable, MHRI has underwritten to cover the Dax relocation.
77

78
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 12: RESERVES
(A) CAPITAL FUND 1(E)
(B) ASSET REVALUATION RESERVE
(C) ACCUMULATED RESEARCH FUNDS
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Balance at the beginning of the period 5,713,141 5,713,141
Transfers to/from Capital Fund 1,200,000 -
Transfer from Accumulated Deficit/Surplus 11,005,660 -
Balance at the end of the financial period 17,918,801 5,713,141
Balance at the beginning of the period - -
Revaluation of buildings and improvements - 155 Oak St, Parkville 2,526,383 -
Balance at the end of the financial period 2,526,383 -
(i) Directed Donations/Interest and Research Funds
Balance at the beginning of the period 2,622,738 2,641,811
Transfers to/from reserves 50,882 (19,073)
Transfer from Accumulated Deficit/Surplus (1,485,204) -
Balance at the end of the financial period 1,188,416 2,622,738
Represented by :
Research and General Reserves 1,136,406 2,614,894
Claudia Wright Interest Fund 12(iii) 52,010 7,844
Balance at the end of the financial period 1,188,416 2,622,738

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 13: ACCUMULATED SURPLUS
(ii) Perpetual Fund
Claudia Wright Perpetual Fund
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Balance at the beginning of the financial period 176,664 176,664
Donations - -
Balance at the end of the financial period 176,664 176,664
1,365,080 2,799,402
(iii) Movement in Claudia Wright Interest Fund
(included in Directed Donations & Interest Fund)
Balance at the beginning of the financial period 7,844 6,300
Interest Received 14,191 6,044
Salaries Paid - (4,500)
Expenses Paid - -
Balance at the end of the financial period 22,035 7,844
Accumulated surplus at the beginning of the financial period (1,800,113) (1,266,404)
Adjustment due to change in accounting policy - -
Net surplus for the period 11,320,569 (533,709)
Transfer from Accumulated Deficit/Surplus (9,520,456) -
Transfer to perpetual fund - -
Accumulated surplus at the end of the financial period - (1,800,113)
NOTE 14: LEASING AND CAPITAL COMMITMENTS
Operating lease commitments - motor vehicles
Aggregate lease expenditure contracted at balance date
but not provided for in the accounts
Not later than 1 year 35,429 27,112
Later than 1 year and not later than 2 years 28,958 15,090
Later than 2 years and not later than 5 years 7,202 8,400
Total lease commitments 71,589 50,602
79

80
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 15: EXECUTIVE REMUNERATION
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
(A) Remuneration of Board Members - -
The names of each person who held office as a Board Member of The Mental Health
Research Institute during the financial period ended 31 December 2010 are:
Dr Sandra Hacker Professor Colin Masters
Mr Trevor Clark Professor Steve Wesselingh
Professor James Angus Professor Ingrid Winship
Mr Rob Gerrand Mr Andrew Stripp
Ms Jennifer Labourne Ms Katarina Klaric
No Board Member has received or has become entitled to receive any benefit from the Institute,
apart from Executive Director Professor Colin Masters who receives remuneration in respect
of his employment as Executive Director.
(B) Remuneration of Key Management Personnel
Aggregate remuneration paid or
payable to key management personnel 1,855,545 898,916
Key management personnel are comprised of a Senior Executive Committee
which includes; the Executive Director, the Chief Operating Officer,
the Laboratory Facilities Manager, five Laboratory Heads,
the Development Manager and the Accountant.

Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 16: CASH FLOW INFORMATION
(A) RECONCILIATION OF CASH
12 months 6 months
to 31 Dec 10 to 31 Dec 09
$ $
Cash on hand 2,491 1,831
Cash at bank 433,899 326,300
Cunningham Dax Gallery cash at bank 137,886 45,035
(B) RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO NET SURPLUS
574,276 373,166
Net surplus / (deficit) 11,320,569 (533,709)
Non-cash flows in surplus:
Recognition of land asset on transfer of Committee of Management (8,981,000) -
Relocation grant income received in a prior period (2,024,660) -
Depreciation 938,655 418,188
Provision for doubtful debts - -
Changes in assets and liabilities:
Decrease (increase) in receivables (651,026) (127,726)
Increase (decrease) in trade and other payables 100,456 1,419
(Decrease) increase in unexpended grants and relocation accounts (73,876) (249,156)
Increase in provisions for employee benefits (76,782) 10,185
Cash flows from operating activities 552,336 (480,799)
81

82
Audited Financial Statements
for the year ended 31 December 2010
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2010 - Continued.
NOTE 17: EVENTS SUBSEQUENT TO BALANCE DATE
The Cunningham Dax has incorporated as a separate entity in preparation for separation from
The Mental Health Research Institute. Within the next 12 months, the assets of the Cunningham
Dax Collection managed by the Institute, together with relevant liabilities, will be transferred to
the new entity.
The following table indicates the impact of the transfer on the Institute.
MHRI Dax Collection Total
Statement of Comprehensive Income 2010
Income $11,951,903 $701,856 $12,653.759
Expenses -$11,652,626 -$686,224 -$12,338,850
Net surplus / (deficit) $ 299,277 $ 314,909
Balance Sheet as at 31 December 2010
Total assets $35,642,412 $787,495 $36,429,907
Total liabilities -$14,566,039 - -$14,566,039
Net assets $21,076,373 $787,495 $21,863,868
Cash Flow Statement 2010
Net cash provided by operating activities $536,704 $15,632 $552,336
Net cash from financing activities $ - - -$351,226
Net increase / (decrease) in cash held $536,704 $15,632 $201,110
There were no other events since balance date which
significantly affected or may significantly affect the operations
of the Institute, the results of those operations or the state of
the Institute in future years.

Audited Financial Statements
for the year ended 31 December 2010
DIRECTORS’ DECLARATION
The Directors of the company declare that:
(1) The financial statements and notes, as set out on pages 56 to 86 are in accordance with the Corporations Act 2001:
(a) comply with Accounting Standards Reduced Disclosure Requirements and the Corporations Regulations 2001;
and
(b) give a true and fair view of the Institute’s financial position as at 31 December 2010 and of its performance
for the year ended on that date.
(2) In the Directors’ opinion there are reasonable grounds to believe that the Institute will be able to pay its debts as
and when they become due and payable.
This declaration is made in accordance with a resolution of the Board of Directors.
S Hacker AO
Chair
Signed at Melbourne on the 11th April, 2011.
83

84
Audited Financial Statements
for the year ended 31 December 2010
INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF THE MENTAL HEALTH RESEARCH INSTITUTE
Report on the financial report
We have audited the accompanying financial report of The Mental Health Research Institute (the company), which comprises
the Balance Sheet as at 31 December 2010, and the Statement of Comprehensive Income, Statement of Changes in Equity
and Cash Flow Statement for the year ended on that date, a summary of significant accounting policies and other explanatory
notes and the Directors’ Declaration.
Directors’ responsibility for the financial report
The directors of the company are responsible for the preparation and fair presentation of the financial report in accordance
with Australian Accounting Standards - Reduced Disclosure Requirements and the Corporations Act 2001 and for such internal
control as the directors determine is necessary to enable the preparation of the financial report that is free from material
misstatement, whether due to fraud or error.
Auditor’s responsibility
Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance
with Australian Auditing Standards. Those Standards require that we comply with relevant ethical requirements relating to
audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free
from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report.
The procedures selected depend on the auditor’s judgment, including the assessment of risks of material misstatement of the
financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to
the entity’s preparation of the financial report that gives a true and fair view in order to design audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal
control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of
accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Matters Relating to the Electronic Publication of the Audited Financial Report
This auditor’s report relates to the financial report of The Mental Health Research Institute for the year ended 31 December 2010
included on the Institute’s website. The company’s directors are responsible for the integrity of the Institute’s website.
We have not been engaged to report on the integrity of the Institute’s website. The auditor’s report refers only to the subject
matter described above. It does not provide an opinion on any other information which may have been hyperlinked to/from
these statements. If users of the financial report are concerned with the inherent risks arising from publication on a website, they
are advised to refer to the hard copy of the financial report to confirm the information contained in this website version of the
financial report.

Audited Financial Statements
for the year ended 31 December 2010
Independence
In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001.
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors
of the company, would be in the same terms if given to the directors as at the time of this auditor’s report.
Audit Opinion
In our opinion, the financial report of The Mental Health Research Institute is in accordance with the Corporations
Act 2001 including:
(i) giving a true and fair view of the Institute’s financial position as at 31 December 2010 and of its
performance for the year ended on that date; and
(ii) complying with Australian Accounting Standards - Reduced Disclosure Requirements and the
Corporations Regulations 2001.
UHY Haines Norton Joella Gould
Chartered Accountants Partner
Signed
Melbourne
Dated this the 11th day of April 2011.
Liability limited by a scheme approved under Professional Standards legislation.
85

86
Audited Financial Statements
for the year ended 31 December 2010
AUDITOR’S INDEPENDENCE DECLARATION
TO THE BOARD OF DIRECTORS OF THE MENTAL HEALTH RESEARCH INSTITUTE
I declare that, to the best of my knowledge and belief, during the year ended 31 December 2010, there have been:
(i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation
to the audit: and
(ii) no contraventions of any applicable code of professional conduct in relation to the audit.
Joella F Gould
Partner
UHY Haines Norton
Chartered Accountants
Dated this the 11th day of April 2011.
Liability limited by a scheme approved under Professional Standards Legislation.

Personnel
Annual Report 2010
Rebecca L Cooper Laboratory
Head of Laboratory / NHMRC Senior
Research Fellow
Professor Brian Dean HND ApplBiol,
MSc, PhD, Fl Biol
Head of Muscarinic Receptor Group /
Royce Abbey Postdoctoral Fellow
Dr Elizabeth Scarr BSc (Hons), PhD
Research Officers
Dr Andrew Gibbons BSc (Hons), PhD
Dr Madhara Udawela BSc (Hons), PhD
Dr Jung Yoon Um BSc, PhD
Graduate Research Assistant
Geoffrey Pavey BSc (Hons)
Doctoral Students
Tammie Money BSc (Hons)
Nahed Tawadros BSc (Hons)
Ajeet Singh (MBBS)
Myoung Suk Seo BSc, MSc
Won Je Jeon BSc, MSc
Masters Students
Lucy Brooks (BSc)
Collaborators
Dr Andrew Aquilina
(University of Woolongong)
Professor Michael Berk
(Barwon Health and The Geelong
Clinic, The University of Melbourne)
Dr Olivia Dean
(Barwon Health and The Geelong
Clinic, The University of Melbourne)
Professor Ian Everall (Cato Chair of
Psychiatry, The University of Melbourne)
Professor Vahram Haroutunian
(Mount Sinai School of Medicine,
New York, NY, USA)
Professor James Meadow-Woodruff
(Department of Psychiatry and
Behavioral Neurobiology, University of
Alabama at Birmingham, USA)
Dr Robert McCullumsmith (Department
of Psychiatry and Behavioral
Neurobiology, University of Alabama
at Birmingham, USA)
Professor Christos Pantelis (Melbourne
Neuropsychiatry Centre, The University
of Melbourne)
Dr Victoria Perreau (Centre for
Neuroscience, The University of
Melbourne)
Dr Elizabeth Thomas (The Scripps
Research Institute, California, USA)
Takeo Yoshikawa (RIKEN)
Behavioural Neuroscience
Laboratory
Head of Laboratory
Associate Professor Maarten van den
Buuse BSc (Hons), PhD
Postdoctoral Scientists
Dr Andrea Gogos BSc (Hons), PhD
Dr Rachel Hill BSc (Hons), PhD
Dr Paul Halley BSc (Hons), PhD
(Until March 2010)
Dr Sue Tye BSc (Hons), PhD
(Deakin University) (from June 2010)
Research Assistants
Sally Martin BSc (Hons)
Perrin Kwek BSc (Hons)
Angela Hurley BSc
PhD Students
Maren Klug BSc (Hons)
Shane Thwaites BSc (Hons)
Yee Wen Candace Wu BSc (Hons)
Elizabeth Manning BSc (Hons)
(From July 2010)
Honours student
Jac Kee Low BSc
Visiting Students
Emma Ruimschotel BSc (Netherlands)
(Until June 2010)
Maaike Labots BSc (Netherlands)
(Until March 2010)
Ger Post BSc (Netherlands)
Collaborators
Professor Ashley Bush
(Mental Health Research Institute)
Professor Michael Berk
(The University of Melbourne)
Dr Tony Hannan
(Howard Florey Institute, Melbourne)
Dr Nigel Jones
(Royal Melbourne Hospital, Melbourne)
Professor Terence O’Brien
(Royal Melbourne Hospital, Melbourne)
Dr Simon Murray
(The University of Melbourne)
Dr Jeff Craig
(Murdoch Childrens Research Institute)
Dr Sue Tye (Deakin University)
Dr Manfred Gerlach
(University of Wurzburg, Germany)
87

88
Personnel
Annual Report 2010
Molecular Psychopharmacology
Laboratory
Head
Associate Professor Suresh Sundram
MBBS, MMed, FRANZCP, PhD
Senior Scientist Honorary Professorial
Fellow
Professor George Fink MBBS, DPhil,
MD, FRCPE, FRSE
Senior Research Officer
Dr Avril Pereira BAppSc, MSc, PhD
Research Assistant
Peter Malcolm BSc (Hons)
PhD Students
Sujeevan Sinnatamby MD, FRANZCP
Vaidy Swaminathan MD, FRANZCP
(until February 2010)
Advanced Medical Sciences (AMS)
Students
Yuanna Zhou
Honam Choi
Postgraduate Student
Hanneke Raaijmakers
Northern Psychiatry Research
Centre
Head
Associate Professor Suresh Sundram
MBBS, MMed, FRANZCP, PhD
Senior Research Physician
Dr Russell D’Souza MPM, MD
Research Coordinator
Fiona Bole RN
Research Nurse
Sumathy Sathiyamoorthy RN (Div II)
Research Physician
Dr Rohit Lodhi MD, MRCPsych
PhD Student
Jody Stanley
Postgraduate Students
Lydia Brown
Sarah Arnold
Advanced Medical Sciences (AMS)
Students
Zexi Allan
Collaborators
Professor Michael Berk
(The University of Melbourne)
Dr Olivia Carter
(The University of Melbourne)
Dr Gursh Chana
(The University of Melbourne)
Ms Tiffany Cowie
(The University of Melbourne)
Dr Peter Crouch
(The University of Melbourne)
Professor Brian Dean
(Mental Health Research Institute)
Dr Seetal Dodd
(The University of Melbourne)
Professor Ian Everall
(The University of Melbourne)
Dr John Farhall (La Trobe University)
Ms Marnie Graeco (Northern Hospital)
Professor Brenda Happell
(Central Queensland University)
Ms Alison Harrington
(Northern Area Mental Health Service)
Dr Alexander Holmes
(The University of Melbourne)
Dr Ana Hutchinson
(Northern Clinical Research Centre)
Dr Nigel Jones
(The University of Melbourne)
Dr Gerard Kennedy (Victoria University)
Dr Ken McAnally (Defense Science
Technology Organization)
Professor Ralph Martins (Edith Cowan
University)
Professor Terence O’Brien
(The University of Melbourne)
Dr Meaghan O’Donnell
(The University of Melbourne)
Dr Elizabeth Scarr
(The University of Melbourne)
Dr Elizabeth Thomas
(Scripps Institute, USA)
Professor Cyndi Shannon-Weickert
(Prince of Wales Medical
Research Institute)
Dr Anthony White
(The University of Melbourne)

Personnel
Annual Report 2010
Neuropathology
Head (Group Leader)
Professor Colin Masters
Post-doctoral Scientists
Dr Blaine Roberts BSc, PhD
Dr Tim Ryan BSc (Hons), PhD
Dr Qiao-Xin Li BSc, PhD
Dr Scott Lafoon BSc, PhD
Research Assistants
Monica Lind BChemEng, MBiotech
Kathryn Jones-Ganio BSc
Katrina Laughton BSc
Collaborators
National Collaborators:
Dr Tara Pukala,
(Adelaide University, Adelaide, SA)
International Collaborators:
Professor Edward A. Dratz (Montana
State University, Bozeman, MT)
Oxidation Biology Laboratory
Head of Laboratory
Professor Ashley Bush MBBS, DPM,
PhD, FRANZCP, FTSE
Principal Research Fellow and Deputy Head
Associate Professor Robert Cherny
BSc, PhD
Personal & Administrative Assistant
Suzie McNicol Dip Fin Plan
Senior Research Fellow
Dr Paul Adlard BSc (Hons), PhD
Associate Professor Robert Cherny
BSc, PhD
Associate Professor David Finkelstein
BSc, GradDip, MSc, PhD
Dr James Duce BSc (Hons), PhD
Research Fellows and Post-doctoral
Scientists
Dr Ya Hui Hung BMus, BSc (Hons), PhD
Dr Chris Lim BSc (Hons), PhD
Dr Gawain McColl BSc (Hons), PhD
Dr Lynda O’Sullivan BSc (Hons), PhD
Dr Alan Rembach BSc (Hons), PhD
Research Officer
Dr Toni Lynch BAppSc, MSc, PhD
Research Assistants
Andrew Dalziel, BA, BSc (Hons)
Gulay Filiz BSc (Hons)
Jessica George BSc (Hons), MSc
Lydia Gunawan MappSc
Linh Lam BSc (Hons)
Xiang Liu BSc
Elysia Robb BMedSc (Hons)
Amelia Sedjahtera BSc (Hons)
Andrew Tsatsanis BSc (Hons) (until
June 2010)
Irene Volitakis BSc (Hons)
Helena Kim BSc (Hons)
Varsha Lal BSc, BEng (Hons),
PostgradDipMngt
Amelia Sedjahtera BSc (Hons)
Technical Assistants
Lisa Bray AssocDipAppSc (AnimTech)
Nicole Critch (DipAnimTech)
Bruce Etherton, Animal Technician
Sarah Evans (DipAnimTech)
Rinola Singh (DipAnimTech)
Postgraduate Students
Scott Ayton BBNSc (Hons)
Yif’at Biran BPharmSci, CertIV BusMgt,
BSc (Hons)
Mark Greenough BSc
Adam Gunn BSc (Hons)
Simon James BSc (Hons)
Peng Lei BSc
Rebecca Vaughan BSc (Hons)
Visiting Students
Daniela Zuser (IMC University of
Applied Sciences, Krems, Austria)
Elisa Arthofer (IMC University of Applied
Sciences, Krems, Austria)
National Collaborators
Professor James Camakaris
(Department of Genetics, The University
of Melbourne)
Dr Roger Chung
(University of Tasmania)
Dr Tracey Dickson
(University of Tasmania)
Dr Philip Doble
(University of Technology, Sydney)
Dr John Forsythe (Materials
Engineering, Monash University)
Professor Brett Garner (Illawarra Health
and Medical Research Institute,
University of Wollongong)
89

90
Personnel
Annual Report 2010
Dr Melissa Gresle (Multiple Sclerosis
Group, Howard Florey Institute)
Professor Trevor Kilpatrick
(Centre for Neuroscience/Howard
Florey Institute, Melbourne)
Professor Ralph Martins
(University of Western Australia)
Professor Julian FB Mercer
(Director, Centre for Cellular and
Molecular Biology, School of Biological
and Chemical Sciences, Deakin
University, Burwood)
Associate Professor Christina Morganti-
Kossmann (The Alfred, Melbourne)
Dr David Nisbet (Materials Engineering,
Monash University)
Dr Melanie Pritchard (Department of
Biochemistry and Molecular Biology,
Monash University)
Dr Tara Pukala (University of Adelaide)
Professor James Vickers
(University of Tasmania)
Professor Adrian West
(University of Tasmania)
International Collaborators
United States of America
Professor Julie Anderson (Buck Institute
for Age Research, Novato, CA)
Dr Math Cuajungco (Massachusetts
General Hospital and Harvard Medical
School, Boston, MA)
Dr M Flint Beal (Cornell University,
New York, NY)
Professor Joseph S Beckman
(Linus Pauling Institute, Corvallis, OR)
Professor Edward A Dratz (Montana
State University, Bozeman, MT)
Dr Jane Flinn
(George Mason University, Fairfax VA)
Dr Jonathan Fox (Neurology,
Massachusetts General Hospital,
Boston, MA)
Dr Avi Friedlich (Bedford Veterans
Affairs Hospital, Boston, MA)
Dr Lee Goldstein (Brigham and
Women’s Hospital, Harvard Medical
School, Boston, MA)
Professor Elizabeth Head
(University of Kentucky, Lexington, KY)
Assistant Professor Xudong Huang
(Department of Psychiatry,
Massachusetts General Hospital,
Boston, MA)
Dr Deepinder Kaur (Buck Institute for
Age Research, Novato, CA)
Dr Mahmoud Kiaei (Weill Medical
College of Cornell University,
New York, NY)
Dr Lenore Launer (National Institute on
Aging, Bethesda, MD)
Associate Professor Christopher D Link
(Institute for Behavioral Genetics;
University of Colorado, Boulder, CO)
Associate Professor Gordon J Lithgow
(Buck Institute for Age Research,
Novato, CA)
Associate Professor Simon Melov
(Buck Institute for Age Research,
Novato, CA)
Associate Professor Martha Clare Morris
(Rush Institute for Healthy Aging, Rush
University Medical Center, Chicago, IL)
Dr Dan Ory (Washington University
School of Medicine, St Louis)
Associate Professor Michael Petris
(Department of Biochemistry,
University of Missouri-Columbia, MO)
Associate Professor Jack Rogers
(Psychiatry, Massachusetts General
Hospital, Boston, MA)
Professor Rudolph Tanzi (Director,
Genetics and Aging Research Unit
at Massachusetts General Institute for
Neurodegenerative Disease,
Boston, MA)
Assistant Professor Robert Moir
(Massachusetts General Hospital &
Harvard Medical School, Boston, MA)
Professor Dennis Thiele (Duke University
Medical Center, Durham, NC)
Dr Hui Zheng (Baylor College of
Medicine, Houston, Texas)
United Kingdom
Dr Janet Johnston (Division of
Psychiatry and Neuroscience, Queen’s
University, Belfast, Ireland)
Dr Craig W. Ritchie
(Royal Free & University College
Medical School, Hampstead)
Professor Robert Evans
(School of Health Sciences and Social
Care, Brunel University, West London)
Chile
Professor Nibaldo Inestrosa,
(Catholic University of Chile, Santiago)
Dr Carlos Opazo (University of
Concepcion)

Personnel
Annual Report 2010
Republic of Korea
Professor Jae Koh (University of Ulsan
College of Medicine, Seoul)
Assistant Professor Joo-Yong Lee
(University of Ulsan College of
Medicine, Seoul)
Japan
Assistant Professor Yoichi Kato
(University of Hyogo)
Dr Seiichi Nagano (Harvard
Medical School, Massachusetts
General Hospital)
Spain
Dr Juan Hidalgo (Universidad
Autonoma de Barcelona)
Hungary
Dr Zsolt Datki (University of Szeged)
Israel
Professor Irit Sagi (The Weizmann
Institute of Science, Rehovot, Israel)
Dr Inna Solomonov (The Weizmann
Institute of Science, Rehovot, Israel)
List of Scientific Visitors
Professor Julie Anderson
(Buck Institute, California, USA)
Dr Scott Laffoon
(Montana State University,
Bozeman, MT, USA)
Assistant Professor Math Cuajungco
(California State University,
Fullerton, USA)
Professor Gordon Lithgow
(Buck Institute, California, USA)
Clinical Research Group
Head
Dr Kathryn Ellis BSc (Hons), PhD
Clinical and Neuropsychology
researchers
Adrian Kamer BSc (Hons),
Candidate DPsych (ClinNeuropsych)
Carolina Restrepo (Psych)
Fiona Lamb BASc(Psych)(Hons),
DPsych(ClinNeuro)
Harriet Downing BA, PGrad Dip Psych,
Candidate DPsych (ClinNeuropsych)
Jo Robertson BA(Psych)(Hons)
Karra Harrington BA
Rachel Buckley BSc(Psych)(Hons)
Stacey Walker
Molecular Biology Researchers
Brett Trounson BSc (Hons) - AIBL Blood
Processing Laboratory Manager
Dr Christopher Fowler BSc (Hons) - PhD
Kelly Pertile BSc (Hons) -
Research Assistant
Rebecca Rumble BBioSc (Hons) -
Research Assistant
Postdoctoral Fellows
Dr Alan Rembach BSc (Hons),
PhD - Postdoctoral Research Fellow
Dr Noel Faux BSc (Hons), Grad Dip
Comp Sci, PhD
DIAN Study
Alicia Rooney BSc, BNurs,
GCHumanFact
Research Nurses
Fairlie Hinton RN
Alison Boyd
Susan Dickie RN
Administration
Yumiko Matsumoto
Visiting Scientist
Gobhathai Sittironnarit MD
Senior AIBL Study Scientists
and Collaborators
Professor David Ames
(National Ageing Research Institute)
Professor Kaarin Anstey
(Australian National University)
Associate Professor Marc Budge
(Australian National University)
Professor Ashley Bush
(Mental Health Research Institute)
Associate Professor David Darby
(CogState)
James Doecke (CSIRO Mathematical
and Information Sciences)
Dr Maree Farrow
(Alzheimer’s Australia Victoria)
Associate Professor Jonathan Foster
(Edith Cowan University)
Norm Good (CSIRO Mathematical and
Information Sciences)
Professor Richard Head (CSIRO)
Professor Peter Hudson (CSIRO)
Professor Nicola Lautenschlager
(The University of Melbourne)
Dr Qiao-Xin Li
(The University of Melbourne)
91

92
Personnel
Annual Report 2010
Dr Lance Macaulay (CSIRO)
Simon McBride (The Australian e-Health
Research Centre)
Professor Paul Maruff
(Mental Health Research Institute)
Professor Ralph Martins
(Edith Cowan University)
Professor Colin Masters
(Mental Health Research Institute)
Andrew Milner (Neurosciences Victoria)
Lynette Moore
(Alzheimer’s Australia Victoria)
Dr Timothy O’Meara (CSIRO)
Glenn Rees (Alzheimer’s Australia)
Professor Chris Rowe (Austin Health)
Olivier Salvado (CSIRO e-Health)
Associate Professor Greg Savage
(MACCS)
Jack Sach
(Alzheimer’s Australia Victoria)
Dr Wichat Srikusalanukul
(Australian National University)
Dr Cassandra Szoeke
(CSIRO Preventative Health)
Kevin Taddei (Edith Cowan University)
Associate Professor Victor Villemagne
(Austin Health)
Associate Professor Michael Woodward
(Austin Health)
Associate Professor Olga Yatsrubetskaya
(The University of Melbourne)
Clinical Discovery Unit
Head of Program
Professor Michael Berk MBBCh, MMed,
FF(Psych)SA, FRANZCP, PhD
Co-Investigators
Professor Ashley Bush MB BS, DPM, PhD,
FRANZCP
Associate Professor Maarten van den
Buuse PhD
Professor Gin Malhi BSc Pharmacl (Hons),
MBChB, MRC Psych, FRANZCP, MD
Professor Flavio Kapczinki MD, PhD
Professor Brian Dean MSc, PhD
Postdoctoral Scientist
Dr Olivia Dean PhD
Trial Clinicians
Dr Sue Jeavons BA Psych (Hons),
MPhil (Clinical Psychology), PhD
Karen Hewitt
Michelle Tanious BmedSci (Hons),
GradDipPsych
Postgraduate Students
Kristi-Ann Villagonzalo BSc (Hons)
Collaborators and Visiting Fellows
Dr Tina Andreazza PharmD, PhD
Dr Clarissa Gama MD, PhD
Dr Pedro Magalhaes PhD
Dr Marc Udina MD
Dr Yimming Wang PhD
Victorian Brain Bank Network
Head, Tissue Bank
Professor Catriona McLean BSc, MBBS,
FRCPA, MD
Consultants
Professor Brian Dean HND ApplBiol,
MSc, PhD, Fl Biol
Professor Colin Masters BMedSc (Hons),
MBBS, MD, HonDLitt WAust, FRCPath,
FRCPA, FAA, FTSE
Associate Professor Suresh Sundram
MBBS, MMed, PhD, FRANZCP
Coordinator
Fairlie Hinton
Research Assistants
Geoff Pavey BSc (Hons)
Leanne Frazer BSc (Hons)
Consultant Histologist
Dr Ian Birchall BAppSc, MSc, PhD
Collaborators
Transplant and Family Liaison Coordinators
(Donor Tissue Bank of Victoria)
Pathologists, Medical Liaison Officers
and Mortuary Technicians (Victorian
Institute of Forensic Medicine)
Psychotropic Drug Advisory Service
Head
Professor Nicholas Keks MBBS, MPM,
PhD, FRANZCP
Staff
Christine Culhane BPharm, Grad Dip
Hosp Pharm
The Dax Centre
Director
Dr Eugen Koh BSc (Hons), MBBS, MPM,
FRACGP, FRANZCP
Senior Lecturer in Arts & Psychiatry
(The University of Melbourne)

Personnel
Annual Report 2010
Collection Manager
Anthony Fitzpatrick BA (Hons), Postgrad
Certificate(Art Conservation Studies),
MA (Art Curatorship)
Exhibition Manager
Loretta Shepherd BA (Psychology
& Economics), Grad Dip
Communications, Grad Dip Art History,
MA (Art Curatorship)
Education Manager
Penelope Lee RN, RPN, BA (Hons), FPV
Certificate (Acting until April 2010)
Anita Kopiec(Until Aug 2010)
Emma Last Grad Dip Family Therapy,
BA Social Work, Bach of Arts (From
Aug 2010)
Psychoanalyst in Residence
Associate Professor Frances Salo
Communication and Administration
Manager
Kirsten Kachab BEd (Primary),
Grad Cert (Counseling)
Project Managers
Margaret Nixon DipEdDipArts
PiaBrous (Honorary) MBBS, BMedSc,
MPM, FRANZCP, Certif Child Psychiatry
Public Programs, Partnerships &
Professional Development Manager
Penelope Lee RN, RPN, BA (Hons), FPV
Certificate
Curatorial Staff
Juliette Hanson BA (Art History &
Philosophy), MA(Art Curatorship)
Alison Langley BSc, BA (Fine Art)
(casual)
Zoe Evershed BA (Hons Visual) (casual)
Charlotte Christie BCA, DML, MA
(Art Curatorsip)
Dr Hassanah Briedis BA, MA
(Creative Arts Therapy), PhD (Arts)
Transition Manager
Dr Kim Selling BA (Hons), Phd
(Doctor of Philosophy), MA
(Sustainable Heritage Development
& Management) (Until Sep 2010)
Communications Officer
Cara Schultz BA (Hons)
(From November 2010)
Schools Coordinator
Glenda UrquartBEd , Grad Dip
Psychology
Megan LeeBBNsc, DipEd
Education Officers
Penelope Lee RN, RPN, BA (Hons),
FPV Certificate
Deb Zipper BA Occupational Therapy
Cassie Redlich (Until July 2010)
Rachel Lysaght (Until Aug 2010)
Personal Assistant to the Director
Jo Whatley BA, Postgrad Dip (Art
Curatorial Studies) (Until March 2009)
Amy Middleton BA (Hons), MA (Arts
Management) (from March 2010)
Julia Robinson Grad Dip Marketing
(From November 2010)
Executive Assistant and Development Officer
Bridget MacLeod BFA MA (Art
Curatorship) (from June 2009)
Administration Officer
Susan Murphy BEd
Publication & Grants Officer
Jessica Raschke PhD, BA
Fundraising Consultant
Stephanie Joseph
Conservation Students
Louise Allen
Johanna Ellersdorfer
Tegan Broderick
Jane Manallack
Curatorial Scholarship Students currently
enrolled in MA (Art Curatorship),
The University of Melbourne
Nikki Anderson
Georgie Adams
Advisory Committee
Chair: Associate Professor Elizabeth
Dax, AM
Dr Sandra Hacker, AO, Board Chair,
Mental Health Research Institute
Professor Sid Bloch, Professor of
Psychiatry,St Vincent’s Hospital
93

94
Personnel
Annual Report 2010
Ms Suzanne Davies, Director and Chief
Curator, RMIT Gallery
Ms Caroline Hogg, Former Minister
for Health
Mr Robert Knowles, Former Minister
for Health
MrJohn Lesser, Legal Member
Executive Director’s Office
Executive Director
Professor Colin Masters BMedSc (Hons),
MBBS, MD, HonDLitt WAust, FRCPath,
FRCPA, FAA, FTSE
Emily Cuningham BBiomedSci (Hons
Sci) - Personal Research Assistant
Brenda Huckstepp - Secretary
Administrative Services
Chief Operating Officer and Company
Secretary
Lisa Keam GradDip IP Law, BSc
Commercialisation and Business
Development
Michael Vovos - (from 9 September 2010)
Development and Communications
Ross Johnstone MFIA - Development
and Communications Manager
Nichole Alfreds BA, MFIA - Fundraising
Communications Coordinator
Dianne Clark FFIA - Bequests
(from April 2010)
Jo-Anne Morgan - Events
Babita Narayan - Development Assistant
Finance and Administration
Nick Catton LLB, BMS - Accountant
Brian Fleming BBus(Acc) - Assistant
Accountant
Marinos Tsikkos - Receptionist
Alistair Kittson - Administration Assistant
Human Resources
Rachel Mostacci - HR and
Administrative Officer
Information Technology
Rik Casama BSc - IT Manager
Gena Shoykhet BIS - IT Officer
Laboratory Services
Anna Sellens BSc (Hons) -
Laboratory Facilities Manager
Jason Verde Dip Animal Tech -
Animal Facility Manager
Lisa Madigan Dip Animal Tech -
Animal Facility Technician
(until 5 March 2010)
Malcolm Marshall - Animal Facility
Assistant (until 7 July 2010)
Melissa Cameron - Technical Assistant
(from 15 March 2010)
Elissa Wells Dip Animal Tech - Technical
Assistant (from 8 November 2010)
Elsa Tsui - Laboratory Assistant
Michael Kent - Property &
Maintenance Manager
Don Kuruppu, NDT, CGI (London) -
Laboratory Assistant
Governors
Mr Charles Allen AO
Dr Di Bresciani
Mr Richard Buxton
Mr Peter Clemenger AM
Professor David Copolov OAM
Mr Ian Farrington
Professor George Fink
Mr Roger Flynn
Mr Doug George AM
Dr David Greatorex AO
Ms Caroline Hogg
Mr John Kearney AM QC
Dr Ben Lochtenberg
Mr Geoff Marshall
Mr George McMaster
Dame Elisabeth Murdoch AC DBE
Emeritus Professor Sir Gustav Nossal
Mr Ross Oakley
Mr Andrew Wardlaw
Mrs Liz Wardlaw
Ms Meredith Woods

Donations
Annual Report 2010
Thank you
We are grateful to the many
individuals, businesses and
philanthropic trusts and foundations
who support our work by donating,
participating in events, purchasing
our Christmas cards or sharing their
expertise, all of whom are listed in
these pages.
In-kind Supporters
Audi Penfold
Barbecues Plus
Block Arcade
Briner Signs
CAMCARE Charity Christmas Card Shop
Mr Alf Caruana
Coopers
Department of Human Services, Mental
Health Branch
Dulux
Gerrand & Associates
Melbourne Theatre Company
Middletons Lawyers
Monash University
Mr Ross Oakley
Mutual Ltd
One in Five Association
Royal Yacht Club of Victoria
Sanpellegrino
The Age
The Egg
The University of Melbourne
Whybin / TWBA
Wardlaw Family
Woods Family
Yering Station
$50,000 – 199,999
Mrs Anne Kantor
Australian Rotary Health
Estate of Eva Orloff
Joan & Peter Clemenger Trust
Mr J F Kearney AM QC &
Mrs M A Kearney
Mr & Mrs Douglas & Anne Rathbone
The William Buckland Foundation
$10,000 – 49,999
Mr & Mrs John & Lorraine Bates
Geoff & Helen Handbury Foundation
Mr Pieter Huveneers
Mrs Pam Knott
Mrs Norma Leslie
Reece Australia Ltd
The Bailey Charitable Trust
The Isabel & John Gilbertson
Charitable Trust
The Mason Foundation
$2000-9,999
Mrs R Andre & Miss M O’Sullevan
Australian Rotary Health
Ms Helen Baldwin
Berwick Opportunity Shop Incorporated
BP Australia
Mr Ross Bryant
Coventry Group Limited
Cross Docks Australia
Disha
Dixson Trust Pty Ltd
Djerriwarrh Health Services
Mr Andrew Erikson
Esso (BHP Billiton)
Mrs Neilma Gantner
Mr & Mrs Dean & Ilana Harris
Hart Charities Pty Ltd
Health Super
Jianguo Pty Ltd
Mr A P Kelly
Mr John Leaver
Mrs Diana M Lowe
Melbourne Institute of Business and
Technology
NHP Electrical Engineering Products P/L
Parks Victoria
Mr Nigel H Peck AM & Mrs Patricia Peck
Mr David G A Say
Ms Pauline Speedy
Mr Hugh R Taylor
The Angior Family Foundation
Warringal Financial Services Pty Ltd
Dr Robin Wilson
Wilson Security
Mrs Meredith Woods
Lady June Zeidler
$200 – 1,999
Mr Steve Abeckett
Ms Stephanie Aeuckens
Mr Cameron Afrasiabi
Mr Douglas Agnew
Mrs M C Ainsworth
Mr & Mrs Michael Aitken
Ms Nichole Alfreds
Anglican Parish of Wagga Wagga
Mr D M Aston
Mr James Atkins
Mr Robert Audsley
Dr W J Bailey AO
Mr Paul Bartlett
Mr J G Bate OAM
Dr Josephine Beatson
Mr Dean Bedggood
95

96
Donations
Annual Report 2010
Belmore Park Pty Ltd Carroll Family Trust
Mr Mark Bezemer
BHP Billiton
Dr Ian Birchall
Mrs Annette Bird
Mr Andrew Blaak
Mr E Bladeni
Mr G R Blair
Professor Sidney Bloch &
Mrs Felicity Bloch
Dr John P Bomford
Mr Joseph Bounader
Ms Margaret Bounader
Miss Sarah Bowden
Mr John Bowen
Professor Judith Brine
Brookfield Mulitplex Construction Pty Ltd
Mr Leo Browne
Mrs Pearl Bruhn
Dr & Mrs Mark & Ann Bryce
Mrs M J Bugg
Burn O’Donoghue Commercial
Mrs Ellen M Burt
Miss E M Butt
Mr Jarrod Byham & Mrs Sally Emerson
C R Kennedy & Company Pty Ltd
Ms Rochelle Cairns
Mr Allan Callender & Mr Tom Callender
Mr Pat Callisto
Camberwell Charity Christmas Card Shop
Mrs June Cameron
Mr John Carey
Mr & Mrs Joe & Samar Chalin
The Hon S P & Mrs J J Charles
Ms Susan Chun
Ms Di Clark
Mr & Mrs Tim & Julie Clarke
Mrs Florence Clarridge
Mr & Mrs J L & E S Cleland
Mr F J Colwell
Confoil Pty Ltd
Dr & Mrs Geoffrey & Joan Conron
Mrs Heather Coombes
Ms Kristine Cooney
Professor David Copolov & Associate
Professor Christine McDonald
Mr Kevin J Cosgrave
Mrs Anne Cowan
Ms Helen Cowan
Mr L Gordon Darling AC CMG
Mr Ernest F Dawes OBE FTS
de Malet & Assoc Pty Ltd
Decor Corporation
Dr & Mrs C M Deeley
Mr A L Dickson
Mr Jim Dingwall
Mr & Mrs J & D Dixon
Ms Billie Donaldson
Ms Sue Donaldson
Ms Felicity Druce
Mr John Duncan
Miss Yvette Dutt
Eastbeth Services Pty Limited
Eastwood Primary School
Mrs F R Edens
Mr Carl Elliott
Mr Z Elton & Dr Diana Elton
Mr David Farnsworth
Mr Julian Feller
Mr Brian Fleming
Mr Roger B Flynn
Mr Andrew Fraser
Dr George Freed
Ms Judith Freund
Dr A K Fryday
Mr G J Fulton
Mr Drew Fyfe
S Gaylard
GCB Bookkeeping Pty Ltd
Mrs Sylvia Gelman AM MBE
Miss Belinda Gibson
Mr R N Gotch
Mrs L M Gourlay OAM
Ms E M Graham
Mrs Lesley Griffin
Mrs J B Guerin
Dr James Guest AM OBE & Mrs Guest
Dr Sandra Hacker AO
Mr Wayne Hall
Ms Kate Hamilton
Justice H R Hansen
Mr Roy Hardcastle
Miss Joan M Harman
Mr Dan Harris
Mr & Mrs Peter & Elaine Harris
Mr Nick Hartigan
Mrs Kathleen Hatch
Mrs June Haughton
Ms Fiona Healy
Ms Elizabeth M Heinze
Mr Eric Herding
Mrs Carolyn J Hewson
Mr Ian Hicks
Mr Jack Hines
Mrs Zara Hines
Ms W E Hirst
Mrs I Y Hoolihan
Mr Peter Horstmann
Ms Jannie Howard
Ms Penny Hughes & Frank Lewis
Mr Michael Hutchison
In Vogue Blinds Pty Ltd
Mr Rowan V Ingpen
Interpath Services Pty Ltd

Donations
Annual Report 2010
Jalna Dairy Foods Pty Ltd
Dr Brian D James
Ms Louise James
Professor Norman James
Ms Therese James
Dr Elcahnan H Januszewicz
Ms Lisa Jeffery
Mr David Joachim
Mr Ross J Johnstone
Karingal Bowling Club Inc
Mr & Mrs D & M Kaufmann
Ms Jane F Kelly
Mr Howard Kemball
Mrs Michelle Kenna
Ms Anna Kerrison
Mr John Kirkhope
Mrs B M Kohane
Dr Jerzy Krupinski
Ms Margaret Ladanyl
Mrs Eve Landman
Mr John Landy AC CVO MBE
Ms Sarah Lane
Mr R F Lauwers
Mr Rod Law
Miss Kate Leddick
Miss Kate Lemon
Mr D W & Mrs W I Leslie
Mr J B Leslie AC & Mrs A Leslie
Mr John Lesser
Mr Lewis Lester
Ms Emily Lewis
Miss Kay Lewisohn
Mr Ambrose Linke
Ms Pearl Lubansky
Lubrimaxx Marketing Pty Ltd
Ludden Group
Mr Paul Ludekens
Mrs J A Lunt
Ms Rosemary B S Macindoe
Mr & Ms R & M Maeder
Mr Don Maloney
Mr Andrew Mansour
Ms Greta Matzat
Mr Kent May
Mr Justin McCarthy
Mrs Vivien McCarthy
Dr Ian W McCay
Ms P T McColl
Mrs Linda McConnell
Miss Ursula McFadden
Mr Bruce Mckenzie
Miss Claire McKeown
Ms Anna McLaren
Dr & Mrs A P & M S McPhate
McPherson’s Limited
Mr & Mrs R A McVicker
MECU Ltd
Mrs Janice Medway
Mr & Mrs Ron & Margot Meldrum
Mr John Michaux
Mr Brad Mogferd
Mr K Moller
Mr & Mrs Brian & Marilyn Moloney
Mr W F Montague OAM
Mr Stephen Moore
Mr & Mrs G A & C R Morgan
Mr Richard Moshinsky
Dr Bruce Munro
Mr Elie Nasri
Mr John Nixon-Smith & Mrs June Nixon-Smith
Ms H M Oakes
Mrs Doreen O’Brien
Mrs S Ohl
Mr Gareth Old
Mr Matthew Osbourne
Mr James Paterson
Mr Jeremy Paterson
Mrs Tina Paterson
Penfold Motors
Ms Rhonda Peters
Dr D M Pinkerton
Mr R G Pitcher AM
Mr Roland Pless
Mrs Margaret Poh Kam Chan
Mrs Jean Potter
Mr Philip Potter
Ms Fiona Powell
Mr Ian Pratt
Mr Greg Rafferty
Mr J T Ralph AC
Ralph Meats
Mr Robert Reed
Mrs Ann Reid
Ms Catherine Reilly
Mr Ralph Renard
Mr Chris Richardson
Ritchies Expense Company
Mr D W Rogers
Rotary Club of Central Melbourne
Mr Peter Rowell
Mrs Margaret Royston
Ms Kirsten Ruddo
Mr Matthew Ryan
Mr & Mrs P & E Ryba
Mr Ron Sacks-Davis
Mr Quin Scalzo
Mr Ian Seymour
Dr Garry Sheehan
The Hon Jim Short
Mr & Mrs M & J Simmons
Miss P Smart
Mr A W Smith
Mr Samuel Smorgon AO &
Mrs Minnie Smorgon
97

98
Donations
Annual Report 2010
Mr Richard Solomons
Solubility Pty Ltd
Ms Fiona Somerville
Mr & Mrs J & L Somerville
Somerville Lions Club
Mrs Lyn South
Mrs Ana Spremic
Mr & Mrs Phillip & Genny Steer
Mr & Mrs A W Stephens
Mr Russell Stewart
Ms Caroline Storm
Mrs Fay Strachan
Mr & Mrs Anthony Sullivan
Ms R E Swanson
Mr James Syme
Mr Rowan Tatchell
Ms Brooke Taylor
Mr Robin Taylor
Mr & Mrs B & P Teague
The Leo & Mina Fink Fund
The William Angliss (Vic)Charitable Fund
Thomson Playford Cutlers
Dr Bruce Thorley
Mr Robert C Thrower
Mr & Mrs J G Thrum
Mr Andrew Tinney
Mrs Marjorie Todd
Dr Diana Tolhurst
Mr David Travers
Dr Gad Trevaks AM
Twentieth Super Place Nominees Pty Ltd
Urbis Pty Ltd
Ms Sally van Doorn
Mr Brian Vernon
Mr David Vernon
Mr Stan Wallis AC & Mrs Judith Wallis
Miss Leisl Walsh
Mrs M Walsh
Mr Ralph Ward-Ambler AM &
Mrs Barbara Ward-Ambler
Mr Tim Watkin
Mr Philip Weickhardt
Mrs Claudine West
Ms Rachela H West
Dr W Whitton
Mr John V Wilkins
Mr Paul A Willee QC
Mrs Lyn Williams AM
Mrs Margaret Wilson
Mr J Wise
Mr Peter C Wolfe
Ms Nadia Woodhouse
Mrs Sheila Wynne
Mr & Mrs L & E Yoannidis
$2 – 199
Mrs Jane Aarons
Mrs Jennifer Abraham
Mrs Heather Abramson
Mr W J Absalom
Ms Sharon Aceret
Mr & Mrs I D Ada
Ms Peta Adams
Mr W Adams OAM
Mr Jaira Adlawan
Mr Michael Agresta
Mr Allan Aitken
Ms Gabrielle Aitken
Ms Kim Aitken
Ms Zoe Aitken
Mr Ebru Akerman
Ms Zexi Allan
Mrs Angela Allen
Ms Cassy Allen
Dr Glenison Alsop
Mrs Alsop
Mr & Mrs FM & H Altman
Ms Fiona Alveyn
Mrs Beverley Alway
Ms Lisa Amad
Ms Angela Anderson
Ms Sally Anderson
Mrs Elizabeth Andrews
Mr Ingmar Apinis
Miss Samantha Appleby
Mrs A M Arbuckle
Mr Andrew Arendsen
J Armstrong
Mrs V Armstrong OAM
Mr Andre Arndt
Miss E Arthur
Mrs Lara M Atkins
Mr Alexandra Auaguostakis
Mr Daniel Auld
Mr Antony Auliso
Mr Matthew Backman
Mr Andrew Badcoe
Mrs Patricia Baddeley
Dr Joseph Badr
Mrs Beth Bailey
Mr Hugh Bailey
Mrs Julie Bailey
Mr Ameet Bains
Mr Peter Baird
Mr & Ms B K & H Baker
Mrs T Baker
Mr Richard Baldwin
Ms Karen Ball
Mr Dale Bangco
Mr Peter Banyasz
Mr Doron Bard
Mr Morris Bardas
Mrs Mary Barker
Ms Jennifer Barnes

Donations
Annual Report 2010
Mr Melvyn Barnett
Mr Merv Barnett
Ms Felicity Barr
Miss Joanna Barrett
Mrs Manola P Barrett
Mr Peter Barrie
Mrs Jane Barron
Mr G Bartle
Miss Layna Bartlett
Mr & Mrs N & L Bartolo
Dr Bridget Bassilios
Mr David Bastian
Mrs Carolyn Bastock
Mr J L Bath
Dr Sue Batista
Mrs Laura Battistella
Mr Richard Baum
Ms Alison Bayne
Ms M P Beard OAM
Mrs Jean Beaumont
Mrs Ann Beck
Mrs Carla Beck
Mr Chris Beckman
Ms Anne Beilby
Mrs Doreen Bell
Mr Aaron Belton
Mr Brucey Belton
Mrs Diana F Benefield
Miss B R Benjamin
Mr David Benjamin
Mr Dean Benjamin
Mr David Bennett
Mr Sol Benporath
Mrs Barb Benson
Mrs Tanya Bentata
Mr Colin Berry
Ms Hollie Bevans
Mrs V Bicknell
Mr Michael Bidey
Mr & Mrs C & I Billinghurst
Ms Margaret Birch
Dr William Birch AM
Dr Ruth Birrell
Ms Franca Bisaz
Mr & Mrs Robert & Patricia Bish
Miss Mel Blackson
Ms Robin Blair
Mr & Mrs BL & MP Blannin
Mr Emilio Blasetti
Miss Melanie Blint
Miss M Blundell
Miss Aimee Board
Ms Sonya Bohlen
Mrs Sharon Boissonneault
Miss Ciara Boland
Miss Nancy Bonarrigo
Miss Helen Bonello
Mr Stephen Booth
Mr Richard Borghesi
Ms Christina Bos
Ms Maria Bottos
Ms Kim Bowers
Miss Kim Boyle
Mrs Emma Bradburn
Miss Madeline Brady
Mrs Mindy Brake
Mr David Bramley
Mr & Mrs A Brecknell
Ms Amy Brennan
Mr B M Brennan
Mr Tim Brennan
Mrs Geni Brewster
Mr John Bride
Mrs Anneliese Bridges
Mrs Joanne Brimelow
Mrs Marietta Brinkley
Ms Sonia Brockington
Mr Adam Broder
Mr Daniel Brooke
Mr Ian Brookman
Ms Kerry Brougham
Ms Beth Brown & Mr Tom Bruce AM
Mr David Brown
Ms Rebecca Brown
Mrs Sally Brown
Mrs Linda Bruce
Ms Caroline Bruckner
Ms Irene Buchanan
Mr J A Buchanan
Mr Aaron Buckley
Mrs Carol Bueno
Mr Rocco & Kristina Bueti
Mr H Bufe
Mrs Huong Bui
Ms Huong Bui
Mr A B Bunnett OAM
Ms Sonya Bunting
Ms Ann-Marie Burgar
Ms Helen Burge
Mr Michael Burke
Ms Colleen Burnes
Ms Fiona Burnes
Miss Georgia Burns
Mr Joel Burstyner
Dr Carol A Burton
Mr G & M Buschmann
Mr William Bussau
Miss R I Byers
Mr & Mrs L & R Calabrese
Mr James Callander
Ms Sophie Callander
Mr David Calleja
Ms Michelle Calligaro
Mr Jeremy Callman
99

100
Donations
Annual Report 2010
Mrs Judy Callman
Mrs Fleur Calvert
Mr Graeme Calway
Ms Margie Cameron
Mr & Mrs Neil & Pam Cameron
Ms Trish Cameron
Mrs B M Campbell
Mr David Campbell
Mr Simon Canny
Mr Paul Canterbury
Mr Adrian Cantwell
Mr Rocco Capogrecco
Ms Dawn Carey
Mrs Zanon Carla
Ms Annette Carlin
Mr Pete Carnell
Miss Una Carney
Mr Jon Carr
Mr Brian Carson
Mr David Carswell
Mrs Susan Carter
Mr Lachlan Carty
Mr Ricardo Casama
Mr Paul Cassidy
Mr Rob Cassr
Mrs B K Cates
Mrs Jocelyn Cato
Mr Hugh Cattermole
Mr Nick Catton
Mrs Yolanda Catton
Ms Tanya Cawthan
Mrs Susie Cay
Mr Neil Chadwick
Mr Anthony E Chaloner
Mr William Chan
Ms Jill Chapman
Mrs Jo Charalamt
Mrs P A Chaston
Ms May Chen
Mr Tony Chen
Dr I G Chenoweth
Mr Jack Chester
Ms Gabriella Chirumbolo
Mr Peter Chisnall
Mrs Jennifer Chrystie
Mr Kenneth Chung
Mr Frank Clark
Mrs H Clark
Ms Penelope Clark
Mr Brian Clarke
Mrs P J Clarke
Ms Heather Clay
Clayton Bowls Club Inc
Mrs Julie Cleary
Mr Peter Cleaver
Mrs Joan Cleeve
Ms Lucy Cleeve
Mr John Xavier Clifton
Miss Kim Clipstone
Ms Heidi Cmager
Mr F J Coates
Mr L E Coburn
Mr Lance Coburn
Mrs Leanne Coburn
Mr Geoff L Code
Mrs Michelle Cody
Ms S M Cohen
Mrs E M Coldwell
Ms Helen Colla
Mr & Mrs A Collins
Ms Benita Collins
Ms Fiona Collins
Mr Haley Collins
Mrs Julie Collins
Miss Amy Colquhoun
Mr Craig Combes
Mrs Nadia Conn
Mr Francis Constantinidis
Mr V A Cooke
Mr & Mrs BB & SH Cooling
Miss Caroline Cooper
Mrs Margaret Cooper
Ms Richard Coorey
Miss Melanie Copelin
Mr Raoul Copolov
Ms Noelene Copper
Mrs Mareeta Corcoran
Ms Irene Corr
Mr Peter Corrigan
Mrs Kate Coryndon
Mr Terry Cosgriff
Mrs N Costello
Ms Norma Cotterell
Ms Sarah Cotton
Mrs Andree Coutts
Mr Joshua Cowan
Ms Deryn Cox
Ms Katrina Cox
Mr Andrew Cramer
Mrs Kylie Crawford
Mrs Pamela Crosthwaite
Mr Scott Crough
Mrs Deborah Crow
Mr Simon Crowther
Mr & Mrs J & C Crutchfield
Ms Christine Culhane
Mr Peter Cummiskey
Miss Sally Cunningham
Ms Hazel Currie
Ms Sue Currie
Mr Kieran Curtain
Mrs Ella Czelen
Miss Rebecca Dabbs
Ms Angela Daffey

Donations
Annual Report 2010
Mr & Mrs R Dafter
Ms Pam Dalrymple
Mr Damian Dalton
Ms Kate Dalton
Mrs Julie Daly
Mr Phillp Daly
Mrs Marissa Damianidis
Mr Anthony Daniel
Ms Claire Daniel
Ms Michelle Daniel
Miss Oliva Darian
Mr A D’Astoli
Mr Adam Davidson
Mrs Irene E Davidson
Miss Kerry Davidson
Ms Megan Davidson
Mr Craig Davis
Ms Lucy Davis
Miss Debbie Davut
Ms Anne Dawson
Mrs R De Fegely OAM
Mr Domenic De Marco
Ms Kristin Dean
Ms Maria DeBartolo
Debstudio Interior Design
Mr Abaran Deep
Mrs S Deeves
Miss Danielle Delaney
Ms Kristina Dellosa
Mr Steve DeLuca
Dr Bill Denholm
Mrs Jacqui Dennis
Mr Richard Dent
Ms Anna Derlin
Ms Catherine Deszcz
Mrs P J Devlin
Mrs Gillian Dickson
Mrs I V Dickson
Ms Paula Dimakos
Mr Paul Dinnage
Mr Naush Dinshaw
Mr Shane Doherty
Mrs June Donald
Ms Wenda Donaldson
Miss Jane Donohoe
Mrs Louise Doquile
Ms Andrea Dore
Ms Hannah Downie
Mrs Rosemary Drenen
Mr Marty Drill
Miss Rebecca Driver
Miss Linda Drvodelic
Ms Janet Duff
Ms Yasmin Dugan
Mrs Clare Duggan
Miss Rachael Duggan
Mr D Dugger
Mr Paul Duncan
Mr Daniel Dungan
Mrs Penny Dunn
Mr Richard Dwyer
Mrs Alexandra Dyball
Ms Sharlene Eade
Mrs Val Earl
Mrs Rebecca East
Mr & Mrs D & I J Eddleston
Ms Annette Edwards
Ms Mary A Edwards
Professor Meredith A Edwards
Mr Scot Edwards
Ms Vanessa Edwards
Mrs Barbara Elliott
Ms Jessica Ellis
Mr Earl Elpers
Miss Nicola Elsom
Mr Ben English
Mrs Ottelina Erceg
Mr & Mrs G Ermer
Mr Bruce Etherton
Miss Cassandra Eyres
Mrs P A Fagg
Ms P K Falcinella
Mr Jim Falzon
Ms Jane Fannon
Mr David Farnsworth
Ms Lynne Faulkner
Mr Morgan Fayle
Ms Jane Fenton
Ms Ann Fernando
Ms Fiona Ferrington
Miss Caroline Ferris
Ms Karen Field
Mr Malcolm Fielden
Mr Duncan Fikkers
Mrs Elizabeth Fikkers
Ms Gulay Filiz
Mr Stephen Fisher
Fit 4 Living
Ms Barbara Flegg
Mr & Mrs FE & KJ Fletcher
Mr Peter Fletcher
Mr Perks Flick
Dr Eleanor Flynn
Mr Chris Fogarty
Ms Madison Foley
Mrs Sue Foran
Mr Clark Forbes
Mrs & Mr Barb & Frank Ford
Mr George Fordyce
Warwick and Sue Forge
Miss Erin Forrest
Mr E C Foster OAM
Mr George Fotakis
Mr Andrew Fox
101

102
Donations
Annual Report 2010
Mrs Lyn Francis
Mr Mircea Frandas
Mr Reginald Freeman
Ms Caroline Freemantle
Ms Vera Freidin
Mrs Vera Friedrich
Ms Tracey Frigo
Mr Fred Frohlich
Mrs Beverley Fuller
Mr Andrew Fulton
Mr Ben Fulton
Mr Stewart Fulton
Mrs J A Gabb
Mrs Susanne E Gabor
Mr Andrew Gador-Whyte
Ms Angela Gahan
Mr Lambis Galanopoulos
Mr Richard Galassi
Miss Sarina Gale
Mr Nikola Galinac
Ms Edwina Gallagher
Mr Scott Gallagher
Mr & Mrs B & R L Gallaway
Mr Neil Gardiner
Miss Sheryl Gardner
Mrs Paula Garnett
Garry & Warren Smith Pty Ltd
The Garry Martin & Associates Pty Ltd
Mr Matt Gazzard
Miss Stephanie Gebert
Mr R Gehrig
Ms Sarah Gelder
Ms Amy George
Mr Justin George
Mr Michael George
Ms Rosemary George
Ms Judith Geraghty
Mr Stuart Getley
Ms V Giannarelli
Ms Grace Giannini
Miss Luisa Giannone
Mr & Mrs D S & V I Gibb
Mrs M J Gibson
Mr Robert Gilbert
Mr Steve Gilbert
Ms Anne Gill
Ms Alison Gilmore
Mr Gary R Gilson
Mr Thomas Gin
Mr David Girolamo
Mr Paul Gladwell
Mr Apoorve Goel
Mr Chong Ming Goh
Mr Raph Goldenberg
Mr John Goldlust
Mr Dennis Goldner
Mrs Tracy Gomall
Ms Isabel Gonzalez
Mr Bill Gooch
Mr Brian Goodwin
Ms Julie Gordon
Mr Peter Gordon
Ms U Gordon
Mrs Doreen Gordon-Kirkby
Mrs Sue Gorman
Ms Irene Gorr
Mrs Erika Gough
Ms Alaina Gougoulis
Mrs Gaylene Gould
Ms Anna Gouttmann
Mr & Ms Dave & Kate Gowans
Ms Doris Graham
Mrs Carmen Granger
Ms Patricia Grant
Mrs M L Gray
Mr Stuart Gray
Mr Charles Grech
Miss Barb Green
Dr Todd Green
Miss Rachel Greene
Mrs Joyce Greenwood AM
Mr Martin Griffith
Mr Jordon Griffiths
Mr Rob Grinter
Mr Des Grogan
Ms Loris L Grote
Mr Guang Guan
Mrs Anne Gugger
Mr Christina Guglielmi
Mrs H Gulson
Mr & Ms M Weir H Densen
H W I Electrical Ltd
Mrs Edna Hackleton
Mrs Andrea Haddad
Mrs Jean Hadges
Haines Muir Hill
Mrs Alice Halasz
Dr L A Hallett
Mrs Shirley Hallows
Mr Craig Hamilton
Ms Eileen M Hamilton
Ms Joan Hamilton
Ms Olive M Hamilton
Miss Kate Hancock
Mrs Sally Hanley
Mr Jake Hanneman
Ms Pauline Hannon
Mr Rick Harcourt
Ms Angel Harden
Miss V E Harding
Mrs Julia Hare
Mr & Mrs G B Hargreaves
Ms Merrie Harkness
Mrs E Harman

Donations
Annual Report 2010
Miss Kate Harper
Ms Alissa Harris
Dr Karen Harris
Mrs Lynette Harris
Ms Ruth Harris
Mrs Elizabeth Harrison
Mr Stephen Harrison
Miss Maura Harty
Mr Simon Harvey
Miss Helen Havryliv
Ms Rosemary Hawkins
Mrs Margaret A Hawksworth
Mr Marty Hayes
Mrs Alex Hayward
Mr Freya Headlam
Health Explanations Pty Ltd
Mr Paul Healy
Mrs Jane Hearn
Ms Kerry Hecht
Mrs Rosemary Heide
Ms Desiree Hemberger
Mr Ian Henderson
Ms Janette Henderson
Mr Tony Hennessy
Mrs Edna A Herbert
Ms Elizabeth Herd
Mr Mark Herding
Mrs Nancy Herding
Mr Werner Herding
Mr Michael Hermann
Mr Erik Hetrick
Mr Paul Thomas Hicks
Mrs Jill Higginbotham
Mr Vincent Higgins
Mrs Margaret Higgs
Mr Kim Hildebrandt
Miss Lyndall Hillbrich
Ms Margaret Hilton
Ms Maureen Hilton
Mr Mark Hindmarsh
Mr Steven Hines
Ms Fairlie Hinton
Ms Pamela Hitchcock
Mrs Deborah Hitchen
Mrs Jean Hofmaier
Ms Kate Holden
Ms Marnie Holden
Ms Jane F Holland
Lady Suzanne Holland
Mrs H Holman
Mrs B Holmes
Mrs Anna Holmstrom
Ms Nanette Home
Mrs J Homewood
Mr Auostasio Hondros
Ms Meni Hondros
Mrs Monica Hopgood
Mrs & Mr Chris & Alan Hopkins
Mr John Hopper
Mr Ted Hormer
Miss Katie Horrell
Mr R K Horsburgh AM
Mr & Mrs W J Hosking
Ms Nadine House
Mr Scott Howard
Ms Corinne Howell
Miss Ceara Howley
Mr Michael Hoyle
Ms Brenda Huckstepp
H J Hughes
Mr L Hughes
Miss L Hughes
Mr Mark Hughes
Mr Christopher Hunt
Ms Mandy Hunt
Mr Eric Hunter
Mrs Anna Huntley
Dr Agim Hymer
Mrs Lisa Hynes
Ms Shelley Hynes
Mr & Mrs N Iddles
Ms Joanne IIsley
Mrs Suzie Jackobovits
Miss Bethany Jackson
Mr G A Jackson
Mrs H E Jackson
Mrs K Jackson
Mr & Mrs K A & N J Jackson
Ms Emma Jacques
Ms Francesca James
Ms Marian James
Mr Peter Jamieson
Miss Sophie Jamieson
Mrs Ursula Jansen
Ms Dianne Jenkins
Mr Tony Jennett
Mrs Olga Jensen
Jeshimon House
Mr John Jessup
Mr Bernard Joffe
Mr Tim Johansen
Mr Myles Johansson
Mr & Mrs Anna & Rhys Johnson
Dr Mark Johnson
Ms Trudi Johnson
Mr Peter Johnstone
Ms Eunice Jolliffe
Mrs C L Jones
Mrs E E Jones
Ms Kaye Jones
Mr Matthew Jones
Mr Peter Jones
Miss Susan Jones
Ms Brenda Jones_Evans
103

104
Donations
Annual Report 2010
Mrs Cathryn Jowett
Miss Ashlee Joyce
Mrs Rachel Kalman OAM
Mr Paul Kam
Mr Andrew Kaplan
Mr Adem Karafili
Ms Linda Karafili
Mrs & Mr Rosemary & Reg Karafili
Ms Valentina Karafili
Mr Andrew Karavias
Mr Phil Karlhuber & Ms Jo- Anne Morgan
Mr Alex Katsaros
Mr E & E Katz
Ms Margaret Kaye
Miss Cathy Kayess
Mrs Peg Keast
Mr Francis C Keen
Mr Samuel Keenan
Mr Tony Kellar
Ms Jennifer Kelso
Ms & Mr Mary Kennedy-Jones & Paul Day
Miss Sarah Kenner
Ms Irene Kenny
Mrs Jillian Kenny
Mr Randall Kent
Mr & Mrs Bryan & June Keon-Cohen
Ms Olivia Kerr
Mrs Baiba Kerrison
Ms Sharon Keys
Ms Cassandra King
Ms Charlotte King
Mr G E King
Mr Julian King
Mr Warrick King
Ms Cora Kipling
Ms Adrienne Kirby
Mr A J Kirkham AM
Mr M C Kirkland
Ms Judith Kloester
Ms Kathy Knight
Mrs Marie Knight
M E Knights
Ms Jan Knox
Mrs Maralyn Kobert
Ms Laura Koh
Mr & Mrs Bill & Dianne Koller
Ms Samantha Korman
Mr Joseph Kosack
Mr & Mrs H & B Kosky
Ms Eleftheria Kotsopoulos
Mrs Justine Koutsoupia
Mrs Antonia Kovic
Mr & Mrs Kowalski
Mr Raymond Krikorian
Mr G Kuran
Mr Don Kuruppu
Ms Magenta Kuzbicki
Ms Helen Lacy
Mr Peter Lalor
Mr Adam Lambourn
Mrs Louise Lampard
Miss Carla Lang
Mr Peter Langford
Mr R Lanini
Mr Sam Laser
Miss Kylie Laurie
Mr John LaVacca
Mr Ian Law
Mr Phillip Lawlor
Ms Nichola Lawman
Ms Suzanne Lawrence
Mr Steven Lawton
Mr & Mrs J & B Le Boeuf
Mr Jonas Le Souef
Ms Angela Leary
Mr John Lechte
Mr Hoe Lee
Miss Melissa Lee
Mr Michael Lee
Ms Nam Yi Lee
Ms Mary Lees
Mr Andrew Leigh
Mr Stephen Leitch
Mr Peter Lemon
Mr & Mrs G F Lenton
Mr & Mrs Paul & Jill Lethlean
Mr Mark Lew
Mr Ed Lewis
Mr Mark Lewis
Mrs Mary Lewis
Miss Michelle Li
Ms Cynthia Lindsay
Ms Mandy Lingard
Mr J M Lippmann OAM
Mr David Lipschitz
Ms Mary Lipshut
Mr & Mrs I Little
Mr Jason Liu
Ms Harris Liz
Ms Sandy Llew
Ms Carolyn Lloyd
Miss Monica Llupar
Miss Chai-Yin Lo
Mr David Loakes
Ms Carmel Lochiano
Mr& Mrs J & A Lodge
Dr Robert Long & Dr Helen Long
Mr & Mrs D & S Lopresti
Mr & Mrs L & F Lopresti
Mrs Rita C Lopresti
Mrs Theresa Lopresti
Mr John Lowry
Mrs Joan Lucas
Mr Rod Lush

Donations
Annual Report 2010
Mrs Doreen Lydeamore
Miss Claire Lynch
Mrs M Lynch
Dr Stephen Lynn
Mrs Lingna Ma
Mr John MacDermott
Mrs Margaret MacDermott
Ms Mary MacDermott
Mr Ryan Mackie
Dr James MacRae
Mrs S P Maher
Ms Georgina Mahony
Ms Anna Makarova
Mr & Ms Cal & Ross Malcolm
Mrs Jacqui Malcolm
Mr Kimberley Malcolm
Mr Paul Malcolm
Miss Alexandra Malfroy
Ms Chelsea Maloney
Mr Evan Maloney
Ms June Mancini
Mr Ray Manley
Mrs Joan Mann
Mr Andrew Manning
Mr Hugh Mapplebeck
Mrs M D March
Miss Roxanne Markovina
Mr & Mrs H & E Marks
Mr S Marks OAM
Miss M I Marris
Ms Jess Marsh
Mrs Joy L Marsh
Mr Christopher Marshall
Mr & Mrs D Marshall
Mr Geoff Marshall
Mr Richard Marshall
Mrs Dorothy Martin
Ms Marie Martin
Ms Sally Martin
Ms Susan Martin
Miss Sara Martinez
Mr Carmine Masino
Ms Diane Mason
Ms Julia Mason
Mr Chris Masterman
Professor Colin L. Masters MD
Mrs Carmel Mastwyk
Mrs F M Matthews
Ms Leigh Matthews
Ms Mariana Matthews
Mr Ryan Matthews
Mrs Mary Maude
Mr James May
Ms Maria May
Ms Valerie May
Mr & Mrs C G & P V McAleer
Mr Cameron McAllister
Miss Jenny McAteer
Mr Matthew McBride
Mrs E M McCann
Mr & Mrs Gwen & Peter McCarthy
Ms Melissa McCartin
Mrs J McCauley
Mr Soctt McClelland
Mr Andrew McComas
Mr Ben J McConchie
Ms Auby McCormack
Mr John McCormack
Ms Jessica McCreadie
Mrs Jennifer McCrohon
Mr Ian McDemott
Ms Margaret McDonald
Mr Paul McDonald
Miss Sarah McDonald
Mr Andrew Mcevoy
Ms Marion McEwin
Mrs Janne McFadden
McFadden Property Pty Ltd
Ms Emma McGoldrick
Miss Anna McGrath
Mr Allan McGregor
Mr & Mrs Jan & Doug McIver
Ms Laura McKenzie
Miss Lyndal Mckenzie
Ms Margaret McKenzie
Mr Toby Mckinnon
Ms Roslyn McKnight
Mrs P A McLean
Mr W G McLean
Mr Rodney McLeish
Miss Tania McLeish
Ms Kathy McLeod
Mrs Catherine Mclntyre
Father Daniel McMahon
Dr Ruth McMahon
Ms Suzanne McManus
Mrs Theresa McManus
Mr Darren McMullin
Mr Andrew McNamara
Mr Brian McNamara
Mr Charles McNamara
Mr Geoff McNamara
Mrs Lidia McNamara
Miss Michie McNamara
Mr Simon McNamara
Mr Grant McNeil
Ms Christina Mcrae
Mr & Mrs P Medding
Mr Brendon Meppem
Ms Henry Michelle
Miss Hannah Middleton
Mr Phillip A Miechel
Mr Stephen Mifsud
Mr Robert Mihart
105

106
Donations
Annual Report 2010
Mr MLaden Milivojevic
Mr Larry Miller
Mrs Lynda Miller
Mr George Mills
Ms Stacey Mills
Dr Fiona Milne
Mr Allen Milner
Mrs A Milojevic
Mr John Milton
Mir Bros Group of Companies
Miss Karla Miranda
Mr James Mitchell
Mrs Loris Mitchell
Ms Sonya Mithen
Mrs Jennifer Monaghan
Mr Paul Monkivitch
Mr Matthew Moon
Mr Andrew Moore
Mr D B Moore
Ms Gaye Moore
Mrs Geraldine Moore
Mr Ian Moore
Mrs Alison Morgan
Mr Christopher Morgan
Miss J Morgan
Mr & Ms Marg & Brian Morgan
Ms E M Morley
Mr Chris Morrey
Mr Darryl Morris
Mr & Mrs PJ & JM Moses
Ms Danielle Moss
Mrs Rachel Mostacci
Mrs Maggie Mote
Mr N Moulden
Mrs Maureen Muir
Ms Anne Muldowney
Mrs Penelope Mullner
Mulwala Football Club
Des Munday & Son
Mrs Alison Munro
Ms Julie Munro
Mr Paul Munslow
Mrs A I Murphy
Ms Kathleen Murphy
Mr A Musolino
Ms Angela Myers
Miss Alexia Naef
Ms Payal Naidu
Mr PLHA Naphtali
Mr Rohit Narayan
Drs J and S Nathar
Mr and Mrs I T & B M Naylor
Mr Don Neame
Ms Jaclyn Ned
Ms Imbi Neeme
Ms Sandra Nelson
Ms Jaclyn Neo
Mr Adam Newell
Mr Jesse Newnham
Mr Chris Newton
Irvine Newton
Mr Thong Nguy
Miss Emma Nicholls
Mrs Rae Nicholls
Ms Ola Niedbalski
Mr C A Nilsen
Mrs Laura Noble
Mr Robert Noble
Mrs Julie Noonan
Ms Michelle Noonan
Mr Sam Norden
Ms Jane Novak
Mr Ian T Oakley
Ms Marianne Oates
Ms Lily Obradovic
Mrs Cynthia O’Brien
Mr Dominic O’Brien
Mrs Helen O’Brien
Mr Peter O’Brien
Mr Geoff Ockleshaw
Mrs & Ms Linda & Greg O’Connell
Ms Rosemary O’Connell
Mr & Ms S & G O’Donoghue
Ms Anne O’Donovan
Miss Erin O’Dwyer
Mrs Rosalind O’Hagan
Ms Meg O’Hanlon
Mr & Mrs Ian & Shirley O’Keefe
Mr John Olive
Mr Marc Olsen
Mrs Clarissa O’Meara
Ms Kerry O’Meara
Mrs M Orloff
Ms Mariana Orrlov
Ms Tamara Orrlov
Mr Damien O’Shea
Ms Marcia O’Shea
Mr Christopher O’Sullivan
Mr Jacob O’Sullivan
Mr & Mrs Michael & Lyn O’Sullivan
Mr & Mrs Richard Oxborrow
Miss Rosemary Pacquola
Ms Alessandra Page
Mr John S Palmer
Mr Nick Pane
Mrs Kamala Paramanathan
Mr G Parham
Mrs Jan Parker
Mrs Jean Parker
Mrs Rebecca Parker
Mr G T Parkes
Mr Muhair Parkes
Ms Anne Parkhill
Miss Kerrie Parr

Donations
Annual Report 2010
Mrs Tracey Parry
Mr Gerald Pascoe
Mr Christopher Patch
Miss Amy Paterson
Mr Jeffrey Paterson
Miss Amanda Patterson
Mr Des Patterson
Mrs Jo Patterson
Mrs Anne Pauchnik
Miss Caroline Paull
Mrs Lina Pavone
Ms Eleisha Pawelek
Mr & Mrs S & K Paxinos
Mr Jason Payne
Ms Marilyn Payne
Mr Peter John Payne
Mrs Joanne Peake
Ms Debra Pearce
Ms Jane Pearson
Mr Robert Pearson
Mrs B Pepper
Ms Julie Percy
Mr S Perelstein
Perfect Vision Systems
Ms Christine Perkal
Mrs H Peters
Mrs Susan Pettit
Mr Tom Pharaoh
Mr Denis Philipatos
Ms Daniella Phillips
Mrs Catherine Philps
Miss Alex Phipott
Miss Lucy Piccoli
Ms Michelle Picker
Miss C A Pickering
Mr Kevin Picton
Mr & Mrs Sergio & Rosa Pinzan
Mr David Pitcher
Mrs Shirley Pitman
Mr & Mrs I & J Pleming
Ms Sussan Pleunik
Mrs Josephine Ploughman
Mr Ruth Polger
Mr A Polglase
Mr S Polistina
Mr Robert Pollock
Ms Margaret Pope
Ms Lydia Popec
Ms Sarah Pottenger
Mr Chris Potter
Ms Jane Potter
Mr Jonathan Potter
Ms Megan Potter
Miss Alison Poulianakis
Mr Matthew Poulton
Dr A Powell
Mrs Merryn Powell
Ms Jessica Power
Mrs Kathy Power
Mr Rob Power
Mr J W R Pratt
Mrs J E Preston
Miss Hannah Price
Mr Richard Price
Mr & Mrs Rod & Sue Price
Mr Shawn Price
Mr & Mrs V J Price
Ms Patricia A Pride
Mrs Maureen Procter
Mr Andrew Prosser
Mrs Jacqueline Provis
Mr J T Prowse
Mrs S Pullen
Miss Sue Pyke
Ms Megan Quinlan
Mrs Alison Quinn
Ms Elizabeth Quinn
Mr Mark Quinn
Mr Liam Quinsee
Mr David Quirk
R & T (Australia) Pty Ltd
Mr Sean Raffery
Ms Carmen Rakic
Mrs Judith Raleigh
Ms Sashi Ram
Mr Grant Ramm
Mr & Ms Marg & Tim Rankin
Mr Tim Rasmusse
Ms Michelle Rasmussen
Mr Philip Ratcliff
Mrs Sharon Rathburn
Mr Steve Rattle
Mr Matthew Rawle
Ms Wendy Raymant
Mr Paul Rayson
Mr Anthony Rees
Ms Marita Regan
Mr & Mrs F Reinke
Ms Carolyn Reynolds
Ms Emma Reynolds
Mrs M Riccio
Mr Tony Rich
Mrs Alice Richardson
Ms Lesley Richardson
Mrs Mary Richardson
Mrs Susan Ridgway
Miss Meagan Riepsamen
Mrs Angela Risstrom
Dr Rachel Robbins
Mrs Annette Roberts
Mr Iain Roberts
Mr J Roberts
Mr Scott Roberts
Ms Shirley Roberts
107

108
Donations
Annual Report 2010
Mr & Mrs A & J Robertson
Mrs Ann Robertson
Mrs Ann Robertson
Mr Hunter Robertson
Mr Andrew Robinson
Mrs Margaret Robson
Ms Larissa Rocchi
Ms Michele Rochwerger
Mrs Ivy E Roebuck
Ms Betty Rogers
Mrs Roslyn Rogers
Ms Sophie Rogers
Ms Mary B Rogers-Springs
Ms Kitty Rohan
Ms Megan Rootes
Mr Trevor Rootes
Mrs Barbara Rose
Mrs Maxine Rose
Mr Alan Rotman
Mr Christopher Rowan
Ms Cynthia Rowe
Mrs Margaret Rowe
Mr Matt Rowe
Mrs Patricia D Rowe
Mrs Sandra Rowlands
Mr Julian Ryan
Mr Paul Ryan
Mrs Carolyn Sadler
Miss Pat Sadler
Ms Christine Sahasrara
Mr Simon Saint-John
Ms Joanne Saleeba
Ms G Salisbury
Ms Francie Salle
Salmon & Co
Mr William Salter
Mr Michael Same
Ms Karen Sanders
Ms Miriam Sandkuhler
Mrs Vasugi Sanjayan
Miss Dorianne D Santo
Mrs Susan Satur
Ms Patricia Saunders
Mrs Sophia Saunders
Miss Morgan Savy
Miss Serren Savy
Miss Fiona Scanlon
Mrs Margaret Scanlon
Mr David Scannell
Mr & Ms P Scannell & J Briant
Mr Ryan Scannell
Dr Elizabeth Scarr
Mr Colin Schasser
Ms Jessica Schauble
Ms April Scheibl
Ms Mary S Schembri
Mr & Mrs Peter & Deb Schembri
Mr & Mrs Stephen & Marie Schembri
Mr G Schickert
Ms Jenny Schlank
Miss Mirielle Schreuder
Mr Roger Schueler
Ms Eda D Schurmann OAM
Ms Amanda Scott
Mr James Scott
Ms Kerin Seal
Mr Peter Seers
Ms Diane F Segall
Ms Vicki Sellars-Jones
Mr Robert Sennitt
Mrs Sarah Serong
Miss Megan Setches
Mrs Jaya Sharman
Ms Julie Sharmock
Mrs Christine Shaw
Ms Lisa Shaw
Professor A G L Shaw AO
Mr Ivor Sheldon
Dr Margaret Sheldon
Mr Andrew Shenton
Miss Ann Shepherdson
Mrs E Sheppard
Mrs Philippa Sheppet
Mr Nick Sherry
Miss Jodie Shew
Mr Gena Shoykhet
Mr Khumo Shuenyane
Mrs Rosemary Simons
Ms Jade Sinclair
Mrs Freda Skelton
Mr Oliver Skelton
Ms Lynne Slade
Ms Jo-Anne Slee
Ms Sandra Sloane
Ms Justine Sloane-Lees
Mr Michael Small
Mr Andy Smart
Mr Peter Smart
Mrs Andrea Smith
Ms Bianca Smith
Mr Cameron Smith
Ms Pattie Smith
Miss Samantha Smith
Mrs Valda Smith
Mrs Justine Smythe
Mr Graham Snell
Ms Simone Snerrelli
Dr Sylvia Solinski
Ms Fiona Somerville
Mr F B Sommervelle
Ms Mavis Sorensen
Mrs Amanda Sorich
Mr Ed Sorich
Mrs Rona Soulsby

Donations
Annual Report 2010
Spark International
Ms Leah Spies
Mr Colin Spurgeon
Miss Melanie Sput
Mr John Stack
Mr Daryll Stalker
Mrs Fay Stalker
Ms Laurelle Stalker
Ms Magda Stamps
Mr Steve Stansfield
Ms Chloe Staskowski
Miss Renee Stathopoulos
Mr John Stedman
Ms Katherine Steen
Ms Stephanie Stepan
Ms Belinda Stephens
Mr Michael Stephens
Mrs Charlotte Stephenson
Dr P Stephenson
Ms Kylie Steven
Mr Julian Stevenson
Mrs Margaret Stewart
Miss Claire Stockdale
Mrs Kim Stoddart
Mr Denise Stone
Mr George Stooke
Mrs Margaret Stratford
Mrs W H Struss
Mr Stephen Stuart
Ms Janet Stuckenschmudt
Mrs Lauren Styles
Mrs Carolyn Sudlow
Mrs Lisa Sultana
Mr Craig Sutton
Ms Rene Sutton
Mrs Susan Svilar
Mr Peter Swan
Mr Jeremy Sy
Mr Charles Syme
Ms Louisa Syme
Mr Peter Syme
Mr Stephen Szental
Tahbilk Pty Ltd
Mrs Georginia Tait
Mrs Kaitlin Tait
Mr Richard Talbot
Mr Aaron Tamblyn
Mr Matthew Tamplin
Dr Ann Tan
Mr Angelo Taranto
Miss Kerrie Taranto
Mr P Taranto
Miss Sheri-Ann Taulla
Mrs Nahed Tawadros
Mr Annika Taylor
Mr Cameron Taylor
Mr Chris Taylor
Mrs Georgina G Taylor
Ms Karlene Taylor
Mrs Kirsty Taylor
Ms Leanne Taylor
Mrs Melissa Teatum
Mr Alexandra Temby
Miss Lanthe Tesselaar
Miss Kalyani Tharmarajah
Ms Kylie Thitchener
Miss Rosie Thom
Ms Victoria Thom
Ms Lisel Thomas
Mrs Sallie Thomas
Mr Brack Thompson
Ms Karlene Thompson
Mr & Mrs A Thomson
Mr Andrew Thomson
Mrs L Thomson
Miss Phoebe Thomson
Miss Emma Thornett
Mrs G G Thrift
Mrs Suzanne Thurn
Mrs Sue Tiller
Ms Joanne Tindall
Mr Allan Titterton
Ms Kathyn Tohill
Mrs V Tolliday
Miss Chloe Tomazi
Tonic Scarf Green Marketing Agency
Miss AiMie Too
Mr Luke Torpey
Ms Virginia Travaglini
Mr Roger Trengove
Mrs E Trevena
Ms Kate Trevillian
Mr Simon Trilsbach
Mr & Mrs Andrew Trimble
Ms Doreen Trinham
Mrs Pamela Troode
Mr & Mrs G & A Tsalamandris
Ms Elsa Tsui
Mr Adam Tucker
Mr Vince Tudini
Mr Gregory Turnidge
Mr Bradley Twite
Mrs Denise Twyford
Dr Caitlin Tzounos
Ms M Ullin
Dr Jung Yoon Um
Mr Rahul Umargamwala
Ms Sybil M Ungar
Mr Gerald Upchurch
Miss Lauren Vagnoni
Ms Christine Vallence
Miss Rosanna van den Berg
Mr Harvey Van Driel
Cinnamon Van Reyk
109

110
Donations
Annual Report 2010
Mrs R Van Riel
Mr Matthew Vanderveer
Mr John Vanek
Mr Joshua Vansittart
Mr John vanTil
Mrs Patricia Varga
Mr Dom Vaughan
Ms Jules Vaughan
Mr Luke Verwey
Mr P W Vincent
Mr Con Vits
Mr Peter Voladis
Mr Ronald VonFelder
Mr Andre Vreugdent
Ms J R Vroland
Mr & Mrs Barry & Tina Wakelin
Mrs J R Walker
Ms Jenny Walker
Mrs Marianne Walker
Mr Scott Walker
Mrs Kathy Wallace
Ms Liisa Wallace
Mrs Meagan Waller
Mr Andrew Walsh
Ms Angela Walsh
Mrs Lee-Anne Walsh
Mr Bill T Walter
Mrs Sarah Wapling
Mr Dylan Ward
Mr Alistair Wardlaw
Mr Andy Wardlaw
Ms Carla Wardlaw
Emily & Eva Wardlaw
Mr Tim Wardlaw
Mrs Dorothy Warren
Miss A D Watson
Mr Malcolm J Watson
Miss Robin Watson
Ms Shelley Watson
Ms Shelley Watson
Mr & Ms Stella & Nigel Watson
Mrs W E Watson
Mrs Norma Watt
Ms Carolyn Wavish
Mr Ian Wavish
Mr Ryan Wavish
Mrs Dina Webb
Ms Joanne Webb
Mr Brett Webber
Ms Melissa Weinstein
Mrs V J West
Mr Neil M Westaway
Mrs Kathleen Westlake
Mrs A Westmore
Mrs Samantha Westmore
Mr Sean Whelan
Mr Vicki Whillance
Mr Bevan White
Mrs C White
White Sky Music
Dr Mark Whiting
Mr Robin Wickett
Mr Evan Wiener
Mr Matthew Wikinson
Mrs Jodi Wiley
Miss J Wilkinson
Mr Jeremy Willamsor
Ms Carol Willenberg
Ms Angela Williams
Mrs Judy Williams
Ms Stacey Williams
Ms Zainabu Williams
Mr Alan Williamson
Mr John Williamson
Ms Kyahn Williamson
Mrs Ros Williamson
Mr Ian Wilmoth
Ms Beth Wilson
Ms Donna Wilson
Mr Justin Wilson
Ms Kirsty Wilson
Ms Leane Wilson
Mrs Mandy Wilson
Mrs Kerry Wiseman
Miss Doris L L Wisniewski
Mrs June Witheford
Ms Claire Withers
Mr Keith Witney
Mr Arnold Wittner
Ms Selena Wong
Dr Alex Wood
Mr Brett Woodhouse
Miss Katrina Woodhouse
Miss Shylie Woods
Dr John Woodward
Mr Geoffrey S Wratten
Ms Carolyn Wright
Mr Chris Wu
Mr Chris Xu
Mr Ramie Yacoub
Ms Grace Yang
Mr Ben Younger
Mrs Diane Yuill
Mr & Mrs P Zajicek
Mr & Mrs G F Zambelli
Mr Steve Zanon
Ms Angela Zarattieri
Dr Robin Zeidler
Dr Leon Zimmet
Ms Maree Zubar
Mrs Eleanor Zubeckis

Further Information
Annual Report 2010
Donor Enquires
Individuals and organizations interested in financially supporting the Institute’s work, or needing to advise a change of
address, should contact the Development & Communications Manager on (03) 9388 1633.
Institute Publications
The annual report is the main source of information for our supporters. Supplementing this publication is a free bi-annual
newsletter which outlines recent developments at the Institute.
Contact the Development Officer on (03) 9388 1633 for placement on the Towards Understanding or annual report mailing
lists, or simply to notify a change of address.
Volunteers To Assist With Research Trials
The Institute is always looking for people to assist us with our research. This assistance can take a number of courses.
For example, sometimes we have new drugs to trial for Alzheimer’s disease, or we may want to compare responses in a
group of people without mental illness with those who have a mental illness.
Please call the Institute on (03) 9388 1633 if you would like to be directly involved in our research.
Bequests
The Institute has been able to continue its research and add strength to its work thanks to the people who have
remembered the organisation’s work in their will. For further information about how to make a bequest to The Mental Health
Research Institute, please contact the Bequest Officer on (03) 9388 1633.
Why Make A Will
Making a Will ensures that your estate is distributed according to your wishes. After considering the needs of your family and
friends, do think about making a gift in your Will to our research. Your gift, no matter what the amount, will help support our
efforts to find better treatments for Alzheimer’s disease, schizophrenia and depressive illnesses. We strongly recommend you
seek the professional advice of a solicitor when making your Will. However, a general guideline for wording is as follows:
I Give Devise And Bequeath to the Mental Health Research Institute Incorporated of 155 Oak Street, Parkville, free of all
duties the sum of……………. (or details of real property, shares or other assets) to be applied by it for its general purposes and
I direct that the receipt of its Treasurer or other proper officer shall be full and sufficient discharge to my Executors.
111

Mental Health
Research Institute
ABN: 48 101 228 451
155 Oak Street, Parkville Victoria 3052
Locked Bag 11, Parkville Victoria 3052
P: +61 3 9388 1633 F: +61 3 9387 5061
www.mhri.edu.au